

ISBN: 978-93-48620-60-6

# EMERGING TRENDS IN PHARMACEUTICAL SCIENCE RESEARCH VOLUME IV

**EDITORS:**

**DR. CHINTAN AUNDHIA**

**MRS. NIVEDITA B. T.**

**DR. SHILPI SHRIVASTAVA**

**DR. P. RIZWAN AHMED**



First Edition: February 2025



Bhumi Publishing, India

## Emerging Trends in Pharmaceutical Science Research Volume IV

(ISBN: 978-93-48620-60-6)

### Editors

#### **Dr. Chintan Aundhia**

Department of Pharmacy,  
Sumandeep Vidyapeeth  
Deemed to be University, Vadodara

#### **Mrs. Nivedita B. T.**

Department of Studies in Botany,  
Davangere University, Shivagangothri,  
Davangere, Karnataka

#### **Dr. Shilpi Shrivastava**

Department of Chemistry,  
Kalinga University,  
Naya Raipur, Chhattisgarh

#### **Dr. P. Rizwan Ahmed**

PG & Research Department of Computer  
Science, Mazharul Uloom College,  
Ambur, Tamilnadu



*Bhumi Publishing*

**February, 2025**

Copyright © Editors

Title: Emerging Trends in Pharmaceutical Science Research Volume IV

Editors: Dr. Chintan Aundhia, Mrs. Nivedita B. T.,

Dr. Shilpi Shrivastava, Dr. P. Rizwan Ahmed

First Edition: February 2025

ISBN: 978-93-48620-60-6



All rights reserved. No part of this publication may be reproduced or transmitted, in any form or by any means, without permission. Any person who does any unauthorized act in relation to this publication may be liable to criminal prosecution and civil claims for damages.

**Published by:**



**BHUMI PUBLISHING**

**Nigave Khalasa, Tal – Karveer, Dist – Kolhapur, Maharashtra, INDIA 416 207**

**E-mail: [bhumipublishing@gmail.com](mailto:bhumipublishing@gmail.com)**



**Disclaimer:** The views expressed in the book are of the authors and not necessarily of the publisher and editors. Authors themselves are responsible for any kind of plagiarism found in their chapters and any related issues found with the book.

## **PREFACE**

*Pharmaceutical science is an ever-evolving field that continuously adapts to new technological advancements, innovative research methodologies, and emerging healthcare challenges. The rapid expansion of knowledge in drug discovery, nanotechnology, pharmacogenomics, and biotechnology has significantly transformed the way we approach disease treatment and patient care. The book "Emerging Trends in Pharmaceutical Science Research" aims to provide a comprehensive overview of the latest developments and breakthroughs shaping the future of pharmaceutical sciences.*

*This volume brings together contributions from esteemed researchers, scientists, and academicians who delve into various aspects of modern pharmaceutical research. Topics such as targeted drug delivery systems, artificial intelligence in drug development, herbal therapeutics, and regulatory frameworks are explored to give readers a holistic understanding of current trends. Emphasis is placed on interdisciplinary approaches that bridge the gap between fundamental science and clinical applications, ensuring that scientific innovations translate into improved healthcare solutions.*

*The book is intended to serve as a valuable resource for students, researchers, and professionals in the pharmaceutical sciences. By shedding light on the dynamic advancements in this field, we hope to inspire further research and innovation that will contribute to the development of safer and more effective pharmaceutical interventions.*

*We extend our heartfelt gratitude to all the contributors, reviewers, and editorial team members who have made this publication possible. Their dedication and expertise have played a crucial role in shaping the content of this book. We also appreciate the unwavering support of our readers and hope this volume enriches their understanding of the ever-evolving landscape of pharmaceutical science research.*

**- Editors**

## TABLE OF CONTENT

<b>Sr. No.</b>	<b>Book Chapter and Author(s)</b>	<b>Page No.</b>
1.	<b>HERBAL APPROACHES TO ASTHMA AND PULMONARY WELLNESS</b> Dhanya B. Sen, Ashim Kumar Sen, Rajesh A. Maheshwari and Nirmal Shah	1 – 10
2.	<b>EFFECTS OF RETRO WALKING TRAINING ON KINESIOPHOBIA AND COGNITION ON GERIATRIC POPULATION- QUASI-EXPERIMENTAL STUDY</b> Suruchi, P. Sathya and Feba Roy	11 – 20
3.	<b>CLINICAL PHARMACISTS IN PERSONALIZED ONCOLOGY: OPTIMIZING TARGETED THERAPIES</b> Rajesh Hadia	21 – 33
4.	<b>NATURALLY OCCURRING CHALCONES: POTENT ANTIOXIDANT AND ANTICANCER AGENTS</b> Yogeshwar R. Ramasane	34 – 39
5.	<b>MENOPAUSE AND ITS IMPACT ON CARDIOVASCULAR DISEASE RISK</b> Yash Rakholiya, Harshkumar Brahmbhatt, Vishwa Patel and Nidhi Patel	40 – 45
6.	<b>ROLE OF PHARMACIST IN ADVERSE DRUG REACTION</b> Komal Pramod Sathe	46 – 52
7.	<b>THE ROLE OF MEDICINAL CHEMISTRY IN ADVANCING PHARMACY AND DRUG DEVELOPMENT</b> Shivkant Patel, Dillip Kumar Dash, Dipti Gohil and Ashim Kumar Sen	53 – 61
8.	<b>ADVANCEMENTS IN HAIR CARE: CHEMICALS AND MATERIALS IN MODERN HAIR COSMECEUTICALS PART 1: FUNDAMENTALS AND KEY INGREDIENTS IN HAIR COSMECEUTICALS</b> Ruchira Gajbhiye, Pratiksha Meshram, Pratiksha Marwadkar and Sonali Shambharkar	62 – 78

---

9.	<b>ADVANCEMENTS IN HAIR CARE: CHEMICALS AND MATERIALS IN MODERN HAIR COSMECEUTICALS PART 2: ADVANCED FORMULATIONS, TRENDS, AND FUTURE PROSPECTS</b>	79 – 94
	Ruchira Gajbhiye, Pratiksha Meshram, Pratiksha Marwadkar and Sonali Shambharkar	
10.	<b>GUT HEALING WITH HERBS: NATURAL WAYS TO SOOTHE ULCERS</b>	95 – 103
	Aarti Zanwar, Ashim Kumar Sen, Dhanya B. Sen and Rajesh A. Maheshwari	
11.	<b>MARCUS GUNN JAW-WINKING SYNDROME: A RARE OCULOMOTOR PHENOMENON AND ITS MANAGEMENT</b>	104 – 116
	Cyril Sajan	

---

## **HERBAL APPROACHES TO ASTHMA AND PULMONARY WELLNESS**

**Dhanya B. Sen, Ashim Kumar Sen, Rajesh A. Maheshwari and Nirmal Shah\***

Department of Pharmacy,

Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara-391760, Gujarat

\*Corresponding author E-mail: [nimspharma@gmail.com](mailto:nimspharma@gmail.com)

### **Abstract:**

The respiratory system is essential for maintaining overall health, playing a critical role in oxygen exchange, immune defense, and cardiovascular function. However, respiratory disorders such as asthma, bronchitis, and chronic obstructive pulmonary disease (COPD) have become more prevalent, affecting the quality of life for many individuals. Traditional treatments like corticosteroids and bronchodilators manage symptoms but often come with side effects, limited long-term effectiveness, and increasing concerns about antibiotic resistance. In this context, herbal remedies present a promising alternative. Herbal therapies offer a holistic approach to respiratory health, with plants like eucalyptus, ginger, and thyme known for their anti-inflammatory, antimicrobial, and expectorant properties. Additionally, herbs such as Billygoat-weed, East Indian Globe Thistle, and Moringa have shown potential in alleviating respiratory symptoms and improving lung function. For instance, Moringa has demonstrated improvements in asthma symptoms and lung function, while *Ficus bengalensis* and Licorice have exhibited antihistaminic and anti-inflammatory effects. These natural treatments are generally safer for long-term use and can complement conventional therapies. Given the rising incidence of respiratory diseases and the limitations of traditional treatments, integrating herbal solutions into a comprehensive approach to lung health could offer significant benefits. This review explores the therapeutic potential of various herbal remedies for managing respiratory conditions and enhancing overall respiratory function, aiming to provide a natural, supportive treatment option alongside conventional medicine.

**Keywords:** Respiratory System, Billygoat-Weed, East Indian Globe Thistle, Moringa

### **Introduction:**

The human respiratory system, consisting of a complex network of organs and tissues, plays a crucial role in maintaining the body's overall balance and health. Its function goes far beyond the simple act of breathing. The respiratory system is integral to a range of physiological processes, including immune defense, cardiovascular health, and even brain function. It enables the efficient exchange of oxygen and carbon dioxide, which is essential for cellular activities and energy production. This exchange makes optimal respiratory function vital for overall well-being and sustaining life. A key aspect of the respiratory system is its protective role in defending the body. It acts as the first line of defense against airborne pathogens, environmental pollutants, and

toxins. By filtering harmful particles, allergens, and bacteria, the respiratory system prevents these harmful substances from entering the bloodstream, where they could potentially cause significant damage. This filtration process is essential for maintaining health and preventing respiratory infections. In addition to its immune function, the respiratory system helps regulate the oxygen levels in the blood, which is crucial for the proper functioning of the heart. Oxygen-rich blood is essential for the heart's ability to pump efficiently and nourish the body's tissues. Respiratory health is also strongly connected to mental and emotional well-being. There is growing evidence of a complex, bidirectional relationship between respiratory function and psychological health. When the respiratory system is compromised, it can exacerbate mental health conditions such as anxiety or depression. On the other hand, stress, anxiety, and other mental health challenges can also disrupt normal breathing patterns, leading to shortness of breath, hyperventilation, or other respiratory issues. This reciprocal relationship emphasizes the importance of addressing both the physical and psychological aspects of health when managing respiratory conditions. Poor respiratory health can take a toll on mental health, and vice versa, making it critical to maintain both. Given these intricate relationships, the potential benefits of herbal remedies for respiratory health are worth exploring. Herbal solutions have been used for centuries to support lung function, enhance immune responses, and alleviate symptoms of respiratory conditions like asthma, bronchitis, and other chronic respiratory illnesses. Plants such as eucalyptus, ginger, and thyme are known for their anti-inflammatory, soothing, and expectorant properties, which can help clear the airways and promote easier breathing. Incorporating herbal remedies into a holistic approach to health can support the respiratory system, improve lung function, and promote overall well-being, addressing both physical and emotional aspects of health.<sup>[1-4]</sup>

The increasing prevalence of respiratory disorders in modern times underscores the significant challenges individuals face in maintaining optimal lung health. Conditions such as allergies, asthma, bronchitis, and respiratory infections are becoming more widespread, significantly affecting the quality of life for those suffering from these ailments. The rise in these respiratory issues can be attributed to several factors, including pollution, urbanization, and changing lifestyle habits. These factors have contributed to the growing number of people afflicted by respiratory diseases, many of which are chronic and debilitating, leading to long-term health concerns. Asthma, one of the most common chronic diseases affecting the respiratory system, is characterized by inflammation and narrowing of the airways. It leads to frequent episodes of wheezing, shortness of breath, chest tightness, and coughing. These symptoms often disrupt daily life, making it difficult for individuals to carry out routine activities. Asthma attacks can be triggered by various factors, including allergens, cold air, and physical exertion, making effective management crucial for those living with the condition.



Chronic bronchitis, another prevalent respiratory condition, is often linked to smoking or long-term exposure to environmental pollutants such as industrial chemicals and dust. This disease causes persistent inflammation of the bronchial tubes, leading to a constant cough, excessive mucus production, and reduced airflow, which can severely impact a person's ability to breathe. Allergies, which occur when the immune system overreacts to harmless substances such as pollen, dust, or pet dander, can lead to respiratory symptoms like nasal congestion, sneezing, and coughing. These allergic reactions are particularly common in individuals who live in areas with high levels of allergens or pollution. Respiratory infections, which can range from mild colds to more severe illnesses like pneumonia, are another leading cause of respiratory distress. These infections are often caused by bacteria or viruses and can result in serious complications, particularly in vulnerable groups such as children, the elderly, and individuals with compromised immune systems. The global healthcare burden of respiratory infections continues to grow, with millions of people affected annually. Given the rising incidence of respiratory diseases and their profound impact on individual well-being, there is an urgent need for comprehensive approaches to lung health. Effective prevention and treatment strategies are necessary to reduce the burden of these conditions on individuals and healthcare systems worldwide. One promising avenue for addressing respiratory issues is the use of herbal remedies, which have been utilized for centuries across various cultures to support respiratory health. These natural solutions offer potential benefits, ranging from alleviating symptoms to improving overall lung function. Combining traditional wisdom with modern scientific research can provide a holistic approach to respiratory care. The upcoming chapters will explore the anatomy of the respiratory system, detailing how it functions and how various respiratory conditions affect lung health. Additionally, we will delve into the historical use of herbs for supporting respiratory function, examining the cultural significance of these plants in traditional healing practices. Scientific studies validating the effectiveness of herbal remedies for respiratory ailments will also be discussed. Finally, practical advice will be provided on how individuals can incorporate these herbs into their daily routines to improve respiratory health. By merging ancient healing practices with modern knowledge, we aim to enhance lung function, prevent respiratory disorders, and promote overall well-being. This integrated approach offers a promising pathway to improving respiratory health for individuals around the world.<sup>[5-9]</sup>

### **Drawbacks of traditional therapy**

Conventional therapy for respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), bronchitis, and pneumonia typically involves medications like bronchodilators, corticosteroids, and antibiotics. While these treatments effectively manage symptoms and control flare-ups, they come with various limitations. One significant issue is the side effects associated with long-term use of medications. For example, corticosteroids can lead

to weight gain, bone thinning, high blood pressure, and an increased risk of infections. Bronchodilators, while helpful in opening airways, may cause tremors, heart palpitations, and nervousness, and overuse of these medications can diminish their effectiveness. Moreover, conventional treatments often lack long-term effectiveness. Although they can manage symptoms temporarily, they may not address the underlying causes of respiratory diseases. For instance, while corticosteroids reduce inflammation, they do not prevent future flare-ups or repair damaged lung tissue. Inhalers and other medications typically offer relief rather than a cure. Another concern is the growing issue of antibiotic resistance. Overuse or misuse of antibiotics to treat respiratory infections has contributed to this problem, making infections harder to treat, particularly in severe cases, and prolonging recovery. Additionally, the cost of conventional treatments can be a barrier, especially for those in low-income or underdeveloped regions. Frequent healthcare visits, ongoing prescriptions, and the price of medications can impose a financial strain on individuals and healthcare systems. Another limitation is the potential for medication dependency. Many patients with chronic respiratory conditions become reliant on medications for symptom management, but these treatments do not necessarily improve lung function or reverse the damage caused by diseases like COPD or long-term asthma. This reliance can lead to a cycle of dependency, with patients seeking symptom relief without achieving lasting improvements in their lung health. Adherence to prescribed treatments is also a challenge, as consistent use of medications is necessary for managing many respiratory conditions. Forgetfulness, side effects, or difficulties accessing medications can lead to inconsistent treatment, worsening symptoms and complications. Furthermore, conventional therapies tend to focus more on managing existing symptoms and treating flare-ups than on preventing respiratory diseases or their progression. Preventive strategies, such as lifestyle changes, improved air quality, and immune support, may not receive enough emphasis in standard treatments. In severe cases, invasive procedures like surgeries or mechanical ventilation may be required, which carry risks and may not always improve a patient's quality of life. These limitations highlight the need for a more holistic and comprehensive approach to respiratory health.<sup>[10-13]</sup>

### **Health benefits of plant-based treatments**

Herbal therapy is often preferred over conventional treatments for respiratory diseases for several compelling reasons. Unlike conventional therapies that primarily target specific symptoms, herbal remedies adopt a holistic approach, focusing on overall health and well-being. This approach helps to boost the immune system and promote general vitality, rather than just addressing isolated issues like shortness of breath or coughing. Additionally, herbal treatments tend to have fewer and less severe side effects compared to conventional medications, such as corticosteroids or bronchodilators, which can cause weight gain, high blood pressure, or

nervousness. When used appropriately, herbal remedies provide milder, more natural effects, making them safer for long-term use. Furthermore, herbal therapy offers preventive and supportive benefits. Herbs like eucalyptus and thyme have anti-inflammatory and antimicrobial properties that can strengthen the respiratory system, reduce the risk of infections, and help maintain lung health over time. Herbal remedies are also seen as more sustainable and eco-friendly because they rely on natural plant compounds, offering an environmentally conscious alternative to synthetic drugs, which often have negative ecological impacts. Herbal therapy is highly customizable, providing personalized care tailored to individual health needs. For instance, peppermint can ease congestion, while ginger supports lung health and enhances circulation. This personalization makes herbal treatment highly adaptable for addressing specific respiratory issues. Moreover, herbal medicine is deeply rooted in cultural and historical traditions, offering a sense of familiarity and relevance for those seeking treatments aligned with their heritage or beliefs. Lastly, herbal remedies can complement conventional therapies, working alongside them to improve effectiveness. They can help manage medication side effects, enhance lung function, and improve overall resilience, offering a supportive treatment option while still following conventional medical guidance.<sup>[14-15]</sup>

### **Herbs for asthma and pulmonary vitality**

#### **Billygoat-weed**

*Ageratum conyzoides*, commonly known as Billygoat-weed, is a perennial herb from the Asteraceae family, originally native to tropical America but now found in tropical and subtropical regions worldwide. Research has shown that the hydroalcoholic leaf extract of *A. conyzoides*, when administered to mice at doses of 250, 500, and 1,000 mg/kg, exhibits antihistaminic properties. This is evidenced by the prevention of clonidine-induced catalepsy in the animals. Further studies have examined the effects of *A. conyzoides* aqueous leaf extract on lung injuries caused by spray paint exposure in adult Wistar rats. These rats exhibited symptoms such as lymphoid tissue activation, pulmonary edema, and interstitial hemorrhage after being exposed to spray paint. However, treatment with *A. conyzoides* helped alleviate these symptoms by reducing the presence of broncho-alveolar immune system aggregates and limiting local immune activation. These findings suggest that *A. conyzoides*, particularly at lower doses, plays an important role in improving lung health and mitigating the damage caused by spray paint-induced lung injuries in Wistar rats. This highlights its potential as a therapeutic option for respiratory health.<sup>[16-17]</sup>

#### **East Indian globe thistle**

The extracts from the *Sphaeranthus indicus* plant, commonly known as East Indian Globe Thistle, have shown potential in preventing mast cell degranulation induced by compound 48/80 and sheep serum. In the sheep serum model, the ethanol extract at doses of 150 mg/kg and

300 mg/kg, along with the ethyl acetate extract at doses of 100 mg/kg, 150 mg/kg, and 300 mg/kg, demonstrated a slightly higher protective effect against mast cell degranulation (77-86%) compared to the standard drug ketotifen (75%). In further experiments, when peritoneal mast cells were exposed to compound 48/80, these extracts exhibited better mast cell stabilizing activity (77-88%) than ketotifen (69%). These findings suggest that *Sphaeranthus indicus* possesses notable mast cell stabilizing properties, effectively inhibiting the release of mediators from mast cells.<sup>[18]</sup>

### **Drumstick tree**

Over a three-week period, twenty participants diagnosed with mild-to-moderate asthma, regardless of gender, were given a daily dose of three grams of finely powdered dried seed kernels from the *Moringa* plant, commonly known as the drumstick tree. The clinical effectiveness was assessed by measuring symptoms and respiratory functions with a spirometer before and after the treatment. While there were no significant changes in blood parameters, a noticeable increase in hemoglobin levels and a decrease in the erythrocyte sedimentation rate were observed. Significant improvements in asthma attack severity and symptom scores were noted. After three weeks, there were substantial improvements in forced vital capacity, forced expiratory volume in one second, and peak expiratory flow rate, showing increases of 32.97%, 30.05%, and 32.09%, respectively. Importantly, no adverse effects were reported, suggesting that the *Moringa* seed kernels may have beneficial effects for individuals with bronchial asthma. In another study, the protective effects of the n-butanol extract (MONB) from *Moringa* on guinea pigs' airways exposed to ovalbumin-induced inflammation were explored. Before exposure, either dexamethasone or MONB was administered orally with aerosolized 0.5% ovalbumin. The results showed that the ovalbumin-sensitized guinea pigs had reduced tidal volume, increased respiratory rate, and higher cell counts in blood and bronchoalveolar lavage fluid. MONB treatment improved all these parameters, except for interleukin-4 and bronchoalveolar lavage tumor necrosis factor- $\alpha$ . MONB therapy also protected against acetylcholine-induced bronchoconstriction and airway inflammation, highlighting its anti-inflammatory benefits for respiratory health.<sup>[19,20]</sup>

### **Common olive**

This small, hardy tree typically reaches a height of 12 to 20 feet, with gray bark and stiff, silvery branches. The mature olive water extract has shown notable antiasthmatic effects, effectively preventing clonidine-induced peritoneal mast cell degranulation in rats and catalepsy in mice when administered at doses of 4 and 8 mg/kg. Furthermore, the extract offers protective properties against histamine-induced contractions in both the goat trachea and guinea pig ileum at a concentration of 100  $\mu$ g/mL. These results indicate that mature olive water extract could be a

promising therapeutic option for respiratory ailments, particularly asthma, by stabilizing mast cells and reducing histamine-induced reactions.<sup>[21]</sup>

### **Licorice**

Licorice (*Glycyrrhiza glabra*), a plant known for its medicinal properties, contains a significant active compound called glycyrrhizin. In a study examining the effects of glycyrrhizin, mice with ovalbumin (OVA)-induced asthma were treated with this compound, which is renowned for its potent anti-inflammatory effects. The study found that glycyrrhizin improved asthma symptoms, including enhanced airway responsiveness to methacholine, reduced airway constriction caused by OVA, and alleviated lung inflammation. A key observation was the significant decrease in eosinophil infiltration in the lungs, a marker of inflammation commonly associated with asthma. Beyond its anti-inflammatory effects, glycyrrhizin also demonstrates antiviral properties against various DNA and RNA viruses, including SARS-CoV-2. Both in vitro and in vivo studies have shown that glycyrrhizin can affect the replication, adsorption, and penetration of SARS-CoV-2, suggesting its potential as an adjunctive treatment for COVID-19. Recent findings indicate that glycyrrhizin might be used as a preventive measure against COVID-19 by targeting the upper respiratory tract. Studies suggest that glycyrrhizin could be applied to the nasal and oral cavities to help block the entry of the virus into cells, especially in areas such as the nasal and tongue epithelium, which are associated with the loss of smell and taste in COVID-19 patients. This application could potentially minimize the viral infection in the early stages and prevent the onset of more severe respiratory symptoms. Given its beneficial effects in both asthma and viral infections like COVID-19, glycyrrhizin shows promise as a versatile treatment for respiratory conditions.<sup>[22-26]</sup>

### **Indian banyan**

*Ficus bengalensis*, commonly known as the banyan tree, can grow up to 30 meters tall and is characterized by its numerous aerial roots that extend from its branches. Extracts from the bark of this tree, including ethanol, ethyl acetate, and aqueous extracts, as well as fractions derived from these, have been shown to possess antihistaminic properties. When administered at a dose of 50 mg/kg, these extracts can prevent clonidine-induced catalepsy in mice, a key indicator of their effectiveness. The antihistaminic activity of *F. bengalensis* extracts is likely attributed to the presence of flavonoids, which are believed to play a significant role in the observed effects. These findings suggest that *F. bengalensis* may have potential therapeutic uses, particularly in conditions related to histamine release, such as allergic reactions or asthma.<sup>[27,28]</sup>

### **Conclusion:**

The respiratory system plays a critical role in maintaining overall health, beyond just enabling breathing. Its functions, including immune defense, oxygen regulation, and its connection to mental health, emphasize the importance of maintaining respiratory wellness. With

the increasing prevalence of respiratory diseases like asthma, bronchitis, and infections, there is a growing need for effective treatments. While conventional therapies are widely used, they often come with limitations such as side effects, lack of long-term efficacy, and medication dependency. Herbal remedies offer a promising alternative, with many plants showing anti-inflammatory, antimicrobial, and immune-boosting properties that can help improve lung function and provide relief from symptoms. Natural treatments like Billygoat-weed, Moringa, and Licorice have demonstrated significant therapeutic potential, supporting respiratory health in a holistic manner. By combining traditional herbal knowledge with modern scientific research, these remedies can enhance conventional treatments, offering a safer and more sustainable approach to respiratory care. Ultimately, the integration of plant-based therapies into routine health practices could improve lung health, prevent respiratory disorders, and contribute to overall well-being.

### References:

1. Vigo, D., Thornicroft, G., & Atun, R. (2016). Estimating the true global burden of mental illness. *The Lancet Psychiatry*, 3(2), 171–178.
2. West, J. B. (2012). *Respiratory physiology: The essentials*. Lippincott Williams & Wilkins.
3. Bosch, A. A., Biesbroek, G., Trzcinski, K., Sanders, E. A., & Bogaert, D. (2013). Viral and bacterial interactions in the upper respiratory tract. *PLoS Pathogens*, 9(1), e1003057.
4. Bolton, C. F. (1994). Assessment of respiratory function in the intensive care unit. *Canadian Journal of Neurological Sciences*, 21(S1), S28–S34.
5. Rogan, M. (2017). Respiratory infections, acute. *International Encyclopedia of Public Health*, 332.
6. Pawankar, R. (2014). Allergic diseases and asthma: A global public health concern and a call to action. *World Allergy Organization Journal*, 7(1), 1–3.
7. Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2021). *Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease*. Retrieved from <https://goldcopd.org/gold-reports/>.
8. Nordling, E., Berglind, N., Melén, E., Emenius, G., Hallberg, J., Nyberg, F., *et al.* (2008). Traffic-related air pollution and childhood respiratory symptoms, function, and allergies. *Epidemiology*, 401–408.
9. Global Initiative for Asthma (GINA). (2021). *Global strategy for asthma management and prevention*. Retrieved from <https://ginasthma.org/gina-reports/>.
10. Slejko, J. F., Ghushchyan, V. H., Sucher, B., Globe, D. R., Lin, S. L., Globe, G., *et al.* (2014). Asthma control in the United States, 2008–2010: Indicators of poor asthma control. *Journal of Allergy and Clinical Immunology*, 133(6), 1579–1587.

11. Wedzicha, J. A., Miravittles, M., Hurst, J. R., Calverley, P. M., Albert, R. K., Anzueto, A., *et al.* (2017). Management of COPD exacerbations: A European respiratory society/American thoracic society guideline. *European Respiratory Journal*, 49(3), 1600791.
12. World Health Organization. (2014). *Antimicrobial resistance: Global report on surveillance*. Retrieved from <https://www.who.int/drugresistance/documents/surveillancereport/en/>.
13. Celli, B. R., Decramer, M., Wedzicha, J. A., Wilson, K. C., Agustí, A., Criner, G. J., *et al.* (2015). An official American Thoracic Society/European Respiratory Society statement: Research questions in chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, 191(7), e4–e27.
14. Barrett, B., Kiefer, D., & Rabago, D. (1999). Assessing the risks and benefits of herbal medicine: An overview of scientific evidence. *Alternative Therapies in Health and Medicine*, 5(4), 40.
15. Ernst, E. (2007). Herbal medicines: Balancing benefits and risks. In *Dietary Supplements and Health: Novartis Foundation Symposium 282* (Vol. 282, pp. 154–172). Chichester, UK: John Wiley & Sons, Ltd.
16. Ehi-Omosun, M. B., & Bello, J. (2023). Effects of aqueous leaf extract of *Ageratum conyzoides* on spray-paint-induced injury in the lungs of adult Wistar rats. *Journal of Applied Sciences and Environmental Management*, 27(4), 863–868.
17. Tote, M. V., Mahire, N. B., Jain, A. P., Bose, S., Undale, V. R., & Bhosale, A. V. (2009). Effect of *Ageratum conyzoides* Linn on clonidine and haloperidol-induced catalepsy in mice. *Pharmacologyonline*, 2, 186–194.
18. Mathew, J. E., Srinivasan, K. K., Dinakaran, V., & Joseph, A. (2009). Mast cell stabilizing effects of *Sphaeranthus indicus*. *Journal of Ethnopharmacology*, 122(2), 394–396.
19. Mahajan, S. G., Banerjee, A., Chauhan, B. F., Padh, H., Nivsarkar, M., & Mehta, A. A. (2009). Inhibitory effect of *n*-butanol fraction of *Moringa oleifera* Lam. seeds on ovalbumin-induced airway inflammation in a guinea pig model of asthma. *International Journal of Toxicology*, 28(6), 519–527.
20. Agrawal, B., & Mehta, A. (2008). Antiasthmatic activity of *Moringa oleifera* Lam: A clinical study. *Indian Journal of Pharmacology*, 40(1), 28.
21. Chandak, R., Devdhe, S., & Changediya, V. (2009). Evaluation of anti-histaminic activity of aqueous extract of ripe olives of *Olea europea*. *Journal of Pharmaceutical Research*, 2(3), 416–420.

22. Ram, A., Mabalirajan, U., Das, M., Bhattacharya, I., Dinda, A. K., Gangal, S. V., & Ghosh, B. (2006). Glycyrrhizin alleviates experimental allergic asthma in mice. *International Immunopharmacology*, 6(9), 1468–1477.
23. Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H., & Doerr, H. W. (2003). Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. *Lancet*, 361(9374), 2045–2046.
24. Chrzanowski, J., Chrzanowska, A., & Graboń, W. (2021). Glycyrrhizin: An old weapon against a novel coronavirus. *Phytotherapy Research*, 35(2), 629–636.
25. Cherry, G., Rocke, J., Chu, M., Liu, J., Lechner, M., Lund, V. J., & Kumar, B. N. (2020). Loss of smell and taste: A new marker of COVID-19? Tracking reduced sense of smell during the coronavirus pandemic using search trends. *Expert Review of Anti-Infective Therapy*, 18(11), 1165–1170.
26. Lao, W. P., Imam, S. A., & Nguyen, S. A. (2020). Anosmia, hyposmia, and dysgeusia as indicators for positive SARS-CoV-2 infection. *World Journal of Otorhinolaryngology-Head and Neck Surgery*, 6(S1), S22–S25.
27. Taur, D. J., & Nirmal, S. A., & Patil, R. Y. (2007). Effect of various extracts of *Ficus bengalensis* bark on clonidine and haloperidol-induced catalepsy in mice. *Pharmacologyonline*, 3, 470–477.
28. Taur, D. J., & Patil, R. Y. (2009). Effect of bio-fractions isolated from *Ficus bengalensis* bark on clonidine-induced catalepsy. *Journal of Pharmacy Research*, 2(11), 1676–1677.



# **EFFECTS OF RETRO WALKING TRAINING ON KINESIOPHOBIA AND COGNITION ON GERIATRIC POPULATION- QUASI-EXPERIMENTAL STUDY**

**Suruchi, P. Sathya\* and Feba Roy**

College of Physiotherapy, School of Health Sciences,  
Dayananda Sagar University, Devarakaggalahalli, Harohalli,  
Kanakpura road, Ramanagara Dt.-562112, Karnataka, India,

Corresponding author E-mail: [duttaroymoumita077@gmail.com](mailto:duttaroymoumita077@gmail.com), [drsathyagp@gmail.com](mailto:drsathyagp@gmail.com),  
[febaroy10@gmail.com](mailto:febaroy10@gmail.com)

## **Abstract:**

**Background:** Aging is associated with challenges like kinesiophobia and cognitive decline, which adversely affect the quality of life and increase fall risk in older adults. Retro-walking, a unique exercise involving backwards walking, has shown the potential to enhance balance and motor control. However, its impact on kinesiophobia and cognitive function in the elderly remains underexplored. This study investigates the effects of retro-walking training on reducing kinesiophobia and improving cognition in the geriatric population, aiming to provide a novel intervention strategy.

**Aim:** This study aimed to assess the effects of retro-walking training on kinesiophobia and cognition in geriatric subjects.

**Method:** A quasi-experimental design was employed with 36 geriatric participants aged 65-75. Pre-tests and post-tests for kinesiophobia and cognition were taken. The participants underwent retro-walking training thrice weekly for six weeks, complemented by home exercises. Kinesiophobia was assessed using the Tampa Scale of Kinesiophobia (TSK), and cognition was evaluated using the Montreal Cognitive Assessment (MoCA) scale.

**Result:** Significant improvements were observed in both TSK (pre:  $50.6 \pm 8.6$ , post:  $27.6 \pm 6.9$ ,  $p < 0.001$ ) and MoCA scores (pre:  $25.0 \pm 3.1$ , post:  $27.7 \pm 1.8$ ,  $p < 0.001$ ) post-intervention. The participants showed a marked reduction in kinesiophobia and enhanced cognitive function.

**Conclusion:** Retro-walking training significantly reduced kinesiophobia and enhanced cognition in geriatric subjects. These findings suggest that retro-walking can effectively improve functional outcomes and mitigate fall risks in the elderly population.

**Keywords:** Retro-Walking, Kinesiophobia, Cognition, Geriatric Population, Fall Prevention

## **1. Introduction:**

Aging is associated with a progressive decline in musculoskeletal strength, balance, and cognitive function, which significantly impacts mobility and independence in older adults.<sup>(1)</sup> One of the major psychological barriers to movement in the elderly population is kinesiophobia.<sup>(2)</sup>

Kinesiophobia, defined as an excessive and irrational fear of movement due to the anticipation of pain or injury, is prevalent among older adults. This fear can lead to avoidance behaviours, reduced physical activity, and increased risk of falls, which in turn can exacerbate physical decline and contribute to a cycle of immobility and dependency. <sup>(3,4)</sup>

Kinesiophobia not only reduces physical activity levels but also contributes to functional disability. <sup>(5)</sup> The Tampa Scale of Kinesiophobia (TSK) is a 17-item tool used to assess fear of movement and injury-related anxiety. Higher scores indicate greater kinesiophobia, leading to reduced mobility and increased fall risk. It is widely used in rehabilitation to monitor progress and guide interventions for improving movement confidence. <sup>(5,6)</sup>

Cognitive impairment is becoming more common among older adults, driven by the aging global population and the increasing prevalence of age-related neurodegenerative conditions such as Alzheimer's disease and other types of dementia. <sup>(7)</sup> Cognitive dysfunction in older adults poses significant personal, social, and economic challenges, with the WHO projecting that dementia cases will triple to 152 million by 2050, while global costs are expected to exceed \$2 trillion by 2030. <sup>(8,9)</sup> The Montreal Cognitive Assessment (MoCA) is a widely used tool for assessing cognitive function, especially for detecting mild cognitive impairment (MCI) and early dementia. It evaluates various cognitive domains, including memory, attention, language, and executive function, providing a quick and reliable screening method in clinical and research settings. <sup>(10)</sup>

However, regular physical activity, cognitive stimulation, and targeted interventions can help maintain mobility, independence, and overall well-being in older adults. Retro-walking, or backward walking, is a unique locomotor activity that challenges balance, coordination, and proprioception. Retro-walking has been studied for its unique neuromuscular benefits. Unlike forward walking, retro walking demands greater proprioceptive feedback, postural adjustments, and neuromuscular control, which may contribute to improved balance and coordination. <sup>(11,12)</sup>

Studies have demonstrated that retro-walking increases quadriceps activation and enhances dynamic stability, making it a valuable tool for rehabilitation in older adults with gait and balance impairments. <sup>(13)</sup> Furthermore, emerging evidence suggests that retro walking may have cognitive benefits as well. The dual-task nature of retro walking, which requires constant motor-cognitive integration, may play a role in preventing cognitive decline in the elderly. <sup>(14)</sup>


Given the link between movement-based interventions and cognitive function, retro walking may offer a novel therapeutic strategy to simultaneously improve kinesiophobia and cognition in the geriatric population

## **2. Materials and Methods**

### **2.1 Study procedure**

This quasi-experimental study was conducted on 36 geriatric participants aged 65-75 years, recruited from a community center using simple convenience sampling. The inclusion

criteria required participants to be independently ambulatory with a Berg Balance Scale (BBS) score between 35-45, while individuals with severe visual impairment, neurological conditions (e.g., Parkinson’s disease, multiple sclerosis, peripheral neuropathy), shoulder pathologies, vertigo/dizziness, or Mini-Mental State Examination (MMSE) scores below 21 were excluded. Prior to the study, ethical clearance was obtained, and the trial was registered with the Clinical Trials Registry-India (CTRI/2024/05/084668). Eligible participants were informed about the purpose and procedure of the study, and written informed consent was obtained before allocation. The subjects were then conveniently assigned to receive retro-walking training for a total duration of six weeks (three days per week). [Fig.1]



**Figure 1: Flowchart (Methodology)**

**Sample size calculation:**

The sample size was estimated using the formula for a **Paired “t” test**: Where,

- **Significance level ( $\alpha$ ) = 5%**
- **Effect size ( $\Delta$ ) = 0.5**
- **Power ( $1 - \beta$ ) = 80%**

Applying these values, the estimated sample size was **33**, and accounting for **10% anticipated dropouts**, the final sample size was determined as **36 participants**.

## Intervention

Participants performed retro-walking three times a week for six weeks, totaling 18 supervised sessions. Each session lasted 30 minutes, including 4-minute retro-walking sets with 5-minute rest intervals. Under professional supervision, participants walked backward on a flat surface, maintaining a steady pace to prevent falls. The intensity was progressively increased as they gained confidence and proficiency. Additionally, they were encouraging to continue practice outside of supervised sessions at home. [Fig 2 &3]



**Figure 2: Track for Retro Walking Figure 3: Retro Walking Training**

## 2.2 Assessment tools

### 2.2.1 Kinesiophobia assessment

Kinesiophobia was assessed using the Tampa Scale of Kinesiophobia (TSK). This validated questionnaire measures the fear of movement and re-injury. The TSK score ranges from 17 to 68, with higher scores indicating greater kinesiophobia.

### 2.2.2 Cognitive assessment

Cognitive function was evaluated using the Montreal Cognitive Assessment (MoCA) scale, which assesses various cognitive domains, including memory, attention, language, and executive functions. The MoCA score ranges from 0 to 30, with higher scores indicating better cognitive performance.

## 3. Statistical analysis

The collected data were summarized by using the Descriptive Statistics: frequency, percentage; mean and S.D. The Paired “t” test was used for the pre to post-test comparison of TSK and MoCA. The Independent sample “t” test was used to compare age, TSK and MoCA according to gender. To find the relation between age, TSK and MoCA; The Pearson correlation coefficient (“r”) was used. The p value < 0.05 was considered as significant. Data were analyzed by using the SPSS software (SPSS Inc.; Chicago, IL) version 29.0.10.

#### 4. Results

**Table 1: Descriptive Statistics for Age**

(n = 36)	Range	Mean	S.D.
Age (Years)	65 to 75	71.1	3.5

Note: The age distribution of participants falls between 65 and 75 years, with a mean age of 71.1 years and a standard deviation of 3.5 years.

**Table 2: Gender distribution**

(n = 36)		Frequency	%
Gender	Male	17	47.2
	Female	19	52.8

Note: The study sample consists of 47.2% male and 52.8% female participants, ensuring a balanced gender representation.

**Table 3: Comparison of age according to gender**


		Mean	S.D.	"t"	p value
Age (Years)	Male	70.5	3.6	-0.84	0.405
	Female	71.5	3.5		

Note: ("t" = Independent sample "t" test) The Independent sample "t" test was used to compare age according to gender. There was no difference ( $p > 0.05$ ) in age between males and females. [Table – 3]

**Table 4: Pre to post-test comparison of TSK and MoCA**

		Mean	S.D.	"t"	p value
TSK	Pre-test	50.6	8.6	18.83	< 0.001*
	Post-test	27.6	6.9		
MoCA	Pre-test	25.0	3.1	-8.50	< 0.001*
	Post-test	27.7	1.8		

Note: The paired t-test indicated a significant difference ( $p < 0.05$ ) in both TSK and MoCA scores from pre-test to post-test. [Table – 4]



**Figure 4: Effectiveness in TSK and MoCA**

**Table 5: Comparison of TSK and MoCA according to gender**

		Pre-test				Post-test			
		Mean	S.D.	"t"	p value	Mean	S.D.	"t"	p value
TSK	Male	49.4	8.5	-0.80	0.428	25.8	5.5	-1.58	0.124
	Female	51.7	8.8			29.3	7.7		
MoCA	Male	25.9	3.1	1.74	0.091	28.5	1.7	2.73	0.010*
	Female	24.2	2.8			27.0	1.5		

Note: There was no significant difference ( $p > 0.05$ ) in TSK and MoCA scores between males and females during pre-test. However, a significant difference ( $p < 0.05$ ) was found in MoCA scores during post-test. [Table – 5]

**Table 6: Relation between TSK and MoCA**

		MoCA	
		Pre-test	Post-test
TSK	"r"	-0.292	-0.381
	pvalue	0.084	0.022*

Note: There was no significant correlation ( $p > 0.05$ ) between TSK and MoCA during the pre-test. However, a positive correlation ( $p < 0.05$ ) was found during the post-test.[Table – 6]

**Table 7: Relation between age, TSK and MoCA**

		Age (Years)	
		Pre-test	Post-test
TSK	"r"	0.272	0.131
	p value	0.109	0.445
MoCA	"r"	0.043	0.067
	p value	0.805	0.696

Note: There was no significant correlation ( $p > 0.05$ ) between age, TSK, and MoCA in both pre-test and post-test conditions. [Table – 7]

### 3. Discussion:

The present study aimed to evaluate the effects of retro-walking training on kinesiophobia and cognition in the geriatric population. The findings revealed a significant reduction in kinesiophobia, as assessed by the Tampa Scale of Kinesiophobia (TSK), and a notable improvement in cognitive function, as measured by the Montreal Cognitive Assessment (MoCA). These results align with previous research emphasizing the benefits of physical exercise in reducing fear of movement and enhancing cognitive performance among older adults.

(15)

#### Impact of retro-walking on Kinesiophobia

Kinesiophobia, or the fear of movement due to pain or injury, is a significant concern in older adults, often leading to reduced physical activity and an increased risk of falls.<sup>(16)</sup> In this

study, retro-walking training resulted in a substantial decrease in TSK scores from pre-test ( $50.6 \pm 8.6$ ) to post-test ( $27.6 \pm 6.9$ ) with a highly significant p-value ( $< 0.001$ ). These results support the notion that structured physical training can improve confidence in movement and reduce fear-avoidance behaviors. <sup>(17)</sup>

Retro-walking may provide a unique neuromuscular challenge by engaging different motor pathways compared to forward walking. Prior studies suggest that balance-focused interventions improve movement confidence and reduce kinesiophobia. <sup>(18)</sup> The present study's findings extend these observations by demonstrating that retro-walking, which demands greater postural control and proprioception, can lead to similar or even enhanced outcomes in mitigating kinesiophobia.

### **Effect of retro-walking on cognitive function**

Cognitive decline is a major concern in the geriatric population, with physical exercise being a well-established intervention for cognitive preservation. <sup>(19)</sup> The significant improvement in MoCA scores from pre-test ( $25.0 \pm 3.1$ ) to post-test ( $27.7 \pm 1.8$ ) ( $p < 0.001$ ) suggests that retro-walking positively influences cognitive function.

Previous research has indicated that engaging in dual-task exercises, such as walking while maintaining balance, stimulates cognitive processing and enhances executive function. <sup>(20, 21)</sup> Retro-walking demands increased attention and coordination, potentially explaining the observed cognitive improvements. Studies by Jia-You *et al.* (2024) have demonstrated that utilizing virtual reality-based training to enhance cognitive function, instrumental activities of daily living, and neural efficiency in older adults with mild cognitive impairment. <sup>(22)</sup>

### **Gender-based differences**

While no significant differences in TSK and MoCA scores were observed between males and females in the pre-test phase, post-test results showed a significant improvement in MoCA scores among males compared to females ( $p = 0.010$ ). This finding suggests that men may derive greater cognitive benefits from retro-walking training, possibly due to differences in baseline physical activity levels or neuroplasticity responses. <sup>(23)</sup>

However, the lack of significant differences in TSK improvements between genders highlights that both males and females benefited equally in reducing kinesiophobia.

### **Correlation between Kinesiophobia and cognitive function**

A noteworthy aspect of this study was the positive correlation between TSK and MoCA scores during the post-test phase ( $p = 0.022$ ). This finding aligns with previous studies indicating that reduced fear of movement is associated with enhanced cognitive function (Callisaya *et al.*, 2020).<sup>(24)</sup> The mechanism underlying this relationship may involve improved neuroplasticity due to increased physical activity and reduced psychological distress. <sup>(25,26)</sup>

### **Age and its relation to kinesiophobia and cognition**

No significant correlation was found between age and TSK or MoCA scores in both pre-test and post-test conditions. This suggests that the observed benefits of retro-walking training were independent of age within the 65–75-year range. These findings are consistent with research indicating that cognitive and psychological benefits from physical exercise are not strictly age-dependent but rather influenced by the nature and consistency of the intervention (Mandolesi *et al.*, 2018).<sup>(27)</sup>

### **Conclusion:**

The findings of this study demonstrate that retro-walking training is an effective intervention for reducing kinesiophobia and improving cognitive function in older adults. The improvements observed in TSK and MoCA scores suggest that retro-walking may serve as a viable therapeutic strategy for enhancing both psychological and cognitive well-being in the geriatric population. Future research with larger sample sizes and long-term follow-up is warranted to further explore the potential benefits of retro-walking and its applicability in different clinical settings.

### **Acknowledgments:**

The authors would like to thank the participants for their involvement in the study. Special thanks to Dayananda Sagar University College of Physiotherapy for providing the facilities and resources needed to conduct the research.

### **References:**

1. Patel, K., *et al.* (2020). Aging and physical decline: A review of factors influencing functional mobility. *Journal of Aging Research*, 2020, 1–12.
2. Chua, S. K. K., Lim, C. J., Pua, Y., Yang, S. Y., & Tan, B. Y. (2024). Is kinesiophobia associated with quality of life, level of physical activity, and function in older adults with knee osteoarthritis? *Clinical Orthopaedics and Related Research*. <https://doi.org/10.1097/CORR.0000000000003278>
3. Varughese, S. S. (2023). Effectiveness of forward walking and retro walking on balance and walking speed in the geriatric population. *International Journal of Research in Medical Sciences*, 11(Dec 2022).
4. Perry, W., Lacritz, L., Roebuck-Spencer, T., Silver, C., Denney, R. L., & Meyers, J., *et al.* (2018). Population health solutions for assessing cognitive impairment in geriatric patients. *Archives of Clinical Neuropsychology*, 33(6), 655–675.
5. Rosenblum, D. J., & Resch, J. E. (2024). The influence of kinesiophobia on time to clinical recovery in collegiate athletes with concussion. *Sports Medicine*. <https://doi.org/10.1007/s40279-024-02144-8>
6. Sharif Nia, H., Sivarajan Froelicher, E., Hosseinzadeh, E., Hejazi, S., Fatehi, R., & Nowrozi, P. (2024). Psychometric and network analysis of kinesiophobia in Iranian



- surgical patients. *Dental Sciences Reports*, 14(1). <https://doi.org/10.1038/s41598-024-78407-1>
7. Naugle, K. M., Blythe, C., Naugle, K. E., Keith, N., & Riley, Z. A. (2022). Kinesiophobia predicts physical function and physical activity levels in chronic pain-free older adults. *Frontiers in Pain Research*, 3, 874205. <https://doi.org/10.3389/fpain.2022.874205>
  8. Ganiyani, M. A., Shah, P. R., Shah, S., Joshi, R., Ashokkumar, C., & Chordia, A. (2023). Managing cognitive dysfunction in geriatric populations: A multidisciplinary approach. *International Journal of Geriatrics and Gerontology*, 6(1). <https://doi.org/10.29011/2577-0748.100051>
  9. World Health Organization. (2012). *Dementia: A public health priority*. Geneva, Switzerland: WHO.
  10. Mykhailichenko, M. O. (2024). Using the Montreal Cognitive Assessment for diagnosing cognitive impairments in neurologist practice: A review. *Ukrainian Neurology Journal*, 2–3, 14–16. <https://doi.org/10.30978/unj2024-2-3-14>
  11. Wimo, A., Guerchet, M., Ali, G. C., Wu, Y. T., Prina, A. M., *et al.* (2017). The worldwide costs of dementia 2015 and comparisons with 2010. *Alzheimer's & Dementia*, 13, 1–7.
  12. Anantha Jyothi, P. S. V. V., Apparao, P., Swamy, G., Chaturvedhi, P., & Mounika, R. G. (2024). Effectiveness of forward and retro walking in subjects with osteoarthritis of the knee: A comparative study. *Journal of Dry SRUHS*, 13(3), 231–235. [https://doi.org/10.4103/jdrysrhuhs.jdrysrhuhs\\_67\\_20](https://doi.org/10.4103/jdrysrhuhs.jdrysrhuhs_67_20)
  13. Nallasamy, A., Arumugam, L., Mohd Zaidi, S. N., Yee, L. P., & Purushothaman, V. K. (2024). The impact of treadmill retro walking on hamstring flexibility and speed in distance runners. *International Journal of Physiotherapy*. <https://doi.org/10.61453/intij.202431>
  14. Kim, J., *et al.* (2015). Effects of backward walking on balance and muscle activity in elderly individuals. *Journal of Geriatric Rehabilitation*, 22(3), 214–220.
  15. Wei, J., Lohman, M. C., Brown, M. J., Hardin, J. W., Xu, H., & Yang, C. H., *et al.* (2024). Physical activity initiated from midlife on risk of dementia and cognitive impairment: The Health and Retirement Study. *Journal of the American Geriatrics Society*. <https://doi.org/10.1111/jgs.19109>
  16. Indrakumar, J., & Silva, S. (2024). Physical activity in older adults: A review of the benefits and recommendations for promoting healthy aging through exercise. *Journal of the Indian Academy of Geriatrics*, 20(4), 207–213. [https://doi.org/10.4103/jiag.jiag\\_49\\_24](https://doi.org/10.4103/jiag.jiag_49_24)
  17. Goubran, M., Farajzadeh, A., Lahart, I. M., Bilodeau, M., & Boisgontier, M. P. (2023). Kinesiophobia and physical activity: A systematic review and meta-analysis. *medRxiv*. <https://doi.org/10.1101/2023.08.17.23294240>

18. Gurudut, P., Patel, R., Mukkannavar, P., & Vira, P. (2019). Effect of retro-walking on treadmill on hamstring flexibility, gait, kinesiophobia, and psychometry in individuals with chronic knee osteoarthritis. *Indian Journal of Physiotherapy Research*, 1(2), 93–99. [https://doi.org/10.4103/ijptr.ijptr\\_29\\_19](https://doi.org/10.4103/ijptr.ijptr_29_19)
19. Erickson, K. I., Leckie, R. L., & Weinstein, A. M. (2019). Physical activity, fitness, and gray matter volume. *Neurobiology of Aging*, 84, 166–180.
20. Zhou, Q., Yang, H., Zhou, Q., & Pan, H. (2021). Effects of cognitive motor dual-task training on stroke patients: A RCT-based meta-analysis. *Journal of Clinical Neuroscience*, 92, 175–182. <https://doi.org/10.1016/j.jocn.2021.08.009>
21. Ali, N., Tian, H., Thabane, L., *et al.* (2022). The effects of dual-task training on cognitive and physical functions in older adults with cognitive impairment: A systematic review and meta-analysis. *Journal of Prevention of Alzheimer's Disease*, 9, 359–370. <https://doi.org/10.14283/jpad.2022.16>
22. Ye, J. Y., Chen, R., Chu, H., Lin, H. C., Liu, D., Jen, H. J., Banda, K. J., Kustanti, C. Y., & Chou, K. R. (2024). Dual-task training in older adults with cognitive impairment: A meta-analysis and trial sequential analysis of randomized controlled trials. *International Journal of Nursing Studies*, 155, 104776.
23. Cortes, C. J., & De Miguel, Z. (2022). Precision exercise medicine: Sex-specific differences in immune and CNS responses to physical activity. *Brain Plasticity*, 8(1), 65–77. <https://doi.org/10.3233/BPL-220139>
24. Callisaya, M. L., Beare, R., Phan, T. G., *et al.* (2020). Brain structural change and gait decline: A longitudinal population-based study. *Journal of Gerontology: Biological Sciences and Medical Sciences*, 75(9), 1922–1929.
25. Nagamatsu, L. S., Chan, A., Davis, J. C., Beattie, B. L., Graf, P., Voss, M. W., Sharma, D., & Liu-Ambrose, T. (2013). Physical activity improves verbal and spatial memory in older adults with probable mild cognitive impairment: A 6-month randomized controlled trial. *Journal of Aging Research*, 2013, 861893. <https://doi.org/10.1155/2013/861893>
26. Ten Brinke, L. F., Bolandzadeh, N., Nagamatsu, L. S., *et al.* (2015). Aerobic exercise increases hippocampal volume in older women with probable mild cognitive impairment: A 6-month randomized controlled trial. *British Journal of Sports Medicine*, 49(4), 248–254. <https://doi.org/10.1136/bjsports-2013-093184>
27. Mandolesi, L., Polverino, A., Montuori, S., *et al.* (2018). Effects of physical exercise on cognitive functioning and wellbeing: Biological and psychological benefits. *Frontiers in Psychology*, 9, 509. <https://doi.org/10.3389/fpsyg.2018.00509>

## **CLINICAL PHARMACISTS IN PERSONALIZED ONCOLOGY: OPTIMIZING TARGETED THERAPIES**

**Rajesh Hadia**

Department of Pharmacy,

Sumandeep Vidyapeeth Deemed to be University, Vadodara-391760, Gujarat, India.

Corresponding author E-mail: [docrajesh.hadia@gmail.com](mailto:docrajesh.hadia@gmail.com)

### **Abstract:**

The shift towards personalized oncology has transformed cancer treatment by moving away from a uniform approach to one that tailors therapy based on the molecular profile of tumors. This transformation has been fueled by advancements in genomic technologies, biomarker identification, and targeted therapies, allowing for more precise and effective treatment strategies. Clinical pharmacists play a crucial role in ensuring the safe and effective implementation of personalized oncology by optimizing medication therapy management (MTM), facilitating pharmacogenomic testing, and monitoring treatment responses. Personalized oncology relies on molecular characterization techniques such as next-generation sequencing (NGS), which enable the identification of actionable mutations and guide the selection of targeted therapies. These therapies, including monoclonal antibodies and tyrosine kinase inhibitors, selectively target molecular pathways crucial for tumor survival while minimizing damage to normal cells. Despite their advantages, targeted therapies present challenges such as resistance mechanisms, adverse drug reactions, and complex pharmacokinetic interactions, necessitating the expertise of clinical pharmacists in monitoring and managing drug-related toxicities. Pharmacists play a vital role in patient education, adherence management, and interdisciplinary collaboration with oncologists and genetic counselors. They also contribute to precision medicine by incorporating pharmacogenomic data into clinical decision-making, ensuring that drug selection and dosing are tailored to an individual's genetic makeup. Furthermore, artificial intelligence (AI)-driven clinical decision-support systems are enhancing pharmacists' ability to integrate vast amounts of genomic and clinical data, thereby improving treatment optimization and patient outcomes. Challenges in personalized oncology include the high cost of genetic testing and targeted therapies, ethical considerations surrounding genetic data privacy, and disparities in access to precision medicine. Addressing these challenges requires a multidisciplinary approach involving healthcare professionals, policymakers, and researchers to improve affordability, accessibility, and ethical implementation. Looking ahead, the evolving landscape of personalized oncology will continue to expand with advancements in biomarker discovery, novel drug development, and the increasing integration of clinical pharmacists in oncology teams. Their role will be instrumental in bridging the gap between

cutting-edge molecular oncology and individualized patient care, ultimately enhancing treatment efficacy, minimizing toxicities, and improving survival outcomes for cancer patients.

**Keywords:** Personalized Oncology, Clinical Pharmacists, Targeted Therapy, Pharmacogenomics, Precision Medicine, Molecular Profiling, Medication Therapy Management, Biomarker-Driven Treatment, Adverse Drug Reactions, Patient-Centered Care.

### **Introduction:**

#### **The Rise of Personalized Oncology and the Expanding Role of Clinical Pharmacists:**

The landscape of cancer treatment is undergoing a dramatic transformation, shifting from a generalized approach to a highly personalized strategy known as personalized oncology or precision medicine in oncology [1], [2]. This paradigm shift is driven by a deeper understanding of the molecular heterogeneity of cancer, recognizing that tumors are not monolithic entities but rather complex systems with unique genetic and molecular profiles [3], [4]. This heterogeneity dictates that a “one-size-fits-all” approach to treatment is often ineffective and can lead to suboptimal outcomes, including treatment resistance and increased toxicity [4], [5]. The advent of targeted therapies, designed to selectively inhibit specific molecules or pathways crucial for tumor growth and survival, has been instrumental in realizing the promise of personalized oncology [6], [7], [8]. These therapies, unlike conventional cytotoxic chemotherapies that target rapidly dividing cells indiscriminately, focus on the unique molecular characteristics of the cancer, thereby minimizing harm to healthy tissues [6]. Central to the success of personalized oncology is the evolving role of clinical pharmacists [9], [10], [11]. Their expertise in medication therapy management (MTM) extends beyond simple dispensing; it encompasses a comprehensive approach to medication optimization, encompassing medication selection, procurement, storage, preparation, dispensing, administration, monitoring, and patient education [9]. Within the context of precision oncology, this expertise is paramount in navigating the complexities of targeted therapies, ensuring optimal efficacy, and minimizing the potential for adverse events [12], [13], [14]. The ability to personalize treatment regimens based on individual patient characteristics, including genetic predisposition, comorbidities, and potential drug interactions, is a core component of the clinical pharmacist’s contribution [4], [15], [16]. This collaborative role, working in conjunction with oncologists and other members of the healthcare team, is vital in achieving optimal patient outcomes and maximizing the benefits of targeted therapies [12], [13], [14].

#### **Fundamentals of Personalized Oncology: Deciphering the Tumour’s Molecular Blueprint:**

The cornerstone of personalized oncology is the detailed characterization of the tumour’s molecular profile [3], [4], [17]. This involves employing a range of advanced technologies to identify the specific genetic alterations and molecular pathways driving the cancer’s growth and progression [18], [19], [20]. Next-generation sequencing (NGS), a high-throughput technology

capable of analyzing an entire genome or specific gene panels simultaneously, has revolutionized our ability to achieve this level of molecular characterization [18]. NGS allows for the identification of various actionable genomic alterations, including point mutations, gene fusions, copy number variations, and microsatellite instability (MSI) [8], [5], [21]. These alterations can be used to identify specific targets for targeted therapies, allowing for the selection of the most appropriate treatment strategy for each patient [8], [5], [21]. Furthermore, the analysis of gene expression patterns using techniques like microarrays or RNA sequencing can provide additional insights into the tumour's biology and potential therapeutic vulnerabilities [22], [23]. Biomarkers, measurable indicators of biological processes or disease states, are essential tools in guiding targeted therapy selection and predicting treatment response [24], [25], [18]. Prognostic biomarkers provide information about the likely outcome of the disease, irrespective of treatment, while predictive biomarkers indicate the likelihood of response to a specific treatment [24]. The identification and validation of reliable biomarkers are crucial for the successful implementation of personalized oncology [24], [25], [18]. Examples of clinically relevant biomarkers include mutations in genes such as EGFR, KRAS, BRAF, ALK, and HER2, which are frequently targeted in various cancer types [8], [26], [19]. The use of biomarkers in conjunction with genetic profiling allows for a more precise and effective selection of targeted therapies, maximizing the chances of a positive clinical response and minimizing the risk of adverse events [8], [26], [19].

### **Targeted Cancer Therapies: A Precision Arsenal Against Cancer:**

Targeted cancer therapies have emerged as a transformative approach in oncology, offering enhanced efficacy with reduced toxicity compared to conventional cytotoxic chemotherapies [6], [7], [8]. These therapies function by selectively inhibiting specific molecular pathways crucial for tumor growth, survival, and metastasis, minimizing collateral damage to healthy tissues [6]. The development and clinical application of targeted therapies have significantly improved outcomes across various cancer types, particularly in malignancies with well-characterized molecular drivers. One of the most widely used classes of targeted therapies is monoclonal antibodies (mAbs), which are engineered proteins designed to bind specific tumor antigens, either directly inducing cancer cell death or modulating immune responses [6]. Examples include trastuzumab (Herceptin), which targets HER2 in HER2-positive breast cancer, and cetuximab (Erbix), an epidermal growth factor receptor (EGFR) inhibitor used in colorectal and head and neck cancers [4], [26]. These biologics have revolutionized cancer treatment by providing specificity and durability in response compared to traditional chemotherapy. Another crucial class is small-molecule inhibitors, which are synthetic compounds that interfere with essential intracellular signaling pathways involved in tumor progression [6]. These include tyrosine kinase inhibitors (TKIs), which target receptor tyrosine

kinases (RTKs), critical enzymes that regulate cell growth and proliferation [8], [19], [28]. Notable examples are imatinib (Gleevec), which inhibits BCR-ABL fusion protein in chronic myeloid leukemia (CML) [27], and erlotinib (Tarceva), an EGFR inhibitor used in non-small cell lung cancer (NSCLC) [26]. By selectively inhibiting oncogenic signaling cascades, TKIs have dramatically improved survival rates and quality of life for patients with specific genetic mutations. The introduction of targeted therapies has led to a paradigm shift in cancer management, where molecular diagnostics and biomarker-driven treatment strategies guide therapeutic decisions [18], [4], [17]. The FDA has approved a growing number of targeted agents, reflecting the rapid progress in understanding oncogenic pathways and resistance mechanisms [18]. However, challenges remain, including acquired resistance, adverse effects such as cardiotoxicity and dermatologic reactions, and the high cost of these therapies [6], [7]. Despite these challenges, ongoing research aims to refine targeted therapy approaches by integrating next-generation sequencing (NGS) for patient stratification, developing combination regimens to overcome resistance, and leveraging immunotherapy for synergistic effects [18], [4]. Future advancements are likely to further personalize treatment, ensuring precision medicine continues to improve cancer care while minimizing toxicity. The role of clinical pharmacists in this evolving landscape is critical, as they contribute to optimizing drug selection, managing therapy-associated toxicities, and ensuring patient adherence to complex treatment regimens [8], [19].

### **The Role of Clinical Pharmacists in Personalized Oncology: Guardians of Safe and Effective Therapy:**

Clinical pharmacists are integral to the successful implementation of personalized oncology, acting as crucial intermediaries between complex molecular data and individualized patient care [9], [10], [11]. Their comprehensive MTM expertise extends beyond traditional medication dispensing to encompass a wide range of activities crucial for optimizing targeted therapies [9]. This includes meticulous medication selection, considering patient-specific factors such as genetic variations, comorbidities, and potential drug interactions [4], [15], [16]. They are responsible for procurement and verification of medications, ensuring the timely availability of often-specialized or off-label agents frequently used in precision oncology [11], [29]. Pharmacists also play a critical role in preparing and dispensing medications, adhering to strict protocols to ensure accuracy and safety [9]. The clinical pharmacist's role extends significantly beyond medication preparation and dispensing. They actively participate in monitoring patients for adverse events associated with targeted therapies [12], [14], [30]. This requires a deep understanding of the pharmacodynamics and pharmacokinetics of each agent, allowing for the early identification of potential problems and the implementation of timely interventions [4], [27]. Pharmacists collaborate closely with oncologists and other members of the healthcare team,

participating in MTBs to ensure that treatment plans are tailored to individual patient needs [11], [29], [31]. This collaborative approach enhances communication, facilitates the integration of complex molecular data into treatment decisions, and ensures the optimal management of patient care [11], [29], [31].

**Pharmacogenomics in Oncology Practice: The Genetic Underpinnings of Drug Response:**

Pharmacogenomics, the study of how an individual's genetic makeup influences their response to drugs, is increasingly integrated into personalized oncology [24], [15], [32]. Genetic variations can significantly alter a patient's metabolism of drugs, their sensitivity to targeted therapies, and their susceptibility to adverse drug reactions [33], [34], [35]. Therefore, incorporating pharmacogenomic testing into clinical practice can significantly improve treatment outcomes by enhancing efficacy and minimizing toxicity [36], [37], [38]. Several clinically relevant examples of gene-drug interactions highlight the importance of pharmacogenomics in oncology [33], [34], [35]. Variations in the UGT1A1 gene, which encodes an enzyme involved in the metabolism of irinotecan, can lead to increased risk of severe neutropenia [33], [36]. Similarly, variations in the DPYD gene, which encodes an enzyme involved in the metabolism of 5-fluorouracil, can result in increased toxicity [36], [37]. Knowing a patient's genotype for these genes allows clinicians to adjust drug dosing or select alternative therapies, thereby preventing potentially life-threatening adverse events [36], [37]. Clinical pharmacists are instrumental in interpreting and applying pharmacogenomic test results, working collaboratively with oncologists to make informed treatment decisions that are tailored to each individual's genetic profile [15], [16], [39].

**Pharmacogenomics in Oncology Practice: The Genetic Underpinnings of Drug Response:**

Pharmacogenomics, the study of how an individual's genetic profile influences their response to medications, is increasingly becoming a cornerstone of personalized oncology [24], [15], [32]. By identifying genetic variations that affect drug metabolism, efficacy, and toxicity, pharmacogenomic testing enables oncologists and clinical pharmacists to tailor treatments for optimal therapeutic outcomes. This approach minimizes adverse drug reactions and enhances the precision of cancer therapy, leading to improved patient safety and effectiveness of treatment regimens [33], [34], [35]. One of the most critical applications of pharmacogenomics in oncology is optimizing the use of chemotherapeutic and targeted agents based on patient-specific genetic factors. Genetic polymorphisms in drug-metabolizing enzymes, transporters, and receptors can significantly impact drug efficacy and toxicity profiles [33], [34], [35]. For instance, variations in the UGT1A1 gene, which encodes an enzyme responsible for the metabolism of irinotecan, have been linked to an increased risk of severe neutropenia, a potentially life-threatening condition [33], [36]. Similarly, polymorphisms in the DPYD gene, which encodes dihydropyrimidine dehydrogenase (DPD), an enzyme involved in the metabolism

of 5-fluorouracil (5-FU), can lead to severe toxicity in patients with reduced DPD activity [36], [37]. Identification of these genetic variants allows for dose adjustments or the selection of alternative therapies, thereby preventing adverse events and improving treatment safety [36], [37]. Pharmacogenomic testing also plays a crucial role in targeted therapy selection. Variations in genes encoding tyrosine kinase receptors, such as EGFR, ALK, and BRAF, determine the likelihood of response to targeted therapies, such as EGFR inhibitors (erlotinib and gefitinib) in non-small cell lung cancer (NSCLC) and BRAF inhibitors (vemurafenib) in melanoma [36], [37]. Additionally, genetic alterations in TPMT (thiopurine methyltransferase) and NAT2 (N-acetyltransferase 2) influence patient responses to thiopurine and platinum-based chemotherapies, respectively, further emphasizing the necessity of genetic screening in clinical practice [38], [39]. The integration of pharmacogenomics into oncology practice requires multidisciplinary collaboration, with clinical pharmacists playing a pivotal role in interpreting genetic test results and incorporating them into patient-specific treatment plans. Their expertise in medication therapy management (MTM) ensures that pharmacogenomic data is effectively translated into actionable clinical decisions, helping to optimize drug dosing, monitor potential drug interactions, and manage adverse effects [15], [16], [39]. Moreover, pharmacists contribute to patient education, counseling individuals on the significance of genetic testing and adherence to personalized treatment regimens [33], [34]. Despite its significant potential, challenges remain in the widespread implementation of pharmacogenomics, including high costs, limited accessibility, and ethical considerations surrounding genetic testing and data privacy [36], [37]. As research advances and genomic technologies become more affordable, the integration of pharmacogenomics into routine oncology practice will continue to expand, offering a new era of precision medicine with improved patient outcomes and reduced treatment-related toxicities [38], [39].

### **Monitoring and Managing Drug Toxicities: Proactive Strategies for Patient Safety:**

Targeted therapies, while offering significant advantages over traditional chemotherapies, are not without the potential for adverse effects [4], [15], [27]. The range of toxicities varies depending on the specific agent and the patient's individual characteristics, but they can significantly impact a patient's quality of life, necessitate dose adjustments, or even lead to treatment discontinuation [37], [36], [40]. Therefore, rigorous monitoring and proactive management strategies are crucial for ensuring patient safety and maximizing treatment benefits [4], [15], [27]. Clinical pharmacists play a pivotal role in this process [12], [14]. Their expertise in pharmacokinetics and pharmacodynamics allows for early identification of potential toxicities, often before they become clinically significant [4], [27]. This enables the timely implementation of interventions, such as dose reductions or supportive care measures, to mitigate the severity of adverse effects [36], [40], [16]. Pharmacists work closely with oncologists and other healthcare



providers to develop and implement individualized management plans for common toxicities, such as neutropenia, nausea, vomiting, diarrhea, fatigue, and skin rashes [12], [14], [30]. Furthermore, they provide education and support to patients, empowering them to recognize and manage potential side effects and enhancing their adherence to the treatment regimen [41], [4]. Clinical case studies demonstrate the effectiveness of pharmacist-led interventions in preventing and managing toxicities associated with targeted therapies [30].

### **Clinical Decision Support and AI in Oncology Pharmacy: Harnessing Technology for Personalized Care:**

The increasing complexity of personalized oncology, with its vast amounts of data generated by genomic profiling, biomarker analysis, and clinical observations, necessitates the development of sophisticated clinical decision-support systems [42], [10], [31]. AI and machine learning are emerging as powerful tools to analyze this complex information, providing clinicians with evidence-based recommendations for personalized treatment strategies [30], [11], [29]. These AI-driven systems can integrate diverse data sources, including genomic profiles, clinical history, imaging data, and treatment responses, to identify optimal treatment options and predict potential toxicities [30], [11], [29]. Clinical pharmacists are at the forefront of integrating AI into oncology pharmacy practice [30], [11], [29]. Their expertise in interpreting complex data, understanding drug mechanisms, and managing patient care allows them to effectively utilize AI-driven decision-support systems and incorporate their insights into treatment plans [30], [11], [29]. They also play a crucial role in validating the outputs of AI systems, ensuring that the recommendations are clinically sound and align with current evidence-based guidelines [30], [11], [29]. Real-world applications and case studies highlight the potential of AI to improve the efficiency and effectiveness of oncology pharmacy practice, enhancing treatment outcomes and improving patient care [30], [23], [42].

### **Patient Education and Adherence: Empowering Patients for Optimal Outcomes:**

Patient education and adherence are crucial for the success of personalized oncology, particularly with targeted therapies, many of which require long-term administration and have the potential for significant adverse effects [13], [41], [43]. Clinical pharmacists are ideally positioned to provide comprehensive patient counseling, explaining the purpose, benefits, and potential side effects of the prescribed therapies [9], [14], [44]. They can address patient concerns, answer questions, and provide practical strategies to improve medication adherence, such as pill organizers, reminder systems, or support groups [13], [14], [44]. Furthermore, pharmacists play a key role in emphasizing the importance of patient-reported outcomes (PROs) [14], [41]. PROs, which include data collected directly from patients about their symptoms, quality of life, and treatment experiences, provide valuable insights into treatment efficacy and toxicity [14], [41]. By actively soliciting and incorporating PROs into treatment decision-

making, clinical pharmacists can help personalize care and optimize treatment plans, ensuring that they are both effective and well-tolerated [14], [41]. This patient-centered approach enhances the therapeutic alliance, improves patient satisfaction, and contributes to better overall outcomes [14], [41].

### **Challenges and Ethical Considerations: Navigating the Complexities of Personalized Oncology:**

Despite the considerable progress made in personalized oncology, several challenges remain that require careful consideration [4], [13], [38]. One of the most significant is the high cost of targeted therapies and genetic testing, which can create substantial financial burdens for patients and healthcare systems [4], [13], [38]. This cost disparity can lead to inequities in access to precision medicine, disproportionately affecting underserved and marginalized populations [32], [38], [45]. Strategies to address this challenge include the development of cost-effective diagnostic and therapeutic approaches, targeted insurance coverage policies, and innovative payment models that align reimbursement with clinical outcomes [4], [13], [38]. Ethical considerations also play a crucial role in the implementation of personalized oncology [38], [16], [39]. Genetic testing raises concerns about privacy, informed consent, and the potential for genetic discrimination [38], [16], [39]. Clear guidelines and regulations are needed to protect patient rights and ensure responsible use of genetic information in clinical practice [38], [16], [39]. Furthermore, the complexities of interpreting genomic data and making informed treatment decisions require careful consideration of the limitations of current knowledge and the need for ongoing research and education [38], [16], [39]. A multidisciplinary approach, involving oncologists, genetic counselors, clinical pharmacists, and ethicists, is essential to address these ethical challenges and ensure that personalized oncology is implemented in a responsible and equitable manner [38], [16], [39].

### **Future Directions and Innovations: The Evolving Landscape of Personalized Oncology:**

The field of personalized oncology is rapidly evolving, with continuous advancements in targeted therapies, diagnostic tools, and bioinformatics approaches [1], [17], [46]. The development of next-generation targeted therapies, such as antibody-drug conjugates, bispecific antibodies, and CAR T-cell therapies, is expanding the therapeutic options available for cancer patients [6], [47], [48]. These innovative approaches offer the potential for increased efficacy and reduced toxicity compared to earlier generations of targeted therapies [6], [47], [48]. Furthermore, advancements in NGS and other molecular profiling techniques are enhancing our ability to identify novel biomarkers and therapeutic targets [1], [17], [46]. This improved understanding of cancer biology is driving the development of more precise and effective treatment strategies [1], [17], [46]. The role of clinical pharmacists in personalized oncology is also expanding [29], [11], [42]. As the complexity of treatment regimens increases, pharmacists

are becoming increasingly involved in clinical trials, developing novel MTM strategies, and integrating AI-driven decision-support systems into clinical practice [29], [11], [42]. Their expertise in pharmacogenomics, drug interactions, and patient education is crucial for ensuring the safe and effective use of these advanced therapies [29], [11], [42]. Future research will focus on identifying novel biomarkers, developing more effective targeted therapies, and improving the accessibility and affordability of precision medicine [3], [46], [49]. The close collaboration between clinical pharmacists, oncologists, and other healthcare professionals is essential for translating these advancements into improved outcomes for cancer patients [12], [29], [13].

### **Conclusion: A Collaborative Approach to Optimizing Cancer Care:**

Personalized oncology, driven by the development of targeted therapies and advanced molecular profiling techniques, has revolutionized cancer treatment [1], [2]. Clinical pharmacists are emerging as vital members of the interdisciplinary team, playing a crucial role in optimizing treatment efficacy, minimizing toxicity, and improving patient outcomes [12], [29], [13]. Their expertise in MTM, pharmacogenomics, and the use of AI-driven decision-support systems is indispensable for navigating the complexities of personalized oncology [9], [10], [11]. However, challenges remain, particularly concerning cost-effectiveness, accessibility, and ethical considerations [4], [38], [32]. Addressing these challenges requires collaborative efforts among healthcare providers, policymakers, researchers, and patients to ensure equitable access to precision medicine and to establish responsible clinical practices [32], [16], [38]. The future of personalized oncology hinges on continued advancements in targeted therapies, improved diagnostic tools, and greater integration of clinical pharmacists into multidisciplinary care teams [46], [3], [49]. By working collaboratively, we can harness the full potential of personalized oncology to improve the lives of cancer patients.

### **References:**

1. Pauli, C., *et al.* (2017). Personalized *in vitro* and *in vivo* cancer models to guide precision medicine. *American Association for Cancer Research*. <https://doi.org/10.1158/2159-8290.cd-16-1154>
2. Yates, L. R., *et al.* (n.d.). The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. *Annals of Oncology*. <https://doi.org/10.1093/annonc/mdx707>
3. Arajo, L., Krook, M., & Roychowdhury, S. (2016). Impact of genomic sequencing on precision medicine for clinical oncology. *None*. <https://doi.org/10.1080/23808993.2016.1184966>
4. Martin, J., & Olver, I. (2020). Precision medicine-based drug treatment individualization in oncology. *Wiley*. <https://doi.org/10.1111/bcp.14512>

5. Dienstmann, R., *et al.* (2012). Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. *American Association for Cancer Research*. <https://doi.org/10.1158/1535-7163.mct-12-0290>
6. Liu, D. (2019). Cancer biomarkers for targeted therapy. *BioMed Central*. <https://doi.org/10.1186/s40364-019-0178-7>
7. Tóth, L., Mokánszki, A., & Méhes, G. (2024). The rapidly changing field of predictive biomarkers of non-small cell lung cancer. *Springer Science+Business Media*. <https://doi.org/10.3389/pore.2024.1611733>
8. Li, T., Kung, H. J., Mack, P. C., & Gandara, D. R. (2013). Genotyping and genomic profiling of non-small-cell lung cancer: Implications for current and future therapies. *Lippincott Williams & Wilkins*. <https://doi.org/10.1200/jco.2012.45.3753>
9. Ma, C. (2014). Role of pharmacists in optimizing the use of anticancer drugs in the clinical setting. *Dove Medical Press*. <https://doi.org/10.2147/iprp.s40428>
10. Saadeh, C., Bright, D. R., & Rustem, D. R. (2019). Precision medicine in oncology pharmacy practice. *Academy of Sciences and Arts of Bosnia and Herzegovina*. <https://doi.org/10.5644/ama2006-124.246>
11. Raheem, F., Kim, P., Grove, M. E., & Kiel, P. (2020). Precision genomic practice in oncology: Pharmacist role and experience in an ambulatory care clinic. *Pharmacy*. <https://doi.org/10.3390/pharmacy8010032>
12. Dighriri, I., *et al.* (2024). Recent advancements and techniques regarding the roles of pharmacists, nutritionists, nurses, laboratory technicians, and other healthcare professionals in the care of cancer patients: A comprehensive review. *Journal of Ecohumanism*. <https://doi.org/10.62754/joe.v3i8.4907>
13. Polasek, T., Rowland, A., Wiese, M., & Sorich, M. (2015). Pharmacists in Australian general practice: An opportunity for expertise in precision medicine. *Therapeutic Advances in Drug Safety*. <https://doi.org/10.1177/2042098615599947>
14. Maleki, S., Alexander, M., Fua, T., Liu, C., Rischin, D., & Lingaratnam, S. (2018). A systematic review of the impact of outpatient clinical pharmacy services on medication-related outcomes in patients receiving anticancer therapies. *SAGE Publishing*. <https://doi.org/10.1177/1078155218783814>
15. Reizine, N., & O'Donnell, P. H. (2022). Modern developments in germline pharmacogenomics for oncology prescribing. *Wiley*. <https://doi.org/10.3322/caac.21722>
16. Reizine, N. M., *et al.* (2020). Implementation of pharmacogenomic testing in oncology care (PhOCus): Study protocol of a pragmatic, randomized clinical trial. *Therapeutic Advances in Medical Oncology*. <https://doi.org/10.1177/1758835920974118>

17. Tremmel, R., Hübschmann, D., Schaeffeler, E., Pirmann, S., Frühling, S., & Schwab, M. (2024). Innovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomes. *American Society for Pharmacology and Experimental Therapeutics*. <https://doi.org/10.1124/pharmrev.124.001049>
18. Malik, S., Pazdur, R., Abrams, J. S., Socinski, M. A., Sause, W. T., Harpole, D. H., Welch, J. J., Korn, E. L., Ullmann, C. D., & Hirsch, F. R. (2014). Consensus report of a joint NCI Thoracic Malignancies Steering Committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of master protocols in lung cancer. *Elsevier BV*. <https://doi.org/10.1097/jto.0000000000000314>
19. Zhang, Y., Du, Z., & Zhang, M. (2016). Biomarker development in MET-targeted therapy. *Impact Journals LLC*. <https://doi.org/10.18632/oncotarget.8276>
20. Müller, E., *et al.* (2015). Genetic profiles of cervical tumors by high-throughput sequencing for personalized medical care. *Wiley*. <https://doi.org/10.1002/cam4.492>
21. Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024). Tumor biomarkers for diagnosis, prognosis and targeted therapy. *Springer Nature*. <https://doi.org/10.1038/s41392-024-01823-2>
22. Mihály, Z., & Gyórfy, B. (2013). Improving pathological assessment of breast cancer by employing array-based transcriptome analysis. *Multidisciplinary Digital Publishing Institute*. <https://doi.org/10.3390/microarrays2030228>
23. Keck, J. M., *et al.* (2019). Abstract 4929: Leveraging multi-omics tumor boards for precision medicine in the OHSU SMMART treatments program. *Clinical Research*. <https://doi.org/10.1158/1538-7445.SABCS18-4929>
24. Nalejska, E., Młczyńska, E., & Lewandowska, M. A. (2014). Prognostic and predictive biomarkers: Tools in personalized oncology. *Adis, Springer Healthcare*. <https://doi.org/10.1007/s40291-013-0077-9>
25. Suenaga, M., Lenz, H., & Scherer, S. (n.d.). Chapter 2: Overview of oncology biomarkers. *None*. <https://doi.org/None>
26. Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J. A., & Bardelli, A. (2009). Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. *Oxford University Press*. <https://doi.org/10.1093/jnci/djp280>
27. Wang, Z., Jiang, L., Yan, H., Xu, Z., & Luo, P. (2021). Adverse events associated with nilotinib in chronic myeloid leukemia: Mechanisms and management strategies. *Expert Review of Clinical Pharmacology*. <https://doi.org/10.1080/17512433.2021.1894129>

28. Rahimi, M., Kakroodi, S. T., & Tajvidi, M. (2022). The importance of RTK signaling genes and their inhibitors in breast cancer. *Journal of Obstetrics Gynecology and Cancer Research*. <https://doi.org/10.30699/jogcr.7.4.258>
29. Walko, C., Kiel, P., & Kolesar, J. (2016). Precision medicine in oncology: New practice models and roles for oncology pharmacists. *American Journal of Health-System Pharmacy*. <https://doi.org/10.2146/AJHP160211>
30. Astras, G., Papagiannopoulos, C., Kyritsis, K., Markitani, C., & Vizirianakis, I. S. (2020). Pharmacogenomic testing to guide personalized cancer medicine decisions in private oncology practice: A case study. *Frontiers Media*. <https://doi.org/10.3389/fonc.2020.00521>
31. Rumyantsev, P. O. (2023). Molecular tumor board and theranostics. *Meditisina*. <https://doi.org/10.14341/probl13220>
32. Banji, A. F., Adekola, A. D., & Dada, S. A. (2024). Pharmacogenomic approaches for tailoring medication to genetic profiles in diverse populations. *World Journal of Advanced Pharmaceutical and Medical Research*. <https://doi.org/10.53346/wjapmr.2024.7.2.0049>
33. O'Dwyer, P. J., & Catalano, R. B. (2006). Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: Practical pharmacogenomics arrives in cancer therapy. *Lippincott Williams & Wilkins*. <https://doi.org/10.1200/jco.2006.07.3031>
34. Pinto, N., & Dolan, M. E. (2011). Clinically relevant genetic variations in drug metabolizing enzymes. *Bentham Science Publishers*. <https://doi.org/10.2174/138920011795495321>
35. Miteva-Marcheva, N., Ivanov, H., Dimitrov, D. K., & Stoyanova, V. K. (2020). Application of pharmacogenetics in oncology. *BioMed Central*. <https://doi.org/10.1186/s40364-020-00213-4>
36. VelezVelez, L. M., Hughes, C. L., & Kasi, P. (2018). Clinical value of pharmacogenomic testing in a patient receiving FOLFIRINOX for pancreatic adenocarcinoma. *Frontiers in Pharmacology*. <https://doi.org/10.3389/fphar.2018.01309>
37. Arafat, Y., Loft, M., Cao, K., Reid, F., Kosmider, S., Lee, M., Gibbs, P., Faragher, I., & Yeung, J. (2022). Current colorectal cancer chemotherapy dosing limitations and novel assessments to personalize treatments. *Wiley*. <https://doi.org/10.1111/ans.18046>
38. Cuffe, S., *et al.* (2014). Cancer patients' acceptance, understanding, and willingness-to-pay for pharmacogenomic testing. *Pharmacogenetics & Genomics*. <https://doi.org/10.1097/FPC.0000000000000061>
39. Aimono, E., & Nishihara, H. (2020). [Required human and system resources for genomic medicine]. *None*. <https://doi.org/10.1248/yakushi.19-00217-1>
40. Baldeo, C., Hughes, C. L., Shahjehan, F., Kamatham, S., & Kasi, P. (2019). Identifying the importance of integrating routine pharmacogenomic testing for UGT1A1 and

- DPYD/TYMS genetic variants in patients receiving irinotecan and/or 5-fluorouracil chemotherapy. *Journal of Clinical Oncology*.  
[https://doi.org/10.1200/JCO.2019.37.4\\_SUPPL.660](https://doi.org/10.1200/JCO.2019.37.4_SUPPL.660)
41. Patel, J. N., Wiebe, L. A., Dunnenberger, H. M., & McLeod, H. L. (2018). Value of supportive care pharmacogenomics in oncology practice. *AlphaMed Press*.  
<https://doi.org/10.1634/theoncologist.2017-0599>
  42. Li, R. (2025). Abstract IA05: Toward multi-modal foundation AI for precision oncology. *Clinical Cancer Research*. <https://doi.org/10.1158/1557-3265.targetedtherap-ia05>
  43. Nevidjon, B. (2018). Oncology nurses: Innovating precision care in a changing treatment environment. *Asia-Pacific Journal of Oncology Nursing*.  
[https://doi.org/10.4103/apjon.apjon\\_1\\_18](https://doi.org/10.4103/apjon.apjon_1_18)
  44. Iqbal, M. Z., Khan, A. H., Iqbal, M. S., & Sulaiman, S. A. S. (2019). A review of pharmacist-led interventions on diabetes outcomes: An observational analysis to explore diabetes care opportunities for pharmacists. *Medknow*.  
[https://doi.org/10.4103/jpbs.jpbs\\_138\\_19](https://doi.org/10.4103/jpbs.jpbs_138_19)
  45. Marcello, K., Owonikoko, T., Reckamp, K., Tafe, L., Andrie, R., & Obholz, K. (2022). Clinical uptake of precision medicine advances in NSCLC: A case study in RET fusions. *Journal of Clinical Oncology*. [https://doi.org/10.1200/jco.2022.40.28\\_suppl.032](https://doi.org/10.1200/jco.2022.40.28_suppl.032)
  46. Scheuenpflug, J. (2017). Precision medicine in oncology and immuno-oncology: Where we stand and where we're headed. *Biomedicine Hub*. <https://doi.org/10.1159/000481878>
  47. Subbiah, V. (2015). Fast-tracking novel drugs in pediatric oncology. *Taylor & Francis*.  
<https://doi.org/10.1080/15384101.2015.1018049>
  48. Kerna, N. A., *et al.* (2024). Current strategies and future directions in multiple myeloma: Disease overview and pathophysiology, conventional treatments and emerging therapies, challenges and innovations in management. *None*.  
[https://doi.org/10.59324/ejmhr.2024.2\(5\).02](https://doi.org/10.59324/ejmhr.2024.2(5).02)
  49. Rodak, O., Peris-Diaz, M. D., Olbromski, M., Podhorska-Okow, M., & Dzigiel, P. (2021). Current landscape of non-small cell lung cancer: Epidemiology, histological classification, targeted therapies, and immunotherapy. *Cancers*. <https://doi.org/10.3390/cancers13184705>

## **NATURALLY OCCURRING CHALCONES: POTENT ANTIOXIDANT AND ANTICANCER AGENTS**

**Yogeshwar R. Ramasane**

Department of Chemistry,

Department of Analytical Chemistry, Agrochemicals & Fertilizers,

N. E. S. Science College, Nanded (M.S.)

Corresponding author E-mail: [yr.ramasane@gmail.com](mailto:yr.ramasane@gmail.com)

### **Abstract:**

Chalcones, a significant class of flavonoids, have garnered immense attention due to their diverse pharmacological properties, particularly their antioxidant and anticancer activities. Their unique chemical structure, consisting of an  $\alpha$ ,  $\beta$ -unsaturated ketone moiety, contributes to their biological effectiveness. Chalcones exhibit potent antioxidant properties by neutralizing free radicals, modulating enzymatic activity, and enhancing cellular defense mechanisms. Additionally, their anticancer potential is linked to their ability to induce apoptosis, inhibit cell proliferation, and interfere with signalling pathways essential for tumour growth. This chapter explores the antioxidant and anticancer properties of chalcones, elucidating their mechanisms of action and potential applications in therapeutic interventions. The discussion encompasses their natural sources, molecular interactions, and emerging research that highlights their significance in medicinal chemistry.

**Keywords:** Natural Chalcones, Antioxidant Activity, Anticancer Activit

### **Introduction:**

Chalcones belong to the flavonoid family and are widely distributed in nature, predominantly found in fruits, vegetables, spices, and medicinal plants. Their structural backbone, featuring two aromatic rings linked by a three-carbon  $\alpha$ ,  $\beta$ -unsaturated carbonyl system, renders them highly reactive and biologically potent. The pharmacological importance of chalcones has been well documented, with studies emphasizing their role in combating oxidative stress and malignancies. Oxidative stress, a condition resulting from an imbalance between reactive oxygen species (ROS) and cellular antioxidant defenses, has been implicated in various chronic diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. Chalcones exhibit strong antioxidant activity due to their ability to scavenge free radicals, modulate key antioxidant enzymes, and activate protective signalling pathways. Cancer remains one of the leading causes of mortality worldwide, necessitating the development of more effective and less toxic treatment options. Chalcones have demonstrated significant anticancer properties through various mechanisms, including cell cycle arrest, apoptosis induction, inhibition of metastasis, and suppression of angiogenesis. The potential of chalcones as natural



therapeutic agents provides a promising alternative to conventional chemotherapy, which often involves severe side effects and drug resistance issues. This chapter provides a comprehensive analysis of the antioxidant and anticancer properties of chalcones, exploring their molecular mechanisms, natural sources, and therapeutic potential in disease management. By understanding their biological effects, researchers can further optimize chalcone-based compounds for clinical applications.


### **Antioxidant Activity of Chalcones**

Antioxidants are important in the human body because of their crucial role in cellular protection from damage caused by radicals and oxidative stress [1]. Free radicals are unstable molecules that can damage cells and contribute to aging and vulnerability to disease [1]. High concentrations of free radicals can lead to cancer, cardiovascular disease, and even neurodegenerative disorders [2]. Antioxidants scavenge and neutralize these molecules by donating electrons, stabilizing them, and preventing further cellular action [3]. By reducing oxidative stress, antioxidants act as a preventative measure against the negative effects of radical oxygen species [2]. Chalcones exhibit promising antioxidant properties due to their chemical structure and reactivity; their electron-rich phenolic structure makes chalcones ideal antioxidant molecules [4]. Additionally, chalcones have been found to modulate antioxidant enzyme activity and gene expression, further enhancing their protective effects against oxidative damage [4]. Their ability to target multiple pathways involved in oxidative stress makes chalcones valuable candidates for therapeutic interventions to promote health and prevent disease [5]. Furthermore, the abundance of chalcones in dietary sources such as fruits, vegetables, and medicinal plants highlights their potential as natural antioxidants for maintaining overall well-being [6]. Antioxidant chalcones exert their effects through various cellular targets and mechanisms. They enhance enzymatic antioxidant defenses such as superoxide dismutase, catalase, and glutathione peroxidase while activating the Nrf2-ARE pathway to upregulate antioxidant and detoxification genes [7].

Additionally, chalcones may inhibit reactive oxygen species (ROS) production by interfering with enzymes like NADPH oxidases and xanthine oxidases, and they possess metal-chelating properties to prevent metal-catalyzed ROS generation [7]. Furthermore, their anti-inflammatory activity, modulation of mitochondrial function, and direct scavenging of ROS contribute to cellular redox balance [8]. Foods rich in antioxidant chalcones offer a natural source of compounds known for their health-promoting properties [9]. Previous studies have noted that some naturally occurring chalcones have even contributed to reducing obesity via inhibiting adipocyte generation, decreasing cholesterol through NPCL1

inhibition, decreasing enzymatic lipase activity, and decreasing lipid accumulation in the adipose layer [10]. These effects are made possible through the contents of citrus fruits like oranges, lemons, and grapefruits. These contain naringenin chalcone, contributing to their antioxidant activity. Similarly, apples provide phloretin, while tomatoes are a good source of naringenin and phloretin. Soybeans and almonds contain isoflavonoids and naringenin, respectively, enhancing their antioxidant profile. Moreover, green tea, red wine, and hops (*Humulus lupulus*) used in beer production are documented sources of xanthohumol, a potent chalcone with antioxidant properties [9].

Butein (Figure 1) is another chalcone isolated from the bark of *Rhus vernici-flua* (*Toxicodendron vernicifluum*), while licorice (*Glycyrrhiza glabra*) presents licochalcone A and licochalcone E (Figure 1), further diversifying the array of antioxidant chalcones found in foods [11]. Antioxidant-containing foods are sought after and may be responsible for the health benefits associated with plant-rich diets. These corresponding chalconoids are shown in the structures below.




**Figure 1: Structures of representative antioxidant chalcones in edible plants and food products**

### Anticancer Properties of Chalcones

Globally, cancer is a leading cause of death and disease, with over 10 million deaths annually [2]. To make the situation worse, there is a projected 47% increase in the incidence of cancer disease over the next 20 years [12]. Cancer is an often-life-threatening condition that is caused by various mechanisms (immune, oxidative, genetic, or inflammatory) [13]. Despite the multitude of research studies conducted to cure various types of cancer, research cannot

keep up with the constant mutation and changes in cell lines [13]. Additionally, since treatment has the goal of stopping division or eradicating malignant cells, there is a high number of detrimental side effects associated with traditional therapies like radiation or chemotherapy [14]. Classical chemotherapy often entails severe toxic side effects mainly because the selectivity of malignant cells is very low [12]. Furthermore, the increasing resistance against these therapies increases the need to discover new targeted treatment methods to reduce toxicity and increase the efficiency of eradication [2]. Due to their unique nature and bioavailability as small molecule inhibitors, natural chalcones have the potential to become new anticancer agents. Previous review articles have covered chalcones used for treating various types of cancers. One article focused solely on gastrointestinal (GI) cancer found that natural chalcones decrease enzyme activity, increase apoptosis, increase cell cycle arrest, increase reactive oxygen stress, decrease multidrug-resistant proteins, angiogenesis, and inflammation in gastrointestinal cancer [15]. However, this review focuses on carcinomas of the lungs, liver, and breast. This is partly because the three chalcones described are in the process of evaluating possible therapeutic agents for cancer as opposed to more traditional and potentially harmful options [2]. These natural chalcones (Figure 2) interfere with cancer processes through many mechanisms of action similar to the ones described for GI cancer [15]. Chalcones showed promising activity against breast cancer, liver cancer, lung cancer, and a multitude of carcinoma-related diseases. This section will focus on the three cancers listed and their remedial chalconoid molecules.



**Figure 2: Structures of important anticancer chalcones**

### **Conclusion:**

Chalcones represent a promising class of bioactive compounds with significant antioxidant and anticancer properties. Their ability to modulate oxidative stress, regulate key signalling pathways, and selectively target cancer cells underscores their potential as therapeutic agents. As research continues to uncover their mechanisms of action, chalcones may pave the way for the development of novel, plant-derived pharmaceuticals for managing oxidative stress-

related diseases and cancer. Further studies focusing on their bioavailability, pharmacokinetics, and clinical applications will be crucial in advancing chalcone-based therapeutics into mainstream medicine.

## References

1. Janković, T., Turković, N., Kotur-Stevuljević, J., Vujić, Z., & Ivković, B. (2020). Differences in antioxidant potential of chalcones in human serum: In vitro study. *Chemico-Biological Interactions*, 324, 109084. <https://doi.org/10.1016/j.cbi.2020.109084>
2. Matos, M. J., Vázquez-Rodríguez, S., Uriarte, E., & Santana, L. (2015). Potential pharmacological uses of chalcones: A patent review (from June 2011–2014). *Expert Opinion on Therapeutic Patents*, 25(4), 351–366. <https://doi.org/10.1517/13543776.2015.1009504>
3. Aoki, N., Muko, M., Ohta, E., & Ohta, S. (2008). C-geranylated chalcones from the stems of *Angelica keiskei* with superoxide scavenging activity. *Journal of Natural Products*, 71(8), 1308–1310. <https://doi.org/10.1021/np800196q>
4. Vasil'ev, R. F., Kancheva, V. D., Fedorova, G. F., Batovska, D. I., & Trofimov, A. V. (2010). Antioxidant activity of chalcones: The chemiluminescence determination of the reactivity and the quantum chemical calculation of the energies and structures of reagents and intermediates. *Kinetics and Catalysis*, 51(4), 507–515. <https://doi.org/10.1134/S0023158410040160>
5. Jasim, H. A., Nahar, L., Jasim, M. A., Moore, S. A., Ritchie, K. J., & Sarker, S. D. (2021). Chalcones: Synthetic chemistry follows where nature leads. *Biomolecules*, 11(8), 1203. <https://doi.org/10.3390/biom11081203>
6. Brahimawad, M., Abdullah, H. D., Nadeem, A. M., & Hamid, H. (2018). Characterization of two chalcone derivatives isolated from finger root with nutraceutical potentials. *International Journal of Advanced Research*, 6(8), 1089–1094.
7. Ngo, V., & Duennwald, M. L. (2022). Nrf2 and oxidative stress: A general overview of mechanisms and implications in human disease. *Antioxidants*, 11(12), 2345. <https://doi.org/10.3390/antiox11122345>
8. Wu, L., Wang, Z., Zhao, L., & Li, S. (2020). Pharmacological modulation of mitochondrial dysfunction: A promising therapeutic approach for neurological disorders. *Acta Pharmaceutica Sinica B*, 10(1), 33–41. <https://doi.org/10.1016/j.apsb.2019.10.009>
9. Mah, S. H. (2021). Chalcones in diets. In J. Xiao, S. D. Sarker, & Y. Asakawa (Eds.), *Handbook of dietary phytochemicals* (pp. XX-XX). Springer.
10. Maisto, M., Marzocchi, A., Keivani, N., Piccolo, V., Summa, V., & Tenore, G. C. (2023). Natural chalcones for the management of obesity disease. *International Journal of Molecular Sciences*, 24(15), 15929. <https://doi.org/10.3390/ijms241515929>

11. Chen, X., Liu, Z., Meng, R., Shi, C., & Guo, N. (2017). Antioxidative and anticancer properties of Licochalcone A from licorice. *Journal of Ethnopharmacology*, 198, 331–337. <https://doi.org/10.1016/j.jep.2016.12.042>
12. Michalkova, R., Mirossay, L., Kello, M., Mojziso, G., Baloghova, J., Podracka, A., & Mojzis, J. (2023). Anticancer potential of natural chalcones: In vitro and in vivo evidence. *International Journal of Molecular Sciences*, 24(10), 10354. <https://doi.org/10.3390/ijms241010354>
13. Constantinescu, T., & Lungu, C. N. (2021). Anticancer activity of natural and synthetic chalcones. *International Journal of Molecular Sciences*, 22(21), 11306. <https://doi.org/10.3390/ijms222111306>
14. Kulkarni, R. R., Tupe, S. G., Gamble, S. P., Chandgude, M. G., Sarkar, D., Deshpande, M. V., & Joshi, S. P. (2014). Antifungal dimeric chalcone derivative Kamalachalcone E from *Mallotus philippinensis*. *Natural Product Research*, 28(4), 245–250. <https://doi.org/10.1080/14786419.2013.865140>
15. Michalkova, R., Kello, M., Cizmarikova, M., Bardelcikova, A., Mirossay, L., & Mojzis, J. (2023). Chalcones and gastrointestinal cancers: Experimental evidence. *International Journal of Molecular Sciences*, 24(5), 5964. <https://doi.org/10.3390/ijms24055964>

## **MENOPAUSE AND ITS IMPACT ON CARDIOVASCULAR DISEASE RISK**

**Yash Rakholiya\*<sup>1</sup>, Harshkumar Brahmbhatt<sup>2</sup>, Vishwa Patel<sup>3</sup> and Nidhi Patel<sup>4</sup>**

<sup>1</sup>Department of Paramedical Sciences SBKS MI & RC,  
Sumandeep Vidyapeeth Deemed to be University, Vadodara, Gujarat, India

<sup>2</sup>Department of Pharmacy,  
Sumandeep Vidyapeeth Deemed to be University, Vadodara, Gujarat, India.

<sup>3</sup>Department of Pharmaceutics, Parul Institute of Pharmaceutical Education and Research,  
Faculty of Pharmacy, Parul University, Limda, Waghodia, Gujrat, India.

<sup>4</sup>Department of Pharmaceutics, Parul Institute of Pharmacy and Research,  
Faculty of Pharmacy, Parul university, Limda, Waghodia, Gujarat, India

\*Corresponding author E-mail: [harshsvdu@gmail.com](mailto:harshsvdu@gmail.com)

### **Introduction:**

Menopause represents a crucial biological shift in a woman's life, signalling the end of her reproductive years due to the permanent halt of ovarian function. It usually occurs between the ages of 45 and 55 and is marked by a significant drop in estrogen and progesterone levels. While many associate this transition with symptoms like hot flashes and night sweats, its long-term effects on health, especially the risk of cardiovascular disease (CVD), are becoming increasingly important. CVD is the leading cause of death among postmenopausal women globally, outpacing the risks linked to breast cancer and other chronic illnesses (1). The hormonal shifts that occur during menopause lead to various physiological and metabolic changes that heighten the risk of cardiovascular issues, such as hypertension, dyslipidaemia, insulin resistance, and arterial stiffness. Grasping these changes is essential for creating effective prevention and management strategies to reduce CVD risk in postmenopausal women (2).

This chapter delves into the intricate connection between menopause and the risk of cardiovascular disease. It looks at important factors like hormonal effects, epidemiological patterns, underlying mechanisms, and possible interventions. The subsequent subtopics will offer a thorough overview of what we currently understand about the cardiovascular changes brought on by menopause and their significance for long-term health (3).

### **Hormonal Changes and Cardiovascular Physiology**

Estrogen is essential for cardiovascular health, influencing vascular function, lipid metabolism, and inflammatory processes. When estrogen levels drop during menopause, it can negatively impact endothelial function, increase arterial stiffness, and disrupt lipid balance, all of which elevate the risk of cardiovascular disease (CVD). This section will examine the physiological functions of estrogen in cardiovascular regulation and the effects of its decline on vascular health (4).

## **Epidemiology of Cardiovascular Disease in Postmenopausal Women**

The occurrence of cardiovascular disease (CVD) rises notably after menopause, with studies showing a marked increase in conditions such as hypertension, atherosclerosis, and coronary artery disease among women aged 50 and older. This section will provide statistical insights into the trends of cardiovascular-related illnesses and deaths in postmenopausal women, comparing these figures to those of premenopausal women and men in the same age brackets (5).

## **Pathophysiological Mechanisms Linking Menopause to Cardiovascular Risk**

The cardiovascular changes that occur during menopause stem from intricate interactions between hormonal deficiencies and metabolic changes. This section will explore the key pathophysiological mechanisms that elevate the risk of cardiovascular disease (CVD), such as endothelial dysfunction, oxidative stress, arterial stiffness, dyslipidaemia, and the onset of metabolic syndrome (6).

## **Modifiable and Non-Modifiable Risk Factors**

While menopause is a non-modifiable risk factor for cardiovascular disease (CVD), there are several other factors that can affect cardiovascular health. Genetic predisposition, family history, and ethnicity are important in assessing an individual's baseline risk. On the other hand, modifiable factors like diet, physical activity, smoking, and alcohol consumption have a significant effect on cardiovascular outcomes. This section will examine both genetic and lifestyle-related risk factors in postmenopausal women.

## **Hormone Replacement Therapy (HRT) and Cardiovascular Risk**

Hormone replacement therapy (HRT) has been the subject of extensive research as a possible way to reduce the risk of cardiovascular disease (CVD) associated with menopause. Initial observational studies indicated that HRT might offer some protective benefits, but later randomized controlled trials have brought to light safety concerns, particularly regarding its link to thromboembolic events. This section will examine the latest evidence on the advantages and disadvantages of HRT and its significance in cardiovascular prevention (7).

## **Preventive Strategies and Lifestyle Modifications**

Given the increased cardiovascular risk that comes with menopause, it is crucial to adopt proactive strategies to support heart health in older women. This section will highlight evidence-based preventive measures, such as dietary changes, consistent physical activity, maintaining a healthy weight, quitting smoking, and medical treatments like lipid-lowering and antihypertensive therapies.

## **Structure of the Heart**

The heart is a crucial muscular organ that circulates blood throughout the body, delivering oxygen and essential nutrients while also removing metabolic waste. It is a hollow, four-chambered organ situated in the thoracic cavity, nestled between the lungs and slightly tilted to the left. The rib cage protects it, and it is surrounded by a double-layered membrane known as

the pericardium, which helps reduce friction and provides structural support. The heart's walls consist of three layers: the epicardium (the outer layer), the myocardium (the middle muscular layer responsible for contraction), and the endocardium (the inner lining that prevents friction with the circulating blood) (8).

### **The heart consists of four chambers: Right Atrium:**

This upper chamber collects deoxygenated blood from the superior and inferior vena cava, bringing blood back from the body. Right Ventricle: This chamber pumps deoxygenated blood into the pulmonary artery, sending it to the lungs for oxygenation. Left Atrium: This chamber receives oxygen-rich blood from the pulmonary veins, which transport it from the lungs. Left Ventricle: The strongest chamber, it pumps oxygenated blood into the aorta, supplying the entire body.

### **Valves of the Heart:**

The heart has four valves that help maintain a one-way flow of blood and stop it from flowing backward: Tricuspid Valve: This valve is located between the right atrium and right ventricle, preventing blood from returning to the atrium when the ventricle contracts. Pulmonary Valve: Found between the right ventricle and the pulmonary artery, it ensures that blood moves toward the lungs without coming back. Mitral (Bicuspid) Valve: This valve is situated between the left atrium and left ventricle, allowing only the forward flow of oxygen-rich blood. Aortic Valve: It stops blood from flowing back from the aorta into the left ventricle (9).

### **Circulatory Pathways**

The heart operates through two main circulatory loops: Pulmonary Circulation: This loop transports deoxygenated blood from the right ventricle to the lungs through the pulmonary artery. After picking up oxygen, the oxygen-rich blood returns to the left atrium via the pulmonary veins. Systemic Circulation: In this loop, oxygenated blood is pumped from the left ventricle into the aorta, delivering oxygen to the entire body. Deoxygenated blood then makes its way back to the right atrium.

### **Electrical Conduction System**

The heart has a built-in electrical system that controls its contractions:

- Sinoatrial (SA) Node: Found in the right atrium, this node serves as the heart's natural pacemaker, producing electrical impulses that initiate contractions.
- Atrioventricular (AV) Node: This node slightly delays the impulse to make sure the atria completely contract before sending the signal to the ventricles.
- Bundle of His and Purkinje Fibers: These structures spread the impulses throughout the ventricles, ensuring that contractions occur in sync for effective pumping (10).

### **Effect of Menopause on Cardiovascular Health**

Menopause is a natural biological process that signifies the conclusion of a woman's reproductive years, usually happening between the ages of 45 and 55. This phase is marked by a decrease in estrogen and progesterone levels, which can significantly affect various bodily



functions, including heart health. Although menopause is not classified as a disease, the hormonal shifts that occur during this time elevate the risk of cardiovascular diseases (CVD), highlighting an important health issue for older women (11).

### **Hormonal Changes and Their Impact on the Cardiovascular System**

Estrogen is essential for cardiovascular health as it helps with vasodilation, lowers inflammation, and manages lipid metabolism. When estrogen levels drop during menopause, it can lead to negative effects such as increased arterial stiffness, endothelial dysfunction, and lower nitric oxide production, all of which can contribute to hypertension and atherosclerosis. Moreover, estrogen plays a role in regulating cholesterol by keeping a balance between low-density lipoprotein (LDL) and high-density lipoprotein (HDL). As estrogen levels decrease, LDL levels often rise while HDL levels fall, which can further elevate the risk of heart disease (12).

### **Increased Risk of Hypertension and Atherosclerosis**

Postmenopausal women frequently face elevated blood pressure, which can be attributed to decreased elasticity in their blood vessels and heightened vascular resistance. The decline in estrogen's protective role plays a significant part in the thickening of arteries and the accumulation of plaque, resulting in atherosclerosis. This condition constricts the arteries, limiting blood flow and raising the chances of heart attacks and strokes. Studies indicate that women who undergo early menopause or surgical menopause may have an even higher risk of developing hypertension and associated cardiovascular issues.

### **Changes in Lipid Profile and Metabolic Syndrome**

Menopause brings about negative changes in lipid profiles, which include higher total cholesterol levels, increased triglycerides, and an elevated LDL-to-HDL ratio. These alterations lead to a greater risk of coronary artery disease (CAD). Additionally, metabolic syndrome—a combination of issues like abdominal obesity, insulin resistance, high blood pressure, and dyslipidemia—becomes more common in women after menopause. This syndrome greatly raises the likelihood of developing type 2 diabetes and cardiovascular problems.

### **Weight Gain and Its Role in Cardiovascular Risk**

Weight gain, especially around the abdomen, is a frequent issue during menopause, largely due to a decrease in metabolic rate and changes in hormone levels. The accumulation of visceral fat can lead to insulin resistance, inflammation, and higher blood pressure, which in turn increases the risk of cardiovascular problems. Factors associated with obesity, like higher levels of inflammatory cytokines and oxidative stress, also contribute to the development of cardiovascular disease in postmenopausal women (13).

### **Role of Hormone Replacement Therapy (HRT) in Cardiovascular Health**

Hormone Replacement Therapy (HRT) has been explored as a possible way to reduce cardiovascular risks linked to menopause. Initial observational studies hinted that HRT could offer heart protection, but more recent randomized controlled trials have shown that it might actually increase the risk of blood clots and strokes in some women (14). Therefore, the choice to

pursue HRT should be tailored to each individual, taking into account factors like age, pre-existing health issues, and when treatment begins in relation to the onset of menopause.

### **Preventive Measures and Lifestyle Modifications**

Hormone Replacement Therapy (HRT) has been explored as a possible way to reduce cardiovascular risks linked to menopause. Initial observational studies hinted that HRT could offer heart protection, but more recent randomized controlled trials have shown that it might actually increase the risk of blood clots and strokes in some women. Therefore, the choice to pursue HRT should be tailored to each individual, taking into account factors like age, pre-existing health issues, and when treatment begins in relation to the onset of menopause (15).

### **Conclusion:**

Menopause significantly affects cardiovascular health due to the drop in estrogen levels, which influences blood pressure control, cholesterol management, and overall vascular function. This decline increases the risks of hypertension, atherosclerosis, metabolic syndrome, and obesity, making postmenopausal women more susceptible to heart diseases. Although hormone replacement therapy is a topic of ongoing debate, adopting lifestyle changes like a heart-healthy diet, consistent exercise, and effective weight management is crucial for lowering cardiovascular risks. Early intervention, regular health check-ups, and increased awareness are vital for enhancing cardiovascular health and ensuring overall well-being in postmenopausal women.

### **References:**

1. El Khoudary, S. R., Aggarwal, B., Beckie, T. M., Hodis, H. N., Johnson, A. E., Langer, R. D., Limacher, M. C., Manson, J. E., Stefanick, M. L., Allison, M. A., American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention, & Council on Cardiovascular and Stroke Nursing. (2020). Menopause transition and cardiovascular disease risk: Implications for timing of early prevention: A scientific statement from the American Heart Association. *Circulation*, *142*(25), e506–e532. <https://doi.org/10.1161/CIR.0000000000000912>
2. El Khoudary, S. R., & Nasr, A. (2022). Cardiovascular disease in women: Does menopause matter? *Current Opinion in Endocrine and Metabolic Research*, *27*, 100419. <https://doi.org/10.1016/j.coemr.2022.100419>
3. Anagnostis, P., Lambrinoudaki, I., Stevenson, J. C., & Goulis, D. G. (2022). Menopause-associated risk of cardiovascular disease. *Endocrine Connections*, *11*(4), e220091. <https://doi.org/10.1530/EC-22-0091>
4. Eleazu, I. C., Jones-O'Connor, M., & Honigberg, M. C. (2020). The impact of premature menopause on future risk of cardiovascular disease. *Current Treatment Options in Cardiovascular Medicine*, *22*(12), 1–11. <https://doi.org/10.1007/s11936-020-00884-1>
5. Rosano, G. M., Vitale, C., Marazzi, G., & Volterrani, M. (2007). Menopause and cardiovascular disease: The evidence. *Climacteric*, *10*(sup1), 19–24. <https://doi.org/10.1080/13697130601114917>

6. Zhu, D., Chung, H. F., Dobson, A. J., Pandeya, N., Brunner, E. J., Kuh, D., Greenwood, D. C., Hardy, R., Cade, J. E., Giles, G. G., & Bruinsma, F. (2020). Type of menopause, age of menopause, and variations in the risk of incident cardiovascular disease: Pooled analysis of individual data from 10 international studies. *Human Reproduction*, 35(8), 1933–1943. <https://doi.org/10.1093/humrep/deaa147>
7. El Khoudary, S. R. (2020). Age at menopause onset and risk of cardiovascular disease around the world. *Maturitas*, 141, 33–38. <https://doi.org/10.1016/j.maturitas.2020.07.010>
8. Atsma, F., Bartelink, M. L., Grobbee, D. E., & Van Der Schouw, Y. T. (2006). Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: A meta-analysis. *Menopause*, 13(2), 265–279. <https://doi.org/10.1097/01.gme.0000191209.93658.19>
9. Mehta, J. M., & Manson, J. E. (2024). The menopausal transition period and cardiovascular risk. *Nature Reviews Cardiology*, 21(3), 203–211. <https://doi.org/10.1038/s41569-023-00847-7>
10. Ryczkowska, K., Adach, W., Janikowski, K., Banach, M., & Bielecka-Dabrowa, A. (2022). Menopause and women’s cardiovascular health: Is it really an obvious relationship? *Archives of Medical Science: AMS*, 19(2), 458. <https://doi.org/10.5114/aoms/144567>
11. Uddenberg, E., Safwan, N., Saadedine, M., Hurtado, M. D., Faubion, S. S., & Shufelt, C. L. (2024). Menopause transition and cardiovascular disease risk. *Maturitas*, 177, 107974. <https://doi.org/10.1016/j.maturitas.2024.107974>
12. Li, Y., Zhao, D., Wang, M., Sun, J. Y., Liu, J., Qi, Y., Hao, Y. C., Deng, Q. J., Liu, J., Liu, J., & Liu, M. (2021). Combined effect of menopause and cardiovascular risk factors on death and cardiovascular disease: A cohort study. *BMC Cardiovascular Disorders*, 21, 1–3. <https://doi.org/10.1186/s12872-021-02446-6>
13. Muka, T., Oliver-Williams, C., Colpani, V., Kunutsor, S., Chowdhury, S., Chowdhury, R., Kavousi, M., & Franco, O. H. (2016). Association of vasomotor and other menopausal symptoms with risk of cardiovascular disease: A systematic review and meta-analysis. *PLOS ONE*, 11(6), e0157417. <https://doi.org/10.1371/journal.pone.0157417>
14. Gu, Y., Han, F., Xue, M., Wang, M., & Huang, Y. (2024). The benefits and risks of menopause hormone therapy for the cardiovascular system in postmenopausal women: A systematic review and meta-analysis. *BMC Women's Health*, 24(1), 60. <https://doi.org/10.1186/s12905-024-02472-5>
15. Nappi, R. E., & Simoncini, T. (2021). Menopause transition: A golden age to prevent cardiovascular disease. *The Lancet Diabetes & Endocrinology*, 9(3), 135–137. [https://doi.org/10.1016/S2213-8587\(20\)30322-9](https://doi.org/10.1016/S2213-8587(20)30322-9)

## ROLE OF PHARMACIST IN ADVERSE DRUG REACTION

**Komal Pramod Sathe**

Hon. Shri. Babanrao Pachpute Vichardhara Trust's,  
Parikrama Diploma in Pharmaceutical Sciences, Kashti- 414701,

Tal- Shrigonda, Dist- Ahmednagar, Maharashtra.

Corresponding author E-mail: [sathekomal0909@gmail.com](mailto:sathekomal0909@gmail.com)

### **Abstract:**

Adverse Drug Reactions (ADRs) are a significant cause of morbidity and mortality worldwide, threatening patient safety. Pharmacists play a crucial role in managing these reactions, often being the first healthcare professionals to recognize potential ADRs during medication reviews, particularly for high-risk groups such as the elderly and those taking multiple medications. Through careful patient interactions and comprehensive history assessments, pharmacists collect essential information that aids in identifying ADRs. For detecting ADRs, pharmacists report them to national pharmacovigilance system, which helps with the overall tracking of medication safety. Additionally, they educate patients, giving them the knowledge and skills to identify and report side effects. Enhancing a multidisciplinary approach to pharmacovigilance is the development of standardized protocols in collaboration with other healthcare providers. Even with their significant contributions, issues like inadequate training and underreporting persist. By empowering pharmacists and implementing effective ADR management, these challenges must be overcome in order to improve patient safety and healthcare outcomes.

**Keywords:** Pharmacist, Adverse Drug Reaction, Patient Education, Monitoring.

### **Introduction:**

The World Health Organization (WHO) defines an Adverse Drug Reaction (ADR) as "A response to a drug which is noxious and unintended, and which occurs at doses normally used in humans for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function." Adverse drug reactions (ADRs) represent a serious threat to patient safety. ADRs not only affect individual patients but also pose significant challenges to healthcare systems. [Karch & Lasagna (1975)] They can result in longer hospital stays, additional medical interventions, and increased overall treatment costs, thereby straining healthcare resources. The World Health Organization (WHO) recognizes the importance of monitoring and managing ADRs as a crucial aspect of pharmacovigilance. Additionally, the need for careful monitoring of adverse drug reactions is highlighted by the growing complexity of prescription regimens, especially in populations with chronic illnesses or those receiving polypharmacy. To effectively participate in national and international pharmacovigilance systems, pharmacists must have

increased awareness of and training in reporting adverse drug reactions. In the end, better drug safety profiles, knowledgeable clinical judgments, and better patient outcomes for people all over the world can result from increased ADR reporting. Being specialists in medications, pharmacists can take the lead in detecting, treating, and disclosing adverse drug reactions. By doing this, they support pharmacovigilance systems, which enhance the safety of drug therapies globally in addition to improving the outcomes for individual patients. [World Health Organization. (2020), Institute of Medicine. (2011).]

### Identification of ADRS

Pharmacists are at the frontline of ADR detection. Their knowledge of drug interactions, side effects, and patient histories allows them to identify potential ADRs during routine medication reviews and patient consultations. Pharmacists often work with high-risk populations such as elderly patients, those with chronic diseases, or individuals on multiple medications (polypharmacy), which are more susceptible to ADRs. In these settings, pharmacists are critical in recognizing symptoms that may be missed by others in the healthcare team, helping to prevent more severe outcomes. Identifying ADRs requires a systematic approach to understanding drug effects, monitoring patient responses, and using clinical judgment to link symptoms to medications. [Ghaleb *et al.* (2018), Moore *et al.* (2007)] Below are the key steps involved:

### Patient Interaction and History Review

Patient Interview: Pharmacists interact with patients directly during prescription refills, counseling, or hospital visits. They can ask specific questions about any new symptoms, unusual experiences, or side effects since starting a medication. Pharmacists review patients' medication profiles. The main points that are included in patient's medication history are shown in figure 1.




Figure 1: Important points for Medication history

### **Symptom Analysis and Monitoring [Sahu *et al.*, 2014]**

- Common Symptoms of ADRs: From minor (headaches, nausea) to severe (anaphylaxis, organ failure), symptoms can vary widely. Pharmacists must be knowledgeable about both common and uncommon adverse effects linked to each medication.
- Physical Examination Data: In hospital settings, pharmacists may work in tandem with physicians or nurses to keep an eye on laboratory values (such as liver/kidney function tests), imaging results that may point to adverse drug reactions, and vital signs (such as blood pressure and heart rate).
- Drug-Drug Interactions: Pharmacists keep a close eye out for possible drug interactions that could result in adverse drug reactions. This is particularly crucial in situations involving polypharmacy, as different medications may have conflicting or additive effects.
- Dose related ADR: Excessive dosages or extended medication use with specific medications may raise the risk of ADRs. Pharmacists evaluate if the recommended dosage is suitable for the patient's age, weight, hepatic or renal function.

### **Use of ADR Detection Tools**

- Clinical Decision Support Systems (CDSS): Many pharmacies and hospitals use electronic systems that flag potential ADRs based on patient data. Pharmacists can review these alerts for further investigation.
- Naranjo Scale: Pharmacists often use causality assessment tools like the Naranjo Algorithm to assess the probability that a drug caused the ADR. This involves a series of questions that quantify the likelihood of a causal relationship. [Naranjo *et al.* (1981)]

### **Reporting ADRS**

Pharmacists play a vital role in ADR reporting, an essential aspect of pharmacovigilance systems worldwide. Through national systems such as the WHO's Uppsala Monitoring Centre, FDA's MedWatch (USA), or Pharmacovigilance Programme of India (PvPI), pharmacists provide crucial data on ADRs that may not have been identified during clinical trials. By reporting suspected ADRs, pharmacists contribute to the monitoring of drug safety on a large scale, helping regulatory bodies to issue safety warnings, update labeling, or withdraw harmful drugs from the market. However, underreporting remains a significant challenge due to a lack of time, awareness, and incentives. [Hazell & Shakir (2006)]

### **Patient Education and Counseling**

Pharmacists play a proactive role in educating patients about the risks and benefits of their medications. By counseling patients on the potential side effects of their prescriptions, they empower patients to be vigilant in monitoring for adverse reactions. Pharmacists also provide clear instructions on what actions to take if symptoms of an ADR appear, thus ensuring early

reporting and intervention. This educational role is especially crucial in outpatient settings, where patients might not have immediate access to healthcare professionals if they experience side effects. [McElnay *et al.* (2000), Bond & Raehl (2007)]

### **Collaboration with Healthcare Professionals**

In order to manage and prevent ADRs, pharmacists work closely with doctors, nurses, and other healthcare professionals as essential members of healthcare teams. In hospital settings, where they participate in multidisciplinary adverse drug reaction (ADR) committees and develop high-risk medication monitoring protocols, their role in medication safety is especially important. Pharmacists can ensure the best possible outcomes for patients by recommending drug discontinuation, dose adjustments, or alternative therapies in cases of suspected adverse drug reactions (ADRs). [Lee *et al.* (2006), Hepler & Strand (1990)]

### **Development of Protocols and Guidelines**

Pharmacists contribute to the development of institutional protocols for ADR management, ensuring standardized responses to prevent and address ADRs effectively. They play a key role in creating educational materials for healthcare professionals regarding ADR prevention and management. [Hepler & Strand (1990), Krska *et al.* (2015)]

### **Research and Quality Improvement**

Engaging in research on ADRs can help identify trends, contributing factors, and potential interventions to enhance patient safety. Quality improvement initiatives led by pharmacists can streamline processes for ADR reporting and management within healthcare systems. [American College of Clinical Pharmacy. (1999), Van Grootheest *et al.* (2008).]

### **Impact on Healthcare Outcomes**

The involvement of pharmacists in ADR reporting and management has been shown to significantly reduce medication-related complications and hospital admissions. Patients are guaranteed safer, more efficient care when pharmacists are able to monitor and modify medication regimens in response to adverse event reports. Moreover, pharmacovigilance programs spearheaded by pharmacists enhance the standard of healthcare worldwide by advancing knowledge about drug safety. In the end, pharmacists who participate in ADR detection and reporting contribute to the prevention of future ADRs, which is advantageous for both specific patients and the general public. [Siegel *et al.* (2017)]

### **Challenges and Barriers**

Despite their crucial role, pharmacists face several barriers in ADR reporting and management. Underreporting remains a significant issue due to various factors such as time constraints, lack of awareness of reporting systems, and insufficient training in pharmacovigilance. Moreover, there is often a lack of integration between ADR reporting systems and pharmacists' daily workflows, making it more challenging for them to submit

reports. To overcome these challenges, it is essential to provide pharmacists with better access to training, integrate ADR reporting tools into electronic health systems, and promote a culture of safety that encourages reporting. [Hurst *et al.* (2016), Krska *et al.* (2008).]

Table 1 shows the important roles of pharmacist in ADR monitoring and management.

**Table 1: Key Roles of Pharmacists in ADR Management and Reporting**

Role	Description	Impact
Identification of ADRs	Pharmacists detect ADRs during medication reviews and patient consultations.	Early detection leads to timely intervention.
ADR Reporting	Pharmacists report ADRs to regulatory authorities via national pharmacovigilance systems.	Contributes to a broader understanding of drug safety.
Patient Education	Pharmacists counsel patients on potential ADRs, encouraging early recognition and reporting.	Reduces the risk of serious ADRs and improves patient safety.
Interprofessional Collaboration	Pharmacists work with healthcare teams to prevent and manage ADRs, suggesting safer alternatives.	Enhances decision-making and patient outcomes.
Reducing Medication-Related Harm	Pharmacists analyze ADR patterns and adjust treatments to prevent recurrence.	Improves healthcare outcomes by minimizing ADR risks.
Addressing Barriers to Reporting	Training programs and systemic support needed to overcome underreporting and lack of awareness.	Increases ADR reporting rates and data accuracy.

**Conclusion:**

Pharmacists are key players in the management and reporting of adverse drug reactions, helping to ensure the safe use of medications globally. Their roles span from identifying ADRs, reporting them to regulatory bodies, educating patients, and working alongside healthcare professionals to improve drug safety. Despite the challenges of underreporting and limited training, enhancing pharmacists’ roles in pharmacovigilance through better education and system support will improve healthcare outcomes and bolster global drug safety systems. By addressing these barriers, pharmacists can further strengthen the effectiveness of ADR reporting and contribute to safer, more reliable drug therapies.



**References:**

1. Karch, F. E., & Lasagna, L. (1975). Adverse drug reactions: A critical review. *JAMA*, 234(12), 1236–1241. <https://doi.org/10.1001/jama.1975.03260120034010>
2. World Health Organization. (2020). The importance of reporting adverse drug reactions. [https://www.who.int/docs/default-source/medicines/safety-of-medicines--adverse-drug-reactions-jun18.pdf?sfvrsn=4fc4f40\\_2](https://www.who.int/docs/default-source/medicines/safety-of-medicines--adverse-drug-reactions-jun18.pdf?sfvrsn=4fc4f40_2)
3. Institute of Medicine. (2011). The role of pharmacists in medication safety. National Academies Press.
4. Ghaleb, M. A., Al-Hazmi, A., Al-Mansour, K., *et al.* (2018). The role of the pharmacist in the prevention and management of adverse drug reactions. *Saudi Pharmaceutical Journal*, 26(2), 169–173. <https://doi.org/10.1016/j.jsps.2017.06.007>
5. Moore, N., Madelain, V., Dautel-Favre, A., *et al.* (2007). Role of pharmacists in reducing medication errors: A review. *Drug Safety*, 30(7), 637–645. <https://doi.org/10.2165/00002018-200730070-00001>
6. Sahu, R. K., Yadav, R., Prasad, P., Roy, A., & Chandrakar, S. (2014). Adverse drug reactions monitoring: Prospects and impending challenges for pharmacovigilance. *SpringerPlus*, 3, 695. <https://doi.org/10.1186/2193-1801-3-695>
7. Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., & Greenblatt, D. J. (1981). A method for estimating the probability of adverse drug reactions. *Clinical Pharmacology & Therapeutics*, 30(2), 239–245. <https://doi.org/10.1038/clpt.1981.154>
8. Hazell, L., & Shakir, S. A. (2006). Under-reporting of adverse drug reactions: A systematic review. *Drug Safety*, 29(5), 385–396. <https://doi.org/10.2165/00002018-200629050-00001>
9. McElnay, J. C., Brown, B., & McKenna, M. (2000). The role of the pharmacist in the detection and management of adverse drug reactions. *Pharmaceutical Journal*, 264(7079), 548–551. <https://doi.org/10.1002/j.2052-2576.2000.tb14694.x>
10. Bond, C. A., & Raehl, C. L. (2007). Clinical pharmacy services, hospital pharmacy staffing, and medication errors in United States hospitals. *Pharmacotherapy*, 27(4), 481–493. <https://doi.org/10.1592/phco.27.4.481>
11. Lee, M., Bensink, M. E., Larkins, S., *et al.* (2006). The role of pharmacists in the management of chronic disease. *Australian Journal of Pharmacy*, 87(1035), 154–158.
12. Hepler, C. D., & Strand, L. M. (1990). Opportunities and responsibilities in pharmaceutical care. *American Journal of Health-System Pharmacy*, 47(3), 533–543. <https://doi.org/10.1093/ajhp/47.3.533>
13. Krska, J., McKeown, J., *et al.* (2015). The role of the pharmacist in ensuring patient safety: A UK perspective. *Pharmacia and Pharmacy Practice*, 13(2), 540. <https://doi.org/10.18549/PharmPract.2015.02.540>

14. American College of Clinical Pharmacy. (1999). Guidelines for the development of clinical pharmacy services. *Pharmacotherapy*, 19(5), 721–734. <https://doi.org/10.1592/phco.19.5.721.34979>
15. Van Grootheest, K., Beijer, H. J., *et al.* (2008). Pharmacovigilance in the Netherlands: Current status and future developments. *Pharmaceutics World Science*, 30(4), 407–412. <https://doi.org/10.1007/s11096-008-9206-0>
16. Siegel, S., Riaz, M., *et al.* (2017). Implementation of a pharmacist-led medication safety program: A pilot study. *American Journal of Health-System Pharmacy*, 74(24), 2074–2081. <https://doi.org/10.2146/ajhp16093>
17. Chisholm-Burns, M. A., *et al.* (2010). US pharmacists' effect on patient care and health outcomes: A systematic review. *Archives of Internal Medicine*, 170(16), 1493–1501. <https://doi.org/10.1001/archinternmed.2010.334>
18. Hurst, C., Tuckey, C., *et al.* (2016). The role of pharmacists in the prevention and management of adverse drug reactions: A qualitative study. *International Journal of Clinical Pharmacy*, 38(3), 561–567. <https://doi.org/10.1007/s11096-016-0349-5>
19. Krska, J., *et al.* (2008). Pharmacists' views on their role in the detection and management of adverse drug reactions. *Pharmaceutical World Science*, 30(3), 318–322. <https://doi.org/10.1007/s11096-008-9205-1>

## **THE ROLE OF MEDICINAL CHEMISTRY IN ADVANCING PHARMACY AND DRUG DEVELOPMENT**

**Shivkant Patel\*, Dillip Kumar Dash, Dipti Gohil and Ashim Kumar Sen**

Department of Pharmacy,

Sumandeep Vidyapeeth Deemed to be University,

At & Po. Piparia, Ta. Waghodia-391760, Vadodara, Gujarat, India

\*Corresponding author E-mail: [shivapatel2609@gmail.com](mailto:shivapatel2609@gmail.com)

### **Abstract:**

Medicinal chemistry is a fundamental discipline in pharmacy that plays a crucial role in the discovery, design, synthesis, and development of pharmaceutical agents. It bridges the gap between chemical sciences and biological systems, ensuring the creation of safe and effective drugs. This field contributes significantly to understanding drug-receptor interactions, optimizing pharmacokinetics and pharmacodynamics, and improving therapeutic efficacy. Additionally, medicinal chemistry aids in the development of novel drug formulations, targeted drug delivery systems, and prodrugs, enhancing patient compliance and treatment outcomes. With advancements in computational drug design, green chemistry, and nanotechnology, medicinal chemistry continues to drive innovation in pharmacy, ensuring the availability of improved therapeutics. This article highlights the significance of medicinal chemistry in pharmaceutical sciences and its impact on modern drug development.

**Keywords:** Medicinal Chemistry, Drug Discovery, Pharmaceutical Sciences, Analytical Drug Design, Pharmacokinetics,

### **1. Introduction:**

Medicinal chemistry is a multidisciplinary field that lies at the intersection of chemistry, biology, and pharmacology, playing a central role in the discovery, design, and development of therapeutic agents. It provides a scientific foundation for drug development and aims to design molecules that can effectively interact with biological systems to treat diseases [1]. Below is a deeper exploration of the key aspects of medicinal chemistry

#### ***1.1. Molecular Design and Drug Discovery***

Medicinal chemistry focuses on designing molecules with specific pharmacological properties to interact with biological targets, such as enzymes, receptors, or nucleic acids, to elicit a desired therapeutic response. This process begins with identifying a target that is involved in a disease process. For example, in cancer therapy, the target might be a mutated protein involved in uncontrolled cell division. The role of medicinal chemists is to rationally design compounds that can specifically bind to and modulate the activity of these targets. Key to this is the application of structure-based drug design, which uses the 3D structures of biological targets

obtained through techniques like X-ray crystallography or NMR (Nuclear Magnetic Resonance) spectroscopy. This allows researchers to predict how small molecules can bind to the target and influence its function [2].

### ***1.2. Chemistry and Biochemistry Integration***

Medicinal chemistry blends organic chemistry with biochemistry. Organic chemistry is used to synthesize potential drug candidates, while biochemistry helps to understand how these compounds interact with biological molecules. The process of optimizing drug candidates involves evaluating their chemical structure to improve their ability to bind to the biological target, as well as improving other properties such as stability and solubility [3].

### ***1.3. Pharmacology and Mechanisms of Action***

Once a compound interacts with its target, understanding its pharmacological effects is essential for predicting its therapeutic benefit and safety. Medicinal chemistry works alongside pharmacology to assess the mechanism of action of new compounds, determining how they influence biological systems. This helps predict the drug's effects, its optimal dose, and its potential side effects. For instance, in cancer therapy, a drug might inhibit a specific protein kinase, preventing the uncontrolled growth of cancer cells. Understanding how a drug works at the molecular level is key to developing drugs with high specificity for the disease target, minimizing off-target effects that could lead to adverse reactions [4].

### ***1.4. Optimization of Drug Properties***

Medicinal chemistry also involves the optimization of several physicochemical properties of drugs, such as solubility, stability, bioavailability, and permeability. These factors significantly influence how a drug behaves in the body. For example, a drug must be able to dissolve in the body's fluids to be absorbed into the bloodstream and distributed to its target site. Chemists design molecules with modifications (e.g., altering functional groups) to enhance these properties and ensure the drug reaches its target in sufficient concentrations [5].

- **Solubility:** Ensuring that the drug dissolves well in bodily fluids like blood or gastrointestinal fluids is crucial for absorption [6].
- **Stability:** The drug must be stable enough to retain its structure and activity during storage and after administration [7].
- **Bioavailability:** The fraction of the administered drug that reaches the systemic circulation must be optimized for efficacy [8].
- **Permeability:** The ability of a drug to cross biological barriers, like the blood-brain barrier, is essential for treating diseases like neurological disorders [9].

### ***1.5. Drug Development and Formulation***

After a drug candidate is identified and optimized, medicinal chemistry plays a role in its formulation and delivery. This includes determining the best method for administering the drug

(oral, intravenous, topical, etc.), and ensuring that the drug is stable and effective in the final dosage form. The development of novel drug delivery systems, such as nanoparticles, liposomes, or sustained-release formulations, is an important aspect of medicinal chemistry that enhances the overall therapeutic effectiveness and patient compliance [10].

### ***1.6. Therapeutic Solutions for Various Diseases***

Medicinal chemistry is instrumental in developing treatments for a wide range of diseases, improving patient outcomes and quality of life. The field has contributed significantly to the creation of treatments for infectious diseases (antibiotics, antivirals), chronic conditions (cardiovascular drugs, diabetes medications), neurological disorders (antidepressants, antipsychotics), and cancer (chemotherapy agents, targeted therapies) [11].

### ***1.7. Drug Repurposing and New Therapeutic Approaches***

Medicinal chemists are also involved in drug repurposing, which is the process of identifying new uses for existing drugs. This can save time and resources compared to developing entirely new drugs. For example, certain existing drugs have shown unexpected efficacy in treating diseases like cancer, Alzheimer's, or COVID-19, and further research is conducted to understand and optimize these effects [12].

### ***1.8. Toxicology and Safety***

An essential part of medicinal chemistry is evaluating the safety of new drugs. This involves assessing their toxicological profiles, including their potential to cause adverse effects in humans. Through preclinical testing, medicinal chemists can predict and mitigate potential toxicity, ensuring that drugs not only work effectively but are also safe for patient use [13].

## **2. Role of Medicinal Chemistry in Drug Discovery:**

### ***2.1. Identification of Lead Compounds***

Medicinal chemists analyse natural and synthetic compounds to identify potential drug candidates. They employ various screening techniques, such as high-throughput screening (HTS), combinatorial chemistry, and computational modelling, to discover compounds that exhibit promising biological activity. Once a lead compound is identified, its structure is systematically modified to enhance its pharmacological properties, such as potency, selectivity, and metabolic stability, while minimizing potential toxicity [14].

### ***2.2. Structure-Activity Relationship (SAR)***

SAR studies help in understanding how different chemical modifications affect biological activity. By systematically altering functional groups and molecular scaffolds, medicinal chemists can identify key structural features responsible for a drug's activity. SAR insights allow chemists to optimize drug candidates by improving their affinity for target receptors, enhancing bioavailability, and reducing side effects. These studies are critical in the iterative process of drug design, leading to more efficient and safer therapeutic agents [15].

### 2.3. Drug Design and Development

**2.3.1. Rational Drug Design:** Rational drug design employs computational tools, such as molecular docking, quantitative structure-activity relationship (QSAR) models, and artificial intelligence (AI)-driven simulations, to predict how a drug candidate will interact with its target. By designing molecules that fit precisely into biological targets, medicinal chemists can create highly selective and effective drugs, reducing unintended interactions and adverse effects [16].

**2.3.2. High-Throughput Screening (HTS):** HTS enables the rapid testing of thousands to millions of compounds in automated systems to identify those with potential therapeutic effects. This approach accelerates the drug discovery process by efficiently narrowing down promising candidates. HTS techniques integrate robotic automation, fluorescence-based assays, and computational analysis to screen large compound libraries for lead identification, significantly improving the efficiency of early-stage drug development [17].

### 2.3. Pharmacokinetics and Pharmacodynamics

#### 2.3.1. Absorption, Distribution, Metabolism, and Excretion (ADME)

Medicinal chemistry contributes significantly to understanding the pharmacokinetics of drugs, which includes their absorption, distribution, metabolism, and excretion (ADME). These processes determine the drug's bioavailability, half-life, and overall effectiveness in the body.

- **Absorption:** The ability of a drug to enter the bloodstream depends on factors such as solubility, lipophilicity, and stability. Medicinal chemists modify drug structures to enhance absorption by improving solubility and permeability across biological membranes.
- **Distribution:** Once absorbed, drugs are distributed throughout the body. Factors such as protein binding, molecular size, and polarity influence how well a drug reaches its target tissues. Medicinal chemistry helps in optimizing these parameters to ensure effective drug delivery.
- **Metabolism:** The biotransformation of drugs, primarily in the liver, can either activate prodrugs into their active form or lead to the inactivation and elimination of compounds. Medicinal chemists modify drug structures to enhance metabolic stability and avoid rapid degradation.
- **Excretion:** Drugs are eliminated from the body through renal or hepatic pathways. Optimizing molecular properties, such as polarity and molecular weight, ensures that drugs are excreted efficiently without causing toxicity [18].

### **2.3.2. Drug-Receptor Interactions**

The interaction between a drug and its target receptor is fundamental to its pharmacodynamic effects. Medicinal chemistry plays a crucial role in designing molecules that bind selectively to specific receptors, ensuring high efficacy while minimizing side effects.

- **Receptor Binding Affinity:** The strength of a drug's interaction with its receptor determines its potency. By modifying chemical structures, medicinal chemists enhance binding affinity, ensuring the drug effectively activates or inhibits the receptor.
- **Selectivity and Specificity:** Drugs should ideally interact only with their intended targets to avoid off-target effects. Medicinal chemists achieve this by fine-tuning molecular shape, electronic properties, and steric factors to maximize specificity.
- **Agonists vs. Antagonists:** Medicinal chemistry helps differentiate between agonists, which activate receptors, and antagonists, which block them. Structural modifications allow for the precise tuning of drug behavior to achieve the desired pharmacological response.
- **Allosteric Modulation:** Some drugs bind to sites other than the active site on a receptor, leading to enhanced or inhibited receptor activity. Understanding allosteric interactions allows medicinal chemists to design drugs with unique mechanisms of action [19].

## **3. Importance in Drug Formulation and Optimization:**

### ***3.1. Prodrug Development***

Prodrugs are chemically modified versions of active drugs designed to improve solubility, stability, or bioavailability. Medicinal chemists develop prodrugs to overcome challenges such as poor absorption, rapid metabolism, or low bioavailability. These compounds undergo enzymatic or chemical transformations in the body, releasing the active drug in a controlled manner, thereby enhancing therapeutic outcomes [20].

### ***3.2. Overcoming Drug Resistance***

Antimicrobial and anticancer drug resistance is a significant challenge in medicine. Medicinal chemistry plays a crucial role in modifying existing drugs or developing new molecules to combat resistant strains of bacteria, viruses, and cancer cells. Strategies include designing drugs that evade efflux pumps, inhibit resistance-related enzymes, or target alternative pathways to maintain efficacy against resistant pathogens [21].

### ***3.3. Toxicology and Safety Assessment***

Toxicological studies are essential in drug development to identify potential adverse effects. Medicinal chemistry helps modify molecular structures to reduce toxicity while maintaining efficacy. This involves reducing reactive metabolites, minimizing off-target interactions, and enhancing selectivity for therapeutic targets, ensuring patient safety and improving treatment outcomes [22].

#### 4. Contribution to Personalized Medicine by medicinal chemistry:

Medicinal chemistry plays a critical role in the development of personalized medicine, which tailors treatments to individual genetic, metabolic, and physiological differences. By analysing patient-specific biomarkers, medicinal chemists design targeted therapies that optimize efficacy while minimizing adverse effects [23].

- **Genetic Profiling:** Advances in pharmacogenomics enable the identification of genetic variations that affect drug metabolism, response, and toxicity. Medicinal chemists use this knowledge to design drugs that are more effective for specific genetic subgroups [24].
- **Targeted Drug Delivery:** By modifying drug structures, medicinal chemists develop formulations that selectively target diseased cells while sparing healthy tissues. This is especially crucial in oncology, where personalized cancer therapies have improved treatment outcomes [25].
- **Optimized Dosing Strategies:** Understanding individual variations in drug metabolism allows for customized dosing regimens, reducing the risk of side effects and improving therapeutic effectiveness [26].
- **Reduction of Adverse Effects:** Personalized medicine reduces adverse drug reactions by ensuring that medications are compatible with an individual's genetic makeup, thereby enhancing safety and treatment adherence [27].

#### 5. Future Trends in Medicinal Chemistry:

Medicinal chemistry is evolving rapidly, integrating emerging technologies and novel methodologies to enhance drug discovery and therapeutic applications. Some of the key future trends in this field include:

- **Artificial Intelligence (AI) and Machine Learning:** AI-driven models are revolutionizing drug design by predicting molecular interactions, optimizing lead compounds, and accelerating the drug discovery process.
- **Nanotechnology in Drug Delivery:** The use of nanomaterials enhances targeted drug delivery, improving bioavailability and reducing side effects.
- **Biologics and Peptide-Based Drugs:** Advances in protein and peptide therapeutics are expanding treatment options for diseases that were previously difficult to target with small molecules.
- **Green Chemistry Approaches:** Sustainable and environmentally friendly synthetic methods are becoming a priority in medicinal chemistry to reduce chemical waste and improve efficiency.



- **CRISPR and Gene Editing:** The integration of gene editing technologies is paving the way for precision medicine, allowing for the correction of genetic disorders at the molecular level.
- **3D Printing of Pharmaceuticals:** Personalized drug formulations using 3D printing technology enable customized dosing and controlled release mechanisms [28].

### **Conclusion:**

Medicinal chemistry is indispensable in pharmacy, influencing all stages of drug discovery, development, and optimization. It ensures the creation of safe, effective, and innovative drugs that improve patient health. Through rigorous research and chemical modifications, medicinal chemists help develop drugs with enhanced therapeutic potential, fewer side effects, and better patient compliance. As technology advances, medicinal chemistry will continue to play a pivotal role in shaping the future of pharmaceutical sciences. The integration of computational tools, such as AI and machine learning, is revolutionizing drug discovery by predicting molecular interactions and optimizing lead compounds more efficiently. Sustainable practices in drug synthesis are minimizing environmental impact while improving efficiency and cost-effectiveness. Personalized medicine, driven by genetic and biomarker research, is tailoring treatments to individual patient profiles, enhancing efficacy, and reducing adverse effects. The future of medicinal chemistry is promising, with ongoing innovations leading to more targeted and efficient treatments for a variety of diseases. By embracing new technologies and interdisciplinary collaboration, medicinal chemistry will remain at the forefront of pharmaceutical advancements, ultimately improving healthcare outcomes worldwide.

### **References:**

1. Hansch C. Structure of medicinal chemistry. *J Med Chem.* 1976;19(1):1-6.
2. Cheng Y, Gong Y, Liu Y, Song B, Zou Q. Molecular design in drug discovery: a comprehensive review of deep generative models. *Briefings Bioinf.* 2021;22(6):bbab344.
3. Peters MC. Beyond Google: Integrating chemical information into the undergraduate chemistry and biochemistry curriculum. *Chem Libr.: Challenges Oppor.* 2011;30(1):80-8.
4. Biton V. Clinical pharmacology and mechanism of action of zonisamide. *Clin Neuropharmacol.* 2007;30(4):230-40.
5. Meanwell NA. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. *Chem Res Toxicol.* 2011;24(9):1420-56.
6. He CX, He ZG, Gao JQ. Microemulsions as drug delivery systems to improve the solubility and the bioavailability of poorly water-soluble drugs. *Expert Opin Drug Delivery.* 2010;7(4):445-60.

7. Polizzi KM, Bommarius AS, Broering JM, Chaparro-Riggers JF. Stability of biocatalysts. *Curr Opin Chem Biol.* 2007;11(2):220-5.
8. Gonçalves RF, Martins JT, Duarte CM, Vicente AA, Pinheiro AC. Advances in nutraceutical delivery systems: From formulation design for bioavailability enhancement to efficacy and safety evaluation. *Trends Food Sci Technol.* 2018;78:270-91.
9. Mathias K, Machado RS, Stork S, Dos Santos D, Joaquim L, Generoso J, *et al.* Blood-brain barrier permeability in the ischemic stroke: An update. *Microvasc Res* 2024;151:104621.
10. Ali AA, Charoo NA, Abdallah DB. Pediatric drug development: formulation considerations. *Drug Dev Ind Pharm.* 2014;40(10):1283-99.
11. Dehkordi HT, Ghasemi S. Glutathione therapy in diseases: Challenges and potential solutions for therapeutic advancement. *Curr Mol Med.* 2024;24(10):1219-30.
12. Cha Y, Erez T, Reynolds IJ, Kumar D, Ross J, Koytiger G, *et al.* Drug repurposing from the perspective of pharmaceutical companies. *Br J Pharmacol.* 2018;175(2):168-80.
13. Holsapple MP, Farland WH, Landry TD, Monteiro-Riviere NA, Carter JM, Walker NJ, *et al.* Research strategies for safety evaluation of nanomaterials, part II: toxicological and safety evaluation of nanomaterials, current challenges and data needs. *Toxicol Sci.* 2005;88(1):12-7.
14. Rasheed MA, Iqbal MN, Saddick S, Ali I, Khan FS, Kanwal S, *et al.* Identification of lead compounds against Scm (fms10) in *Enterococcus faecium* using computer aided drug designing. *Life.* 2021;11(2):77.
15. Akhtar J, Khan AA, Ali Z, Haider R, Yar MS. Structure-activity relationship (SAR) study and design strategies of nitrogen-containing heterocyclic moieties for their anticancer activities. *Eur J Med Chem.* 2017;125:143-89.
16. Garib Singh RA, Schlessinger A. Advances and challenges in rational drug design for SLCs. *Trends Pharmacol Sci.* 2019;40(10):790-800.
17. Bajorath J. Integration of virtual and high-throughput screening. *Nat Rev Drug Discovery.* 2002;1(11):882-94.
18. Hadrup N, Ravn-Haren G. Absorption, distribution, metabolism and excretion (ADME) of oral selenium from organic and inorganic sources: A review. *J Trace Elem Med Biol.* 2021;67:126801.
19. Vernier P, Cardinaud B, Valdenaire O, Philippe H, Vincent JD. An evolutionary view of drug-receptor interaction: the bioamine receptor family. *Trends Pharmacol Sci.* 1995;16(11):375-81.
20. Rautio J, Meanwell NA, Di L, Hageman MJ. The expanding role of prodrugs in contemporary drug design and development. *Nat Rev Drug Discovery.* 2018;17(8):559-87.

21. Long J, Zhang Y, Yu X, Yang J, LeBrun DG, Chen C, *et al.* Overcoming drug resistance in pancreatic cancer. *Expert Opin Ther Targets.* 2011;15(7):817-28.
22. Noga M, Milan J, Frydrych A, Jurowski K. Toxicological aspects, safety assessment, and green toxicology of silver nanoparticles (AgNPs)—critical review: state of the art. *Int J Mol Sci.* 2023;24(6):5133.
23. Duburs G, Neibecker D, Žarković N. Chemistry and personalized medicine—the research and development future of Europe. *Croat Med J.* 2012;53(4):291-3.
24. Reis RM, Könü-Lebleblicioglu D, Lopes JM, Kleihues P, Ohgaki H. Genetic profile of gliosarcomas. *Am J Pathol.* 2000;156(2):425-32.
25. Manish G, Vimukta S. Targeted drug delivery system: a review. *Res J Chem Sci.* 2011;1(2):135-8.
26. Fourie Zirkelbach J, Shah M, Vallejo J, Cheng J, Ayyoub A, Liu J, *et al.* Improving dose-optimization processes used in oncology drug development to minimize toxicity and maximize benefit to patients. *J Clin Oncol.* 2022;40(30):3489-500.
27. Brianna, Lee SH. Chemotherapy: how to reduce its adverse effects while maintaining the potency. *Medical Oncology.* 2023;40(3):88.
28. Campbell IB, Macdonald SJ, Procopiou PA. Medicinal chemistry in drug discovery in big pharma: past, present and future. *Drug Dis Today.* 2018;23(2):219-34.

# ADVANCEMENTS IN HAIR CARE: CHEMICALS AND MATERIALS IN MODERN HAIR COSMECEUTICALS

## PART 1: FUNDAMENTALS AND KEY INGREDIENTS IN HAIR COSMECEUTICALS

Ruchira Gajbhiye\*, Pratiksha Meshram, Pratiksha Marwadkar and Sonali Shambharkar

Department of Cosmetic Technology,

R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, India

\*Corresponding author E-mail: [ruchiragajbhiye35@gmail.com](mailto:ruchiragajbhiye35@gmail.com)

### Abstract:


This part of the chapter covered the basics and essential components of hair cosmeceuticals, with a focus on addressing common hair concerns. The structure and physiology of hair are discussed at the beginning, emphasizing the significance of hair care in maintaining healthy structure and physiology. Common hair problems including dandruff, hair loss, and premature greying are discussed in this part, along with the underlying reasons, which include environmental stressors, hormone imbalances, and heredity. The main building blocks of hair cosmeceuticals are then discussed, with an emphasis on agents that promote hair growth and strength like peptides, active compounds derived from plants, and substitutes for minoxidil. The chapter also discusses hair pigmentation and anti-greying agents, conditioning and damage repair agents, and ingredients for anti-dandruff and scalp care. The purpose, advantages, and uses of each ingredient in different hair care formulations—such as shampoos, conditioners, serums, and masks are covered.

**Keywords:** Hair Cosmeceuticals, Hair Care, Anti-Dandruff, Hair Pigmentation, Protein Treatments, Scalp Care.

### 1. Introduction:

#### 1.1 Overview of Hair Structure and Physiology

Hair is a complex biological structure made up of keratin, lipids, and melanin, and is essential for protection, thermoregulation, and appearance [1]. Three layers make up the hair shaft: the medulla, which is found in thick hair types; the cortex, which gives strength, flexibility, and pigmentation; and the cuticle, which serves as a protective barrier [2]. Hair density and general health are influenced by the cyclic growth phases that the hair follicle, which is lodged in the scalp, goes through: anagen (growth), catagen (transition), and telogen (resting) [3]. Formulating successful cosmeceutical therapies requires a thorough understanding of hair physiology [4].



**Figure 1: a. Hair Structure, b. Hair Growth Cycle**

### **1.2 Importance of Hair Care in Cosmeceuticals**

Hair care products are now focused on cosmeceutical treatments that address damage healing, hair loss, color enhancement, and scalp health, going beyond simple cleansing and conditioning [5]. Hair cosmeceuticals combine bioactive chemicals, natural extracts, and advanced delivery technologies to improve follicular health, protect against external aggressors, and boost aesthetic appeal as a result of growing consumer awareness of component efficacy [6,7].

### **1.3 Rising Concerns in Hair Health and the Need for Advanced Formulations**

Hair-related issues require scientifically based solutions because of factors like hormonal imbalances, oxidative stress, environmental pollution, chemical treatments, and nutritional inadequacies [8]. Research into peptide-based hair growth stimulators, microbiome-friendly scalp care, oxidative stress modulators, and innovative conditioning technologies has been spurred by the global trend for natural, sustainable, and biotech-based hair care breakthroughs [9].

## **2. Common Hair Concerns and Their Causes**

### **2.1 Hair fall and thinning (genetics, hormonal imbalances, nutritional deficiencies)**

Hair fall and thinning affect both men and women due to genetics, hormonal changes, medical conditions, medications, and stress. Androgenetic alopecia (AGA), or pattern baldness, is linked to genetic sensitivity to dihydrotestosterone (DHT), which shrinks follicles and shortens growth cycles. Hormonal imbalances from PCOS, menopause, thyroid issues, and postpartum changes disrupt hair growth and shedding. Iron, zinc, vitamin D, and biotin deficiency weaken keratin production, leading to breakage of hair and thinning of hair [10].

### **2.2 Dandruff and scalp disorders (fungal infections, dry scalp, seborrheic dermatitis)**

Dandruff and scalp disorders affect nearly 50% of people worldwide, caused by fungal infections, dry scalp, and seborrheic dermatitis. Seborrheic dermatitis, primarily an adult

condition, is linked to *Malassezia* overgrowth, immune response, and hormonal changes. Dry scalp results from moisture deficiency, exacerbated by harsh shampoos and environmental factors [11].

### **2.3 Premature graying (oxidative stress, genetics, deficiency-related causes)**

Premature graying is a common issue influenced by oxidative stress, genetics, and nutrient deficiencies. Excess free radicals damage melanocytes, reducing melanin production and accelerating graying. Genetic predisposition plays a key role, determining melanin depletion rates. Deficiencies in vitamins B12, D, copper, and iron further impair melanin synthesis, contributing to early graying. Although premature graying is largely hereditary, antioxidant-rich diets and targeted supplementation can help slow the process [12].

### **2.4 Hair damage (heat, chemical treatments, environmental stressors)**

Hair is constantly exposed to harmful external factors, leading to damage and loss of smoothness. Excessive heat styling, chemical treatments, and environmental stressors contribute to this issue. Hair shaft damage stems from physical factors like washing, towel drying, and friction from accessories, as well as chemical causes such as dyeing, perming, and bleaching. Frequent use of harsh agents weakens hair structure, while incorrect product application alters hair texture. Additionally, photodamage, daily grooming, and UV exposure dry out hair, causing roughness, discoloration, stiffness, and brittleness [13].

### **2.5 Frizz and loss of moisture (humidity, lack of hydration)**

Frizz and moisture loss result from dehydration, humidity, and cuticle damage. Straight and slightly curly hair are more prone to frizz. Humidity swells the hair shaft, while pollution and UV rays weaken hair structure, leading to dryness. Harsh washes, heat styling, and chemicals strip natural oils, causing brittleness. A damaged cuticle allows moisture loss, increasing frizz and dehydration. Mechanical stress and improper care further deteriorate hair health [14].

### **2.6 Oily scalp and greasy hair (genetics, improper hair care, lifestyle factors, environmental factors)**

Oily scalp and greasy hair result from excessive sebum production, influenced by genetics, hormonal imbalances, over-washing, heavy styling products, diet, stress, and environmental conditions. This overproduction can clog hair follicles, leading to irritation, dandruff, and potential hair thinning. Factors like heat and humidity exacerbate the issue by stimulating sebaceous glands. Additionally, incorrect hair care practices, such as using harsh shampoos or heavy conditioners, can disrupt scalp balance [15].

### **2.7 Slow hair growth (genetics, lack of nutrition, environmental factors)**

Slow hair growth results from genetics, nutrient deficiencies, scalp health, stress, and environmental damage. While hair typically grows about half an inch per month, various factors

can slow this process. Genetics influence growth rate, follicle size, and hair cycle. Deficiencies in biotin, iron, vitamin D, and omega-3s weaken follicles. Poor scalp health, including dandruff and clogged follicles, hinders growth. Chronic stress and hormonal imbalances like PCOS prolong the resting phase. Environmental stressors that impair hair structure and slow down hair development include pollution, UV exposure, and heat styling [16].

## **2.8 Hair texture changes (hormonal shifts, medical conditions, and environmental stressors)**

Hair texture can change due to Age, hormonal changes, illnesses, and environmental stressors. Hair density and curl pattern can be changed by hormonal changes that occur during pregnancy, menopause, or thyroid conditions. Variations in hair texture throughout time are also influenced by genetic predisposition. The structure of the hair can be weakened by outside influences such as excessive heat style, frequent chemical treatments, pollution, and extended sun exposure, which can result in coarser, frizzier, or more brittle hair. Dehydration and nutritional inadequacies also influence the general health of hair by causing changes in texture [17].

## **2.9 Scalp acne and folliculitis (bacterial infections, hormonal imbalances, overactive sebaceous gland)**

Excessive oil production, bacterial infections, clogged hair follicles, and inadequate scalp and hair care are the causes of scalp acne and folliculitis. These disorders are made worse by elements like perspiration, product buildup, hormonal abnormalities, and an overactive sebaceous gland, which causes irritation, redness, and inflammation. Furthermore, comedogenic hair products, tight headgear, and excessive scratching can worsen scalp health and raise the risk of follicular infections and breakouts [18].

## **2.10 Scalp sunburn (UV radiation)**

Scalp sunburn occurs due to long-term exposure to UV radiation, which manifests in redness, irritation, dryness, and peeling of the scalp. Individuals with thinning hair or bald spots are more susceptible due to reduced natural protection. Overexposure to sunlight weakens hair follicles, which results in transient hair loss and heightened sensitivity of the scalp. Long-term UV exposure can also hasten the aging process of the scalp by degrading collagen and reducing its suppleness. Severe sunburns can cause blisters, a higher risk of skin infections, and permanent damage to the scalp [19].

# **3. Key Chemicals and Materials Used in Hair Cosmeceuticals**

## **3.1 Hair Growth and Strengthening Agents**

Hair health is affected by genetics, chemicals, lifestyle, smoking, medication, stress, infections, and hormonal changes like menopause, which can disrupt the hair growth cycle, causing thinning, weakening, or hair loss. Hair growth agents stimulate follicles, improve scalp

circulation, and provide nutrients, promoting healthier, thicker, and stronger hair. They support the growth cycle, reduce thinning, and enhance hair vitality. Peptides, plant-based actives, minoxidil alternatives, and stem cell extracts work together to strengthen hair, boost growth, and improve scalp health, offering a holistic solution for hair thinning [20, 21].

### **3.1.1 Peptides and Protein-based Ingredients**

Peptides and protein-based compounds are commonly utilized in hair products to encourage hair growth, reinforce hair fibers, and improve scalp health. These chemicals promote follicular activity, increase keratin production, and repair damaged hair structures. [22].

#### **a) Keratin**

Keratin, a fibrous structural protein high in cysteine, generates strong disulfide bonds, which increase hair durability and strength. It restores damaged cuticles, strengthens hair structure, and encourages growth by keeping follicles healthy and decreasing hair loss. Keratin's bioactive qualities make it an important element in sophisticated hair care formulations, providing effective solutions for strengthening and rejuvenating hair. [23].

#### **b) Biotinyl-GHK**

Biotinyl-GHK is a synthetic peptide that combines biotin, which is required for keratin formation and hair health, with GHK, a regenerative tripeptide (glycine, histidine, and lysine) which encourages tissue repair and collagen stimulation. This special blend helps the hair bulb produce more keratin, which accelerates follicle growth, strengthens hair attachment, prevents premature hair loss, and increases the strength, flexibility, and resistance to breakage of hair. A promising component for cutting-edge hair care products, biotinyl-GHK can increase hair vitality and decrease hair loss. [24].

#### **c) Copper Peptides**

Copper peptides, such as GHK-Cu, are tiny protein fragments that have biological action because the GHK tripeptide (Gly-His-Lys) binds to copper ions. In order to strengthen the hair shaft, they increase the formation of extracellular matrix, prolong the anagen phase, and decrease breaking. Due to its special qualities, GHK-Cu shows promise as a component in cutting-edge hair care products designed to reduce hair loss, thicken hair, and preserve robust, healthy hair. [25].

### **3.1.2 Plant-derived Actives**

Plant-derived actives provide a natural and effective solution for enhancing hair growth and strengthening hair. They function through multiple mechanisms, including improving scalp health, boosting blood circulation, and delivering essential nutrients to hair follicles [26].

#### **a) Saw Palmetto**

Saw Palmetto (*Serenoa Repens*), a palm plant native to the southeastern U.S., contains bioactive compounds like fatty acids, phytosterols, and antioxidants that promote hair growth



and strength. It works by inhibiting 5-alpha-reductase, reducing DHT levels linked to hair loss, and may slow hair loss, encourage regrowth, and nourish the scalp. Its fatty acids and antioxidants strengthen hair follicles, making it a promising natural ingredient for hair care products targeting thinning hair and scalp health [27].

#### **b) Red Clover Extract and Caffeine**

Red Clover (*Trifolium pratense* L.), rich in isoflavonoids, the main isoflavone is biochanin A and formononetin, soothes scalp conditions like dandruff and eczema with its anti-inflammatory and antimicrobial properties, while improving blood circulation to promote hair growth. Similarly, caffeine, a natural xanthine alkaloid, penetrates the scalp to stimulate hair follicles, extend the growth phase, counteract DHT, and improve microcirculation, promoting hair growth and reducing breakage. Due to their increased use in hair care products to increase thickness, decrease hair loss, and promote scalp health, both substances are useful natural remedies for problems with thinning hair and the scalp [28].

#### **c) Fenugreek**

The Mediterranean herb known as fenugreek (*Trigonella foenum-graecum*) is abundant in bioactive substances such as proteins and amino acids. It prevents hair loss, balances hormones, stimulates hair follicles, and functions as a natural conditioner to increase suppleness and stop breakage. Its antibacterial, antifungal, and anti-inflammatory qualities calm the scalp and guard against infections and dandruff. Fenugreek is a useful component of hair care products for thinning hair, hair loss, and scalp disorders since it also improves blood circulation, guards against oxidative stress, and fortifies hair [29].

### **3.1.3 Minoxidil Alternatives**

Minoxidil is a well-liked and successful topical treatment for hair loss that stimulates dormant follicles, improves blood flow to hair follicles, and dilates blood vessels in the scalp. Additionally, it thickens hair strands, which lessens breakage and encourages the growth of stronger, healthier hair [30].

#### **a) Capixyl and Procapil**

Capixyl and Procapil are innovative hair care formulations that help to prevent hair loss and strengthen hair. Acetyl Tetrapeptide-3 and Red Clover Extract are combined in Capixyl to increase keratin production, decrease DHT, promote follicle growth, and enhance suppleness. Procapil strengthens the hair shaft and improves follicle stimulation, scalp circulation, and DHT reduction in combination with Biotinyl-GHK, Apigenin, and Oleanic Acid. Both encourage denser, thicker hair, lessen shedding and breakage, and enhance scalp health, which makes them perfect for androgenetic alopecia and thinning hair [31].

## **b) Redensyl**

Redensyl, a combination of dihydroquercetin-glucoside, epigallocatechin gallate-glucoside, zinc chloride, and L-methylfolate calcium, stimulates hair growth by targeting hair follicle stem cells and dermal papilla cells. It produces thicker, denser hair by stimulating follicle proliferation, reducing oxidative stress, increasing cellular energy, and reactivating dormant follicles. Redensyl, a common ingredient in hair care products and treatments, provides a non-invasive remedy for alopecia and thinning hair by extending the anagen phase and decreasing hair loss [32].

### **3.1.4 Exosomes and Stem Cell Extracts**

Stem cell extracts and exosomes are novel hair care components known for their healing abilities. Stem cell extracts, derived from plants or human sources, stimulate hair follicle regeneration, prolong the anagen (growth) phase, and enhance scalp health by promoting cellular repair and reducing inflammation. Exosomes, tiny vesicles released by stem cells, deliver growth factors, proteins, and RNA to hair follicle cells, boosting cell proliferation, reducing oxidative stress, and improving follicle function. Both ingredients strengthen hair, reduce breakage, and promote thicker, denser growth. They are increasingly used in advanced cosmetic formulations, to address hair thinning, loss, and scalp conditions effectively [33].

## **3.2 Anti-Dandruff and Scalp Care Ingredients**

Scalp health is impacted by factors like fungal overgrowth, excess sebum, environmental pollutants, stress, hormonal changes, and improper hair care, often resulting in dandruff, itching, flaking, and irritation. Anti-dandruff and scalp care products treat these issues by reducing fungal activity, exfoliating dead skin cells, relaxing inflammation, and regulating the scalp's flora. The natural barrier of the scalp is strengthened, dandruff is reduced, and irritation is lessened by these products. By addressing the fundamental causes of scalp disorders, these remedies improve scalp health, minimize flaking, and lay a solid foundation for healthier, more resilient hair [34].

### **3.2.1 Antifungal Agents**

Antifungal compounds are commonly used in anti-dandruff and scalp care products to combat the proliferation of *Malassezia* fungus that are naturally found on the scalp. When these fungi multiply rapidly, they degrade scalp oils, causing irritation, flaking, itching, and disorders including dandruff and seborrheic dermatitis. These substances are vital for treating and avoiding such problems since they reduce symptoms, enhance scalp health, and regulate fungal growth [35].

#### **a) Ketoconazole**

Ketoconazole is an imidazole-derived antifungal drug having a chemical structure that includes a dichlorophenyl group, an imidazole ring, and a piperazine moiety, all of which contribute to its antifungal properties. It damages fungal cell membranes and results in cell death

by blocking the formation of ergosterol. It lessens the inflammation, itching, and flaking of the scalp by addressing the underlying cause. It offers antifungal and antibacterial properties that support a healthier scalp and better-looking hair, and is frequently found in medicated shampoos and lotions. It is a reliable component in formulations for both therapeutic and cosmetic hair care due to its effectiveness and safety [36].

#### **b) Zinc Pyrithione**

Zinc and pyrithione combine to form zinc pyrithione, an antifungal and antibacterial compound. It lessens flaking, itching, and irritation by rupturing fungal cell membranes and preventing microbiological growth. Its anti-inflammatory qualities calm the scalp and control the production of sebum. It is frequently included in shampoos and other scalp care products that successfully reduce dandruff and support healthy scalps. It is a reliable ingredient in cosmetics because of its stability, effectiveness, and safety. It is frequently used to keep the scalp clean and enhance the general health of the hair [37].

#### **c) Piroctone Olamine**

Piroctone olamine's antifungal qualities are attributed to its piroctone moiety, which is a hydroxamic acid derivative. It reduces peeling, itching, and irritation by rupturing fungal cell membranes and preventing their proliferation. Sensitive scalps can benefit from its gentle yet effective action. It is a well-liked substitute for more potent antifungal medications due to its effectiveness and safety. To encourage a healthy scalp and enhance the appearance of hair, it is included in anti-dandruff preparations and scalp treatments [38].

#### **d) Climbazole**

Climbazole, a synthetic antifungal drug that targets the primary cause of dandruff, has the molecular structure 1-(4-chlorophenoxy)-1-imidazolyl-3,3-dimethyl-2-butanol. By preventing the creation of ergosterol, it damages fungal cell membranes and results in cell death. By treating fungal overgrowth, it lowers flaking, irritation, and inflammation in anti-dandruff and scalp care products. It offers antifungal and antibacterial properties that support a healthy scalp and are frequently found in hair care formulas and scalp treatments. It is a common component of both prescription and over-the-counter hair care treatments because to its gentle yet potent qualities [39].

### **3.2.2. Herbal extracts**

Herbal extracts are widely used for scalp care and dandruff treatment due to their inherent soothing, antifungal, and anti-inflammatory qualities. They reduce scalp infections, eliminate itching, flaking, and irritation, and successfully fight *Malassezia* yeast. These extracts also promote healing, strengthen hair follicles, and improve the general health of the scalp. They offer a mild yet efficient method for keeping a healthy, dandruff-free scalp [40].

**a) Neem**

Neem (*Azadirachta indica*) is a medicinal plant that contains active chemicals such as nimbidin, azadirachtin, and nimbolide, which have antifungal, antibacterial, and anti-inflammatory activities. It promotes a healthy scalp by lowering inflammation, calming irritation, and preventing infections. It works well for controlling dandruff and maintaining the health of the scalp because of its mild and natural activity. Neem is prized for its adaptability, safety, and therapeutic properties and is frequently utilized in herbal and organic hair care products [41].

**b) Tea Tree Oil**

Tea Tree Oil, obtained from *Melaleuca alternifolia*, has a chemical composition rich in terpenes, particularly terpinen-4-ol, which gives it antifungal, antibacterial, and anti-inflammatory effects. It reduces flaking, itching, and irritation of the scalp by breaking down fungal cell membranes and preventing the growth of yeast, the main cause of dandruff. Its calming qualities also aid in the relief of irritated scalp issues. It is added to hair care products and scalp treatments, providing a safe, all-natural way to keep your scalp healthy and free of dandruff while also fostering the health of your hair and scalp as a whole [42].

**c) Aloe Vera**

Aloe vera is high in vitamins A and B, as well as amino acids, which aid with dandruff. Its efficacy is increased by its mild chemical makeup, which includes flavonoids with a variety of medicinal uses and saponins with antibacterial, anti-inflammatory, and cytotoxic qualities. Saponins function by dissolving cell membranes, which allows proteins and enzymes to seep out. They can permeate and disrupt the membrane because of their detergent-like properties, which lower cell wall tension and permeability. This process lessens the visibility of white flakes while gradually moisturizing the parched scalp. Aloe vera is a common component in hair care products because it prevents dryness and flaking by encouraging hydration and repair [43].

**d) Licorice**

Licorice root extract from *Glycyrrhiza glabra* contains active components such as glycyrrhizin, glabridin, and liquiritin, all of which contribute to its medicinal benefits. Its anti-inflammatory and antifungal properties soothe scalp irritation and lessen redness as part of its anti-dandruff and scalp care process. Licorice is useful for dry and itchy scalp disorders since it also helps control sebum production and encourages scalp moisture. It is included in hair care products that provide mild yet efficient ways to keep a healthy, dandruff-free scalp and enhance the appearance of both the hair and the scalp [44].

**3.2.3 Prebiotics and probiotics for scalp microbiome balance**

Strong, vibrant hair depends on maintaining a healthy scalp microbiota, and probiotics and prebiotics are essential for reaching this equilibrium. By outcompeting harmful bacteria and fungus that cause dandruff, irritation, and inflammation, probiotics—beneficial living bacteria—

help reestablish a healthy microbial ecology. Non-digestible fibers called prebiotics serve as food for these good bacteria, allowing them to proliferate and preserve a healthy ecology. When combined, they lessen irritation, increase moisture, and foster the ideal conditions for hair growth. The scalp microbiome can be nourished by using hair care products enhanced with these components. Over time, this results in stronger, healthier hair [45].

### **3.3 Hair Pigmentation and Anti-Graying Agents**

Anti-graying and hair pigmentation products are designed to counteract the loss of melanin, the natural pigment that gives hair its color, which can be brought on by environmental causes, stress, aging, or genetic predispositions. These treatments target the root causes of graying, which include hydrogen peroxide buildup in hair follicles, oxidative stress, and decreased melanocyte activity. These substances function to restore and maintain natural hair color by boosting melanin synthesis and protecting hair follicles, encouraging long-lasting vitality and a young appearance [46].

#### **3.3.1. Melanin boosters**

Melanin boosters are specialized chemicals or therapies that increase melanin production, the natural pigment that causes hair color, which decreases with age, stress, or environmental factors. They function by shielding melanocytes—the cells that make melanin—from oxidative stress brought on by free radicals and by activating them. These substances enhance hair vitality, postpone graying, and restore natural hair color. By treating pigmentation loss at its source, melanin boosters added to hair care regimens encourage healthier, younger-looking hair [47].

##### **a) Catalase**

Catalase is a naturally occurring enzyme with a complex structure, its primary role is to break down hydrogen peroxide ( $H_2O_2$ ), a byproduct of cellular metabolism, into water and oxygen. In hair care, hydrogen peroxide buildup damages melanocytes and inhibits melanin production, leading to graying. By neutralizing hydrogen peroxide, catalase protects melanocytes, supporting melanin synthesis and restoring natural hair color. When incorporated into hair care, catalase helps delay graying and improves hair vitality [48].

##### **b) Melitane**

Melitane, also known as acetyl tetrapeptide-3, is a peptide-based ingredient widely used in hair care for its ability to improve hair color and combat graying. Structurally, it mimics the action of alpha-melanocyte-stimulating hormone ( $\alpha$ -MSH), which stimulates melanocytes to produce melanin, the pigment responsible for hair color. By activating melanin synthesis, Melitane helps restore natural hair pigmentation and delay the onset of graying. Additionally, it protects melanocytes from oxidative stress, a key factor in premature graying. Melitane offers a non-invasive solution to maintain vibrant, youthful hair color while supporting overall scalp and hair health [49]

### 3.3.2. Botanical extracts

Botanical extracts are widely used in hair care for their ability to enhance pigmentation and combat graying by supporting melanin production and protecting hair follicles. They stimulate melanocytes through bioactive compounds and nutrients, activating pigmentation pathways, while their antioxidant properties reduce oxidative stress and prevent melanocyte damage. Some extracts also inhibit hydrogen peroxide buildup, a key factor in pigment loss. By promoting melanin synthesis and safeguarding melanocytes, these natural ingredients help restore hair color, delay graying, and maintain hair vitality [50].

#### a) **Amla**

Amla (*Emblica Officinalis*), is a rich source of antioxidants, vitamins (particularly vitamin C), and minerals that play a significant role in improving hair color and health. Its structure contains potent bioactive compounds like tannins and flavonoids, which help combat oxidative stress, a major contributor to premature graying. Amla works by protecting melanocytes—the cells responsible for melanin production—from damage caused by free radicals, thereby supporting natural hair pigmentation. Additionally, it strengthens hair follicles, promotes scalp health, and enhances shine. Amla is widely put into hair care products to nourish the scalp, delay graying, and preserve vivid, healthy hair [51].

#### b) **Bhringraj**

Bhringraj (*Eclipta Alba*), a beloved Ayurvedic plant, is well-known for its hair-enhancing effects, particularly its ability to improve hair color and prevent premature graying. Its active ingredients, which include flavonoids, ecliptal, and wedelolactone, stimulate melanocyte activity, which in turn promotes melanin formation and restores the natural pigmentation of hair. Bhringraj's antioxidant qualities also aid in the fight against oxidative stress, which is a major cause of graying and damage to hair follicles. Additionally, it promotes healthy hair development by strengthening hair follicles, nourishing the scalp, and increasing blood circulation. Bhringraj, when used to hair care products, provides a natural way to preserve hair color, lessen graying, and improve the general health of hair [52].

#### c) ***Polygonum Multiflorum***

*Polygonum Multiflorum*, sometimes referred to as Fo-Ti or He-Shou-Wu, is a traditional plant that is frequently used in hair care because of its ability to enhance the color and vibrancy of hair. Its active ingredients, which include anthraquinones, flavonoids, and stilbenes, are thought to activate melanocytes, which are the cells in hair follicles that produce pigment, thereby increasing the synthesis of melanin. Its antioxidant qualities also aid in shielding these cells from oxidative stress, which is a major contributor to early graying. In order to encourage darker, richer hair color, lessen graying, and improve overall hair health, it is frequently added to hair care products [53].

### 3.3.3 Tyrosinase activators and Modulators

Tyrosinase activators and modulators are necessary for hair pigmentation and anti-graying because they stimulate melanin formation in hair follicles. Tyrosinase, the primary enzyme in melanogenesis, transforms tyrosine into the melanin pigments that give hair its color. To ensure effective melanin synthesis, a variety of modulators, including copper ions and plant extracts, aid in controlling the activity of this enzyme. These activators and modulators help to preserve natural hair color and postpone the beginning of gray hair by maximizing tyrosinase function. A possible method for delaying premature graying and encouraging healthier, colored hair is to target tyrosinase [54].

**Table 1: Key Chemicals and Materials in Modern Hair Cosmeceuticals**

Sr. No	Category	Function	Active Ingredients
1	<b>Hair Growth and Strengthening Agents</b>	<p><b>Supports Follicle Health</b> Nourishes and maintains the health of hair follicles.</p> <p><b>Promotes Hair Growth</b> Encourages faster and healthier hair growth.</p> <p><b>Strengthens Hair Strands</b> Improves hair resilience, reducing breakage and split ends.</p>	<ul style="list-style-type: none"> <li>● Keratin</li> <li>● Biotinyl-GHK</li> <li>● Copper Peptides</li> <li>● Saw Palmetto</li> <li>● Red Clover Extract &amp; Caffeine</li> <li>● Fenugreek</li> <li>● Capixyl &amp; Procapil</li> <li>● Redensyl</li> <li>● Stem Cell Extracts</li> <li>● Exosomes</li> </ul>
2	<b>Anti-Dandruff and Scalp Care Ingredients</b>	<p><b>Controls Dandruff</b> Reduces flakiness and prevents dandruff formation.</p> <p><b>Maintains Scalp Microbiome</b> Supports a balanced and healthy scalp environment.</p> <p><b>Soothes Irritation</b> Calms itching, redness, and scalp discomfort.</p>	<ul style="list-style-type: none"> <li>● Ketoconazole</li> <li>● Zinc Pyrithione</li> <li>● Piroctone Olamine</li> <li>● Climbazole</li> <li>● Neem</li> <li>● Tea Tree Oil</li> <li>● Aloe Vera</li> <li>● Licorice</li> <li>● Prebiotics &amp; Probiotics</li> </ul>

3	<b>Hair Pigmentation and Anti-Graying Agents</b>	<p><b>Enhances Melanin Production</b> Boosts the natural pigment responsible for hair color.</p> <p><b>Delays Graying</b> Helps maintain natural hair color and slows the onset of gray hair.</p>	<ul style="list-style-type: none"> <li>● Catalase</li> <li>● Melitane</li> <li>● Amla</li> <li>● Bhringraj</li> <li>● Polygonum Multiflorum</li> <li>● Tyrosinase Activators</li> </ul>
---	--	---	---

**Conclusion:**

The review of hair cosmeceuticals emphasizes the importance of advanced ingredients in treating various hair and scalp concerns. The development of targeted formulations has been made possible by a deep understanding of hair physiology, structure, and frequently occurring common problems like premature greying, dandruff, and hair loss. Modern hair care formulations have significantly been improved by the incorporation of hair growth stimulants, scalp care agents, anti-dandruff ingredients, and anti-greying components.

Treatments for hair growth and strengthening keep developing by using bioactive peptides, active ingredients derived from plants, and substitutes for minoxidil. Additionally, innovative scalp care and anti-dandruff agents contribute to maintaining a balanced and healthy scalp environment. Damage repair and conditioning agents further enhance hair resilience, ensuring improved texture and manageability.

Looking forward, research in hair cosmeceuticals is expected to focus on novel bioactive compounds, personalized hair care solutions, and biotechnology-driven innovations. Sustainable ingredient sourcing, microbiome-friendly formulations, and AI-driven customization will likely shape the future of hair care, offering more effective and tailored solutions to meet diverse consumer needs.

**References:**

1. Guryanov, I., Naumenko, E., & Fakhrullin, R. (2022). Hair surface engineering: Combining nanoarchitectonics with hair topical and beauty formulations. *Applied Surface Science Advances*, 7, 100188. <https://doi.org/10.1016/j.apsadv.2021.100188>
2. Anastassakis, K. (2022). The Morphology and Structure of the Hair Shaft. In: *Androgenetic Alopecia from A to Z*. Springer, Cham. [https://doi.org/10.1007/978-3-030-76111-0\\_6](https://doi.org/10.1007/978-3-030-76111-0_6)
3. Tripathi, S., Dwivedi, S., Shrivastav, S., Tripathi, A.K. (2024). Anatomy and Physiology Diversity of Hair: A Multidisciplinary Approach to Understanding Structure and Function.



- In: Dwivedi, A., Pant, A.B., Poojan, S., Kotak, M., Tripathi, A. (eds) *Hair Care Products*. Springer, Singapore. [https://doi.org/10.1007/978-981-97-6740-3\\_2](https://doi.org/10.1007/978-981-97-6740-3_2)
4. Trüeb, R. M. (2006). Pharmacologic interventions in aging hair. *Clinical Interventions in Aging*, 1(2), 121-129.
  5. Srivastava, A., Srivastava, A. K., & Pant, A. B. (2024). Strategic Developments for Pre-clinical Safety/Efficacy Studies of Hair Care Products. In *Hair Care Products: Efficacy, Safety and Global Regulation*. 223-273. Singapore: Springer Nature Singapore. [https://doi.org/10.1007/978-981-97-6740-3\\_14](https://doi.org/10.1007/978-981-97-6740-3_14)
  6. Sadgrove, N., Batra, S., Barreto, D., & Rapaport, J. (2023). An updated etiology of hair loss and the new cosmeceutical paradigm in therapy: Clearing ‘the big eight strikes’. *Cosmetics*, 10(4), 106. <https://doi.org/10.3390/cosmetics10040106>
  7. Sadgrove, N., Batra, S., Barreto, D., & Rapaport, J. (2023). An Updated Etiology of Hair Loss and the New Cosmeceutical Paradigm in Therapy: Clearing ‘the Big Eight Strikes’. *Cosmetics*, 10(4), 106. <https://doi.org/10.3390/cosmetics10040106>
  8. Srivastava, A., Srivastava, A. K., & Pant, A. B. (2024). Strategic Developments for Pre-clinical Safety/Efficacy Studies of Hair Care Products. In *Hair Care Products: Efficacy, Safety and Global Regulation* (pp. 223-273). Singapore: Springer Nature Singapore. [https://doi.org/10.1007/978-981-97-6740-3\\_14](https://doi.org/10.1007/978-981-97-6740-3_14)
  9. Tinoco, Ana & Martins, Madalena & Ribeiro, Artur. (2021). Biotechnology of functional proteins and peptides for hair cosmetic formulations. *Trends in Biotechnology*. 40. 10.1016/j.tibtech.2021.09.010.
  10. Gokce *et al.* (2022): An overview of the genetic aspects of hair loss and its connection with nutrition. *J Prev Med Hyg* 63 <https://doi.org/10.15167/2421-4248/jpmh2022.63.2S3.2765>
  11. Trüeb and Gavazzoni (2023). Fungal Diseases of the Hair and Scalp. In *Hair in Infectious Disease: Recognition, Treatment, and Prevention*, Springer 151-195
  12. Kaur and Kaur (2024). Adequate Nutrition and Premature Hair Graying: A Review of Literature, *Journal of Dermatology Research*, 5(2), 1-8. <https://doi.org/10.46889/JDR.2024.5208>
  13. Lee *et al.* (2011). Hair shaft damage from heat and drying time of hair dryer. *Annals of dermatology*, 23(4), 455-462. <http://dx.doi.org/10.5021/ad.2011.23.4.455>
  14. Song *et al.* (2024). The Anti-Flyaway/Frizz Effect by Inducing the  $\alpha$ -Helical Structure Transition of Hair. *Cosmetics*, 11(6), 189. <https://doi.org/10.3390/cosmetics11060189>
  15. Lanjewar, *et al.* (2020). Review on Hair Problem and its Solution. *Journal of Drug Delivery and Therapeutics*, 10(3-s), 322-329. DOI:10.22270/jddt.v10i3-s.4066
  16. Trüeb, (2020). Value of Nutrition-Based Therapies for Hair Growth, Color, and Quality. In: *Nutrition for Healthy Hair*. Springer, Cham. [https://doi.org/10.1007/978-3-030-59920-1\\_6](https://doi.org/10.1007/978-3-030-59920-1_6)

17. Trüeb, (2015). The impact of oxidative stress on hair. *International journal of cosmetic science*, 37, 25-30. <https://doi.org/10.1111/ics.12286>
18. Lee, *et al.*, (2018). Dissecting folliculitis (dissecting cellulitis) of the scalp: a 66-patient case series and proposal of classification. *JDDG: Journal der Deutschen Dermatologischen Gesellschaft*, 16(10), 1219-1226. <https://doi.org/10.1111/ddg.13649>
19. Gherardini, *et al.* (2019). Transepidermal UV radiation of scalp skin ex vivo induces hair follicle damage that is alleviated by the topical treatment with caffeine. *International journal of cosmetic science*, 41(2), 164–182. <https://doi.org/10.1111/ics.12521>
20. Kesika, *et al.*, (2023). Role and Mechanisms of Phytochemicals in Hair Growth and Health. *Pharmaceuticals*, 16(2), 206. <https://doi.org/10.3390/ph16020206>
21. Natarelli, (2023). Integrative and Mechanistic Approach to the Hair Growth Cycle and Hair Loss, *Journal of Clinical Medicine*, 12(3), 893. <https://doi.org/10.3390/jcm12030893>
22. Tinoco, *et al.*, (2022). Biotechnology of functional proteins and peptides for hair cosmetic formulations. *Trends in biotechnology*, 40(5), 591–605. <https://doi.org/10.1016/j.tibtech.2021.09.010>
23. Tinoco, *et al.*, (2018), Keratin-based particles for protection and restoration of hair properties, *International Journal of Cosmetic Science* 40(4), <http://dx.doi.org/10.1111/ics.12483>
24. Mas-Chamberlin, (2004), Reduction of Hair-loss: Matrikines and plant molecules to the rescue, *Biology, Environmental Science, Medicine*, <https://api.semanticscholar.org/CorpusID:9340761>
25. Liu, *et al.*, (2023). Thermodynamically stable ionic liquid microemulsions pioneer pathways for topical delivery and peptide application, *Bioactive Materials*, 32(7), 502–513. <https://doi.org/10.1016/j.bioactmat.2023.10.002>
26. Choi, (2024), Can Plant Extracts Help Prevent Hair Loss or Promote Hair Growth? A Review Comparing Their Therapeutic Efficacies, *Phytochemical Components, and Modulatory Targets. Molecules*, 29(10), <https://doi.org/10.3390/molecules29102288>
27. Evron, *et al.*, (2020). Natural hair supplement: friend or foe? Saw palmetto, a systematic review in alopecia, *Skin Appendage Disorders*, 6(6), 329-337 <https://doi.org/10.1159/000509905>
28. Hajhashemi V., (2024), Preparation and evaluation of hair growth promoting effect of transfersomes containing red clover extract and caffeine alone or in combination, *Avicenna Journal of Phytomedicine*, 14(6), 645-652 <https://dx.doi.org/10.22038/AJP.2024.23984>
29. Khandelwal S., *et al.*, (2022), Development and Evaluation of Polyherbal Verdant Hair Oil, Career Point, *International Journal of Research (CPIJR)*, 1(2), 26-41
30. Gupta, (2022), Minoxidil: a comprehensive review. *The Journal of dermatological treatment*, 33(4), 1896–1906. <https://doi.org/10.1080/09546634.2021.1945527>

31. Eslahi, (2022), Effectiveness of the active ingredients (Capixyl, Procapil, and rosemary extract) of the Trust? Tonic for the treatment of androgenetic alopecia in comparison to minoxidil. *Our Dermatology Online*, 13(4), 346-351 <https://doi.org/10.7241/ourd.20224.1>
32. Merja, *et al.*, (2024), Safety and efficacy of REGENDIL™ infused hair growth promoting product in adult human subject having hair fall complaints (alopecia). *Journal of cosmetic dermatology*, 23(3), 938–948 <https://doi.org/10.1111/jocd.16084>
33. Salhab, (2022) Stem cell secretome as a mechanism for restoring hair loss due to stress, particularly alopecia areata: narrative review, *Journal of Biomedical Science* 29(1), 77. <https://doi.org/10.1186/s12929-022-00863-6>
34. Trueb, *et al.*, (2018), Scalp Condition Impacts Hair Growth and Retention via Oxidative Stress. *International Journal of Trichology*, 10(6), 262–270. [https://doi.org/10.4103/ijt.ijt\\_57\\_18](https://doi.org/10.4103/ijt.ijt_57_18)
35. Galizia, *et al.*, (2024), Seborrheic Dermatitis: From Microbiome and Skin Barrier Involvement to Emerging Approaches in Dermocosmetic Treatment. *Cosmetics*, 11(6), 208. <https://doi.org/10.3390/cosmetics11060208>
36. Jodh, *et al.*, (2023), Ketoconazole: A Promising Drug for Fungal Infections, *Asian Journal of Research in Pharmaceutical Science*, 13(2), 101-105 <https://doi.org/10.52711/2231-5659.2023.00019>
37. Mangion, *et al.*, (2021), Targeted Delivery of Zinc Pyrithione to Skin Epithelia, *International Journal of Molecular Sciences*, 22(18), 1-30 <https://doi.org/10.3390/ijms22189730>
38. Tang, *et al.*, (2023), Characterization of piroctone olamine for topical delivery to the skin, *International Journal of Cosmetic Science*, 45(3), 345–353. <https://doi.org/10.1111/ics.12839>
39. Narshana, & Ravikumar, (2018), An overview of dandruff and novel formulations as a treatment strategy, *International Journal of Pharmaceutical Sciences and Research*, 9(2), 417-431 <http://dx.doi.org/10.13040/IJPSR.0975-8232>.
40. Pal, *et al.*, (2020), Preparation & Assessment of Poly-Herbal Anti-Dandruff Formulation, *The Open Dermatology Journal*, 14, 22-27 <http://dx.doi.org/10.2174/1874372202014010022>
41. Wylie, Merrell, (2022), The Antimicrobial Potential of the Neem Tree *Azadirachta indica*. *Frontiers in Pharmacology*, 13, 1-16 <https://doi.org/10.3389/fphar.2022.891535>
42. Henzilenah, Surugau, (2019), Formulation and Evaluation of Hair Shampoo Containing Tea Tree (*Melaleuca alternifolia*) Oil and Virgin Coconut (*Cocos nucifera*) Oil, *Journal of Physics: Conference Series*, 1358 1-8 <https://doi.org/10.1088/1742-6596/1358/1/012022>

43. Setiawan, (2024), The Effectiveness of Aloe Vera in Multiple Moist Spray Products as a Hair Tonic to Reduce Students Scalp Irritation, *Jurnal Kesehatan Komunitas Indonesia*, 4(2), 142-149 <https://doi.org/10.58545/jkki.v4i2.354>
44. Cerulli, *et al.*, (2022), Licorice (*Glycyrrhiza glabra*, *G. uralensis*, and *G. inflata*) and Their Constituents as Active Cosmeceutical Ingredients, *Cosmetics*, 9(1), 1-19 <https://doi.org/10.3390/cosmetics9010007>
45. Pagac, M. P., Gempeler, M., & Campiche, R. (2024). A New Generation of Postbiotics for Skin and Scalp: In Situ Production of Lipid Metabolites by *Malassezia*, *Microorganisms*, 12(8), 1-17. <https://doi.org/10.3390/microorganisms12081711>
46. Feng, (2023), Reversing Gray Hair: Inspiring the Development of New Therapies Through Research on Hair Pigmentation and Repigmentation Progress. *International journal of biological sciences*, 19(14), 4588–4607. <https://doi.org/10.7150/ijbs.86911>
47. Zhao, *et al.*, (2022), Fuzhuan Brick Tea Boosts Melanogenesis and Prevents Hair Graying through Reduction of Oxidative Stress via NRF2-HO-1 Signaling. *Antioxidants*, 11(3), 599. <https://doi.org/10.3390/antiox11030599>
48. Boutin, *et al.*, (2020), An Active Ingredient Derived from *Picrorhiza scrophulariiflora* Roots for Prevention and Limitation of Hair Greying: What’s about Self-esteem and Mood? *SOFW Journal*, 11(20), 22-27
49. Shabazi, (2018), Therapeutic effects of a new topical cream formulation in patients with vitiligo, *Surgical and Cosmetic Dermatology*, 10(3)210-15 <http://doi.org/10.5935/scd1984-8773.20181041164>
50. Pang, *et al.*, (2021), Plant-Derived Compounds as Promising Therapeutics for Vitiligo, *Frontiers*, 12, 1-25 <https://doi.org/10.3389/fphar.2021.685116>
51. Gupta, *et al.*, (2022). Formulation and evaluation of herbal hair dye: A review article. *International Journal of Health Sciences*, 6(S6), 3591–3609. <https://doi.org/10.53730/ijhs.v6nS6.10195>
52. Kumari, *et al.*, (2021), ECLIPTA ALBA (BHRINGRAJ): A PROMISING HEPATOPROTECTIVE AND HAIR GROWTH STIMULATING HERB, *Asian Journal of Pharmaceutical and Clinical Research*, 14(7), 16-23. <http://dx.doi.org/10.22159/ajpcr.2021v14i7.41569>
53. Han, *et al.*, (2015), Mechanistic Studies on the Use of *Polygonum multiflorum* for the Treatment of Hair Graying, *BioMed Research International*, 2015(4), 1-8. <http://dx.doi.org/10.1155/2015/651048>
54. Sharma, *et al.*, (2021), Different Natural and Synthetic Tyrosinase Inhibitors and their Application, *Journal of Emerging Technologies and Innovative Research (JETIR)*, 8(1), 179-190

**ADVANCEMENTS IN HAIR CARE: CHEMICALS AND  
MATERIALS IN MODERN HAIR COSMECEUTICALS  
PART 2: ADVANCED FORMULATIONS, TRENDS,  
AND FUTURE PROSPECTS**

**Ruchira Gajbhiye\*, Pratiksha Meshram, Pratiksha Marwadkar and Sonali Shambharkar**

Department of Cosmetic Technology,

R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, India

\*Corresponding author E-mail: [ruchiragajbhiye35@gmail.com](mailto:ruchiragajbhiye35@gmail.com)

**Abstract:**

The advancements in hair cosmeceuticals have led to the development of innovative formulations that address various hair concerns, such as damage repair, frizz control, and environmental protection. This chapter explores the key chemicals and materials used in modern hair care cosmeceuticals, including silicone alternatives like amodimethicone and polyquaterniums, protein treatments such as hydrolysed keratin and silk proteins, and lipid-replenishing agents like ceramides and phospholipids. Additionally, humectants, natural polymers, and film-forming agents are crucial in moisture retention and frizz control. UV filters, antioxidants, and heat protectants have become integral components of hair care formulations to safeguard hair from environmental stressors. Advanced formulation techniques, including emulsions, Nanoemulsions, and smart polymers, enhance the efficacy and controlled release of active ingredients. Furthermore, emerging trends such as biotech-driven hair care, AI-based personalized formulations, and sustainable ingredient sourcing are shaping the future of the cosmetic industry. The chapter concludes by summarizing key advancements and highlighting the future scope of research and innovation in hair cosmeceuticals.

**Keywords:** Hair Cosmeceuticals, Protein Treatments, Silicone Alternatives, UV Protection, Smart Polymers, Sustainable Ingredients.

**1. Key Chemicals and Materials Used in Hair Cosmeceuticals**

**1.1 Damage Repair and Conditioning Agents**

Heat styling, chemical treatments, UV exposure, and environmental pollutants cause daily stress on the hair, which leads to cuticle damage, protein loss, dryness, and brittleness. By restoring lost moisture, strengthening protein structure, and sealing the cuticle, damage repair, and conditioning products help to restore the integrity of hair. Deeply nourish the hair shaft to repair internal damage and improve elasticity are hydrolysed keratin, polyquaterniums, silk proteins, amino acids, ceramides, and moisturizing natural oils. These products provide

smoother, stronger, and healthier hair with more shine and softness by making hair easier to maintain, lowering breakage, and supplying long-lasting moisture [1].

### **1.1.1 Silicone Alternatives for Hair Protection and Smoothing**

Although silicones have long been utilized for heat protection, conditioning, and frizz control, worries about build-up, environmental effects, and conclusiveness have prompted the creation of silicone substitutes [2].

#### **a) Amodimethicone (Amino-Functionalized Silicone Alternative)**

Amodimethicone is a specialty silicone made especially to repair and preserve damaged hair. In contrast to conventional silicones, it binds to weak spots specifically, increasing shine, decreasing frizz, and boosting smoothness without causing undue buildup. Because it forms a thin, protective layer that helps retain moisture, shields against heat and environmental stressors, and makes hair simpler to maintain, it is a crucial ingredient in leave-in conditioners and repair treatments [3].

#### **b) Polyquaterniums (Cationic Conditioning Polymers)**

A broad class of cationic polymers known as polyquaterniums improves the detangling, conditioning, and moisture retention of hair. They provide a protective layer over the hair shaft, making the hair softer and more elastic while lowering frizz and static. It is commonly found in shampoos, conditioners, and styling products, Polyquaterniums such as Polyquaternium-10 and Polyquaternium-7 strengthen hair, enhance shine, and provide long-lasting hydration to hairs [4].

#### **c) Natural Oils (Plant-Based Conditioning Agents)**

Natural oils such as coconut oil, argan oil, jojoba oil, and avocado oil deeply nourish and protect the hair which improves hair care cosmeceuticals. Rich in essential fatty acids, vitamins, and antioxidants, they improve shine, repair damage, restore moisture balance, and enhance shine. These oils penetrate the hair shaft, reducing protein loss, sealing the cuticle, and preventing split ends while offering heat and UV protection. Their lightweight nature makes them ideal for conditioning and scalp care [5].

### **1.1.2 Protein Treatments for Structural Repair**

Hair is mainly composed of keratin, but exposure to external aggressors causes protein loss, leading to weakness, roughness, and split ends. Protein treatments restore lost proteins, strengthening and maintaining the integrity of hair fibers [6].

#### **a) Hydrolysed Keratin**

Hydrolysed Keratin is a broken-down form of keratin protein that penetrates the hair shaft to repair and strengthen damaged strands of the hair. It replenishes lost proteins, reinforces hair structure, and enhances elasticity, reducing breakage and improving the resilience of hair. Hydrolysed keratin helps smooth the cuticle, providing a healthier, shinier appearance while

protecting against further damage from heat, chemicals, and environmental stressors so it is widely used in advanced hair care cosmeceuticals [7].

#### **b) Silk Proteins**

Silk proteins, derived from silk amino acids, are used in haircare cosmetics which provide deep hydration and improve hair texture by forming a smooth, protective layer on hairs. They enhance hair elasticity, reduce frizz, and impart a silky softness and natural shine to the hair which increases the demand for silk proteins in advanced hair cosmeceuticals. They are very good at strengthening delicate hair, preventing breakage, and enhancing general hair manageability without adding weight because of their lightweight nature [8].

#### **c) Collagen**

Collagen is a structural protein found in hair care products that helps to maintain the strength, suppleness, and wetness of hair. By strengthening the hair shaft, it lessens breakage and brittleness and encourages healthier, smoother strands. Collagen, a common element in hair restoration treatments and anti-aging haircare cosmeceuticals is rich in amino acids and improves moisture retention, increases hair resilience, and improves overall thickness [9].

### **1.1.3 Lipid replenishing agents**

The lipid layer of hair acts as a natural barrier that is essential for preserving moisture, adding shine, and fending off damage from the outside. Dryness, brittleness, and an increased risk of breaking can result from the depletion of these vital lipids caused by things like frequent washing, chemical treatments, and exposure to the environment. This essential layer is restored by lipid-replenishing medicines, such as therapies enhanced with fatty acids and ceramides. Smoother, shinier, and more resilient hair strands are the result of these agents' ability to restore lost lipids, seal the cuticle, hold onto moisture, and strengthen the hair's structural integrity [10].

#### **a) Ceramides**

Ceramides are lipid molecules found in haircare cosmeceuticals that assist in re-establishing the natural protective layer of hair by keeping moisture in the cuticle and avoiding hair dehydration. They fortify the fiber structure, enhance hair texture, and guard against chemical treatments and environmental harm. Ceramides are crucial for restoring dry, damaged, and color-treated hair because they increase smoothness, decrease porosity, and promote general hair health. As a result, their applications in haircare cosmeceuticals are growing [11].

#### **b) Phospholipids**

Phospholipids are vital fatty substances that improve the absorption of active components in hair care products, thicken the cuticle, and keep hair hydrated. They improve suppleness and flexibility while lowering moisture loss by creating a protective layer around the hair. They are useful for conditioning treatments and formulations for hair and scalp care because of their emollient and reparative qualities [12].

### **c) Shea Butter**

Shea butter is a naturally occurring emollient that is highly nutritious and well-known for its potent moisturizing and hair-repairing qualities. Packed with antioxidants, fatty acids, and vitamins A and E, it smoothes the cuticle, protects against heat and environmental damage, and helps repair dry, brittle hair. Shea butter is perfect for deep conditioning treatments and protective haircare cosmeceuticals since it increases hair elasticity, minimizes frizz, and delivers long-lasting hydration [13].

## **1.2 Frizz Control and Moisture Retention Ingredients**

Hair care products that reduce frizz and retain moisture frequently have a combination of moisturizing, nourishing, and smoothing substances. Humectants, which draw and retain moisture, and natural oils, which deeply hydrate and seal the hair cuticle, are essential ingredients. Together, these components smooth the hair cuticle, fight frizz, and preserve water for healthier, easier-to-manage hair [14].

### **1.2.1 Humectants**

#### **a) Hyaluronic Acid**

Hyaluronic acid is well-known for its outstanding humectant characteristics, which allow it to attract and retain moisture, making it an essential element for controlling frizz and staying hydrated. Hyaluronic acid smoothes the cuticle and deeply moisturizes dry, frizzy hair by entering the hair shaft and attaching itself to water molecules. It also strengthens the hair's natural moisture barrier, keeping it hydrated and maintaining its elasticity, luster, and smoothness. For hair types that are dry, damaged, or prone to frizz, this makes it especially advantageous [15].

#### **b) Glycerin**

Glycerine is a potent humectant that draws and holds moisture from the surroundings. Because it hydrates dry strands, smoothes the cuticle, and penetrates the hair shaft, glycerine is frequently used in hair care products to prevent frizz and retain moisture. It is an essential component for nourishing and controlling frizzy or damaged hair since it keeps hair from drying out and becoming brittle while simultaneously enhancing its elasticity and sheen [16].

#### **c) Panthenol**

Panthenol, also referred to as pro-vitamin B5, is an alcohol-based derivative of vitamin B5, pantothenic acid, which has the molecular formula  $C_9H_{19}NO_4$ . A hydroxyl group in its structure enables it to attach to hair strands and function as a humectant, drawing and holding onto moisture. When used in hair care, panthenol hydrates the hair deeply and increases elasticity, which lessens frizz and makes hair easier to handle. To avoid dryness and breakage, it also creates a protective layer on the surface of the hair, smoothing the cuticle and retaining moisture. Panthenol is an essential component for keeping hair soft, silky, and frizz-free because it also strengthens hair by improving its capacity to retain water [17].



### **1.2.2 Natural Polymers**

#### **a) Chitosan**

Chitosan is a naturally occurring biopolymer consisting of linear chains of  $\beta$ -(1 $\rightarrow$ 4)-linked D-glucosamine and N-acetyl-D-glucosamine units that is generated from chitin and found in the exoskeletons of crustaceans. Because of its ability to bind to the negatively charged surface of hair and produce a protective, moisture-retaining layer, chitosan is prized in the hair care industry for its film-forming and cationic qualities. Retaining moisture and avoiding swelling brought on by humidity, helps to smooth the hair cuticle, lessen frizz, and improve shine. Furthermore, chitosan's humectant qualities draw and hold onto water, enhancing hydration and elasticity. Its lightweight design also prevents it from weighing hair down, which makes it perfect for controlling frizz and retaining moisture in dry or damaged hair [18].

#### **b) Guar Gum**

Guar gum is a polysaccharide made from guar beans, consisting of a linear chain of  $\beta$  (1-4)-linked D-mannose units with  $\alpha$  (1-6)-linked D-galactose branches. When hydrated, it forms a highly viscous gel-like structure. Guar gum serves as a film-forming polymer and natural conditioning agent in hair care products, ensuring superior moisture retention. By minimizing humidity-induced swelling, it smooths the cuticle, seals in moisture, and reduces frizz by creating a thin, protective layer on the hair shaft. It is a common ingredient in hair care products because of its moisturizing qualities, which also serve to increase the elasticity, smoothness, and manageability of hair [19].

#### **c) Xanthan Gum**

Xanthan gum is a polymer with a complex, branching structure that has good film-forming and water-binding qualities. Because it creates a thin, flexible layer on hair strands that helps to seal in moisture and smooth the cuticle, it is frequently used in hair care products for frizz control and moisture retention. This barrier is a common component in leave-in conditioners, styling gels, and serums because it prevents moisture loss and protects hair from frizz caused by humidity. It is also a useful ingredient in formulas made for dry and curly hair types because of its capacity to increase product spreadability and improve texture [20].

### **1.2.3 Film-forming agents**

#### **a) Polyvinylpyrrolidone**

Polyvinylpyrrolidone (PVP) is a water-soluble polymer having a repeating structure of vinylpyrrolidone monomers and a lactam ring that promotes strong hydrogen bonding. PVP is a useful element in hair care products for moisture retention and frizz control because of its special structure, which enables it to form flexible, transparent films. To prevent dryness, it reduces static and seals in moisture by creating a thin layer on hair strands. Furthermore, PVP maintains elasticity while improving the hold of styling products, guaranteeing manageable, silky hair free of residue or stiffness [21].

## **b) Polyquaterniums**

Polyquaterniums are a class of cationic polymers generated from quaternary ammonium compounds, distinguished by a positively charged structure that successfully attaches to the negatively charged surface of hair. This adherence creates a thin, protective layer that smoothes the cuticle, improving its smoothness and gloss while decreasing breakage, frizz, and static. Polyquaterniums, which are widely found in shampoos, conditioners, and styling products, help to retain moisture, untangle hair, and offer long-lasting conditioning without buildup. They are perfect for keeping hair silky, manageable, and looking healthy because of their anti-static and film-forming qualities [22].

## **1.3 UV Protection and Environmental Shielding Agents**

Environmental stressors such as pollution, UV rays, severe weather, and free radicals are continuously present in hair and can lead to damage, early aging, dryness, and weakening of the hair structure. By creating a protective barrier, reducing oxidative stress, and stopping moisture loss, UV protection and shielding agents aid in the defense against these aggressors. Together, antioxidants, botanical extracts, UV filters, and ingredients that stop pollutants protect hair and keep it strong, healthy, and vibrant. These substances promote general resistance, lessen their negative effects on the environment, and improve long-term defense against external hair damage [23,24].

### **a) Octyl Methoxycinnamate**

Octyl Methoxycinnamate, also known as Ethylhexyl Methoxycinnamate, is a commonly used UVB filter in cosmetic formulations. Because it absorbs UVB rays, it shields hair from sun-induced damage such as photoaging, color fading, and structural weakening. To provide broad-spectrum protection, OMC readily combines with other UV filters and is photostable. It is an essential component of haircare cosmeceuticals made for sun defense because of its capacity to prevent photoaging [25].

### **b) Titanium Dioxide**

Titanium Dioxide, a mineral-based UV filter, provides broad-spectrum protection by reflecting and scattering UVA and UVB radiation. It reduces oxidative stress and guards against solar damage by acting as a physical barrier against environmental aggressors. It is appropriate for sensitive skin due to its non-comedogenic properties, and it protects hair strands from UV-induced deterioration in hair care cosmeceuticals [26].

### **c) Zinc Oxide**

Zinc oxide is a natural mineral that provides excellent broad-spectrum UV protection. It prevents sun damage to hair by creating a physical barrier that scatters and reflects UVA and UVB rays. Its antibacterial and anti-inflammatory qualities also promote scalp health by lessening irritation and enhancing the resilience of hair in general [27].

### **1.3.1 Antioxidants**

#### **a) Vitamin C**

Vitamin C is a powerful antioxidant that neutralizes free radicals, decreases oxidative stress, stimulates collagen formation, and strengthens hair follicles. In terms of hair care, it shields the hair from oxidative stress, stops color fading, and enhances the general health of the scalp, resulting in stronger, glossier hair. By lessening the effects of sun exposure, minimizing premature aging, and enhancing the general health of hair, vitamin C also improves UV protection [28].

#### **b) Vitamin E**

Vitamin E is a powerful antioxidant that combats oxidative stress, which can lead to hair loss. Tocotrienol, a kind of vitamin E, was shown to dramatically improve hair count in people who were experiencing hair loss in a randomized, double-blind, placebo-controlled research. This effect is ascribed to vitamin E's capacity to promote hair development by lowering oxidative stress and lipid peroxidation in the scalp [29].

#### **c) Green Tea Polyphenols**

Green tea polyphenols, notably epigallocatechin-3-gallate (EGCG), have powerful antioxidant qualities that promote hair health. According to research, EGCG can promote the formation of hair follicles by increasing the number of outer root sheaths and dermal papilla cells. Better hair growth results from the stimulation of the protein kinase B (AKT) and sonic hedgehog signaling pathways, which promote the formation of hair follicles [30].

### **1.3.2 Heat Protectants**

#### **a) Silicone Blends**

Silicone blends are lightweight, resilient substances that build a barrier around hair strands, limiting moisture loss and safeguarding them from environmental stress. They provide UV and heat protection while adding smoothness, luster, and frizz control. Haircare cosmeceuticals use common silicones like Cyclopentasiloxane and Dimethicone to make hair easier to manage, less prone to breakage, and smooth without making it seem heavy [31].

#### **b) Quaternium Compounds**

Quaternium compounds are cationic conditioning agents commonly used in haircare cosmetics to enhance smoothness, manageability, and protection. They reduce static, improve moisture retention, and create a protective film against environmental pollutants and UV damage. These compounds also exhibit antimicrobial properties, helping to maintain scalp health and prolong product shelf life. Quaternium-80 and Quaternium-91 are often used in advanced hair care cosmeceuticals to provide long-lasting conditioning effects [32].

**Table 1: Key Chemicals and Materials in Modern Hair Cosmeceuticals**

Sr. No	Category	Function	Key Ingredients
1	<b>Damage Repair and Conditioning Agents</b>	<p><b>Restores Damaged Hair</b> Repairs and revitalizes hair that is dry, brittle, or damaged.</p> <p><b>Improves Texture</b> Makes hair smoother, softer, and more manageable.</p> <p><b>Enhances Shine</b> Adds a healthy, natural luster to hair for a radiant appearance.</p>	<ul style="list-style-type: none"> <li>● Amodimethicone</li> <li>● Polyquaterniums</li> <li>● Natural Oils</li> <li>● Hydrolyzed Keratin</li> <li>● Silk Proteins</li> <li>● Collagen</li> <li>● Ceramides</li> <li>● Phospholipids</li> <li>● Shea Butter</li> </ul>
2	<b>Frizz Control and Moisture Retention Ingredients</b>	<p><b>Reduces Frizz</b> Tames unruly hair and smooths flyaways for a sleeker look.</p> <p><b>Enhances Hydration</b> Deeply moisturizes hair, preventing dryness and brittleness.</p> <p><b>Forms a Protective Barrier</b> Shields hair from environmental damage, heat, and pollutants.</p>	<ul style="list-style-type: none"> <li>● Hyaluronic Acid</li> <li>● Glycerin</li> <li>● Panthenol</li> <li>● Chitosan</li> <li>● Guar Gum</li> <li>● Xanthan Gum</li> <li>● Polyvinylpyrrolidone.</li> <li>● Polyquaterniums</li> </ul>
3	<b>UV Protection and Environmental Shielding Agents</b>	<p><b>Protects Hair from UV Damage</b> Shields hair from harmful ultraviolet rays that can cause dryness and color fading.</p>	<ul style="list-style-type: none"> <li>● Octyl Methoxycinnamate</li> <li>● Titanium Dioxide</li> <li>● Zinc Oxide</li> <li>● Vitamin C</li> <li>● Vitamin E</li> </ul>

		<p><b>Defends Against Pollution</b> Forms a barrier to prevent damage from environmental pollutants and toxins.</p> <p><b>Reduces Oxidative Stress</b> Neutralizes free radicals to prevent damage and maintain hair health.</p>	<ul style="list-style-type: none"> <li>● Green Tea Polyphenols</li> <li>● Silicone Blends</li> <li>● Quaternium Compounds</li> </ul>
--	--	--	--

## 2. Formulation Approaches in Hair Cosmeceuticals

### 2.1 Types of hair formulation

#### 2.1.1 Shampoo:

Based on their purposes, shampoos can be divided into two types; cleaning shampoos: sulphate-based and sulphate-free. They aid in the removal of debris, oil, and product accumulation [33]. To offer hydration, humectants and emollients like glycerine and ceramides are added to moisturizing shampoos. Active chemicals including zinc pyrithione, selenium sulphide, and ketoconazole are found in anti-dandruff shampoos to help fight off dandruff and scalp problems [34].

#### 2.1.2 Conditioners:

Many hair issues are addressed by modern conditioners, especially hydration, damage restoration, scalp health, and environmental protection. They have proteins, silicones, fatty alcohols, and cationic surfactants that help soften, detangle, and shield hair. Hydrolysed proteins, dimethicone, panthenol, and behentrimonium chloride are typical components [35]

#### 2.1.3 Hair Serums

In order to strengthen damaged hair and repair broken disulphide bonds, bond-repair serums integrate advanced chemicals like bis-aminopropyl diglycol dimaleate, which is frequently found in hair serum formulations [36].

#### 2.1.4 Hair styling products

In addition to supplying flexibility and protection, hair styling products are produced to maintain and enhance hairstyles. Polymer resins include PVP and acrylates are used in hair sprays to give hair flexibility and grip, providing long-lasting styles. Film-forming agents and fixatives are used in the preparation of hair gels and mousses to give them structure and control [37].

### 2.1.5 Hair colorant and Dyes

To modify and enhance hair color, hair colorants and dyes are needed. Permanent hair dyes alter the color of hair permanently by entering the hair shaft with oxidative compounds like ammonia and hydrogen peroxide. Peroxides and persulfates are found in bleaching and lightening chemicals, which are used to lighten hair or prepare it for additional color treatments by enhancing its natural color [38].



**Figure 1: Hair Care Benefits**

### 2.2 Emulsion technology and novel drug delivery systems

In hair cosmeceuticals, particularly in delivering active ingredients, improving product stability, and enhancing sensory qualities, oil-in-water (O/W) and water in oil (W/O) emulsions are widely used in hair care formulations [39]. Three requirements are necessary for the emulsification mechanism to work: the particles must be compatible with both phases but not dissolve in them, have a size smaller than the goal emulsion's droplet size, and remain wettable with the phases. The wettability of the particles is the property that most affects the mechanism. The direction of the emulsion is determined by their contact angle (between the particles, the oil phase, and the aqueous phase). A phase's likelihood of becoming the continuous phase increases with its wettability [40]. The distribution and stability of ingredients are improved by a variety of emulsions, such as Water-in-Oil-in-Water (W/O/W) and Oil-in-Water-in-Oil (O/W/O), which are sophisticated dual-layer systems. They provide dual-phase protection by stabilizing both water- and oil-soluble actives, allow controlled release for gradual and long-lasting effects [41].

In hair cosmetics; novel drug delivery systems (NDDS) by enhancing the penetration, stability, and effectiveness of active compounds, innovative drug delivery systems enhance hair care. Phospholipid vesicles are used in liposomal delivery to encapsulate and boosting hair protection and scalp health. With their submicron-sized droplets, nano emulsions raise the hydration and solubility of serums and therapies [42]. Hair recovery and UV protection are improved by the regulated release of bioactive substances provided by solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) [43]. Micellar technology is perfect for fragile and color-treated hair since it holds debris and oils while maintaining scalp moisture, ensuring gentle yet effective cleansing [44].

### **2.3 Smart polymers for controlled release**

Smart polymers, also known as stimuli-responsive polymers, are advanced materials capable of reversible changes in response to environmental variations, making them highly suitable for controlled drug delivery. These polymers can be engineered to respond to stimuli such as temperature, pH, light, and enzymes, enabling precise drug release at specific sites and times. [45]. Recent developments focus on multi-stimuli-responsive systems, that enhance precision and therapeutic efficacy by combining properties like pH and temperature responsiveness. Despite barriers like slow response times and biocompatibility concerns, smart polymers hold great promise for intelligent drug delivery systems, improving treatment efficiency while minimizing side effects. Polymers that respond to change solubility with temperature shifts, pH-sensitive polymers swell or collapse in different pH environments, photoresponsive polymers change configuration upon light exposure, and enzyme-responsive polymers degrade in certain biological settings [46].

### **3. Trends and Future Perspectives in Hair Cosmeceuticals**

The trends in future of hair cosmeceuticals is being shaped by advancements in biotechnology, artificial intelligence, and sustainable innovations [47]. Hair regrowth and scalp health are being revolutionized by biotech-driven technologies such as CRISPR, peptide therapies, and exosome therapy [48]. AI-powered tools, including smart scalp analyzers and virtual try-on technologies, enable personalized hair care formulations tailored to individual needs [49]. Genomic hair care and DNA-based solutions offer targeted treatments, while stem cell and growth factor therapy pave the way for regenerative approaches [50]. Sustainable formulations, lab-grown ingredients, and waterless hair care products are gaining traction to minimize environmental impact. Additionally, neurocosmetics are emerging to combat stress-related hair damage, and 3D-printed hair follicles present potential breakthroughs in hair restoration. As clinical advancements continue, regulatory frameworks will evolve to ensure safety and efficacy, shaping the next era of innovative and science-driven hair care cosmeceuticals [51].

## Conclusion:

Innovations in ingredient research, formulation technology, and sustainability initiatives have propelled notable progress in the hair cosmeceuticals industry. To address common hair issues including damage repair, frizz control, and moisture retention, modern formulations now include a wide variety of active ingredients, such as silicone substitutes, protein-based treatments, and lipid-replenishing agents. Furthermore, it is now crucial to use protective products like heat protectants, UV filters, and antioxidants to shield hair from environmental stresses.

The effectiveness and targeted delivery of active substances have been further improved by advanced formulation techniques, including nanoemulsions and smart polymers, which have improved the health and appearance of hair. Furthermore, new developments like AI-powered customized formulas, biotech-driven hair care, and sustainable ingredient sourcing are reshaping the market and opening the door for more efficient and eco-friendly goods.

In the future, hair cosmeceuticals will undergo yet another revolution thanks to new bioactive chemicals, advanced formulation methods, and ongoing research in hair fiber biology. Future developments might concentrate on microbiome-friendly formulations, biomimetic techniques, and AI-driven personalization to meet the needs of different hair types. The next generation of hair cosmeceuticals will be greatly influenced by continuous developments in materials science and green chemistry as the market for high-performance and environmentally friendly hair care products expands.

## References:

1. Won, H. J., Kim, T. M., An, I.-s., Bae, H. J., & Park, S. Y. (2023). Protection and Restoration of Damaged Hair via a Polyphenol Complex by Promoting Mechanical Strength, Antistatic, and Ultraviolet Protection Properties. *Biomimetics*, 8(3), 296. <https://doi.org/10.3390/biomimetics8030296>
2. Li, Z., Li, Y., Tang, X., & Nazaroff, W. W. (2023). Siloxane emissions and exposures during the use of hair care products in buildings. *Environmental Science & Technology*, 57(48), 19999–20009. <https://doi.org/10.1021/acs.est.3c05156>
3. Li, Q., Zou, S., & Wei, L. (2022). Silicone to Reduce Combing Force, Control Flyaway, Repair Damage in Transparent Shampoo. *Journal of Cosmetic Science*, 73(6).
4. Lenick (2018), Comparison of Silicone Quaternium 20 and Polyquaternium 10 in hair care formulations, *13*(4), 74.
5. Abelan, U. S., de Oliveira, A. C., Cacoci, É. S. P., Martins, T. E. A., Giacon, V. M., Velasco, M. V. R., & Lima, C. R. R. D. C. (2022). Potential use of essential oils in cosmetic and dermatological hair products: A review. *Journal of Cosmetic Dermatology*, 21(4), 1407-1418. <https://doi.org/10.1111/jocd.14286>



6. Healthline. (2020, March 1). *Keratin and hair loss*. <https://www.healthline.com/health/what-are-the-side-effects-of-a-keratin-treatment>
7. Malinauskyte, E., Shrestha, R., Cornwell, P. A., Gourion-Arsiquaud, S., & Hindley, M. (2021). Penetration of different molecular weight hydrolysed keratins into hair fibres and their effects on the physical properties of textured hair. *International journal of cosmetic science*, 43(1), 26–37. <https://doi.org/10.1111/ics.12663>
8. Qadir and Islam, (2024), Potential of silk proteins in cosmetics, *Journal of Scientific Agriculture* 8, 79-87, DOI:[10.25081/jsa.2024.v8.9070](https://doi.org/10.25081/jsa.2024.v8.9070)
9. Igielska-Kalwat J, *et al.* Human Hair Care Using Products Containing Naturally Obtained Collagen from Salmon Skin Waste. *J Dermatol Res.* 2024;5(2):1-13. <https://doi.org/10.46889/JDR.2024.5202>
10. Coderch, L., Di Lorenzo, R., Mussone, M., Alonso, C., & Martí, M. (2022). The role of lipids in the process of hair ageing. *Cosmetics*, 9(6), 124. <https://doi.org/10.3390/cosmetics9060124>
11. Mendez, S., Manich, A. M., Marti, M., Parra, J. L., & Coderch, L. (2011). Damaged hair retrieval with ceramide-rich liposomes. *Journal of Cosmetic Science*, 62(6), 565.
12. Choi SH, Moon JS, Jeon BS, Jeon YJ, Yoon BI, Lim CJ. Hair growth promoting potential of phospholipids purified from porcine lung tissues. *Biomol Ther (Seoul)*. 2015 Mar;23(2):174-9. doi: 10.4062/biomolther.2014.108
13. Ayanlowo, O., Ebie, C., Cole-Adeife, O., Ilomuanya, M., & Adegbulu, A. (2021). Shea butter as skin, scalp, and hair moisturizer in Nigerians. *Dermatologic Therapy*, 34(2).
14. Shrinivas, LD, M. H. (2022). Preparation and evaluation of hair serum, *International Journal of Advances in Engineering and Management (IJAEM)*, 4(6), 2389-2393.
15. Boira, *et al.*, (2024). Hyaluronic acid: elucidating its penetration into, and effect on hair fibers using confocal Raman spectroscopy and biometric techniques, *Preprints*. 1-13 <https://doi.org/10.20944/preprints202401.1325.v1>
16. Kiruthiga, *et al.*, (2024). FORMULATION OF HERBAL HAIR CONDITIONER AND EVALUATION OF ITS PHYSICOCHEMICAL PARAMETERS, *World Journal of Pharmaceutical Research*, 13(5), 1358
17. Cole, Wolf, (2014). Cyberspace Chat: An Examination of the Potential Benefits of Caffeine, Niacinamide, and Panthenol, *Hair Transplant Forum International*, 24(5) 178-180
18. Bailei., *et al.*, (2020). Recent Advancement of Molecular Structure and Biomaterial Function of Chitosan from Marine Organisms for Pharmaceutical and Nutraceutical Application. *Applied Sciences*, 10(14), 4719. <https://doi.org/10.3390/app10144719>

19. Thombare, (2016), Guar gum as a promising starting material for diverse applications: A review. *International journal of biological macromolecules*, 88, 361-372 <https://doi.org/10.1016/j.ijbiomac.2016.04.001>
20. Furtado, (2022), Xanthan gum: Applications, challenges, and advantages of this asset of biotechnological origin, *Biotechnology Research and Innovation Journal*, 6(1), 1-8 <https://doi.org/10.4322/biori.202205>
21. Abu Hijleh, Ameer Nasser, (2011), Improving of Hair Care Product, *Chemical Engineering*, 20-21 <https://hdl.handle.net/20.500.11888/13780>
22. Rigoletto, *et al.*, (2007), Polyquaternium-69: A New Fixative Polymer with Enhanced Styling Benefits. *Cosmetic Science Technology*, 142-156.
23. Qu, X., Niu, L., Kroon, B., & Foltis, L. (2018). Pollution Damage and Protection of Asian Hair. *Cosmetics*, 5(1), 17. <https://doi.org/10.3390/cosmetics5010017>
24. Won, H. J., Kim, T. M., An, I. S., Bae, H. J., & Park, S. Y. (2023). Protection and Restoration of Damaged Hair via a Polyphenol Complex by Promoting Mechanical Strength, Antistatic, and Ultraviolet Protection Properties. *Biomimetics (Basel, Switzerland)*, 8(3), 296. doi: [10.3390/biomimetics8030296](https://doi.org/10.3390/biomimetics8030296)
25. Maillan, P. (2002). UV protection of artificially coloured hair using a leave-on formulation. *International journal of cosmetic science*, 24(2), 117-122. <https://doi.org/10.1046/j.1467-2494.2002.00132.x>
26. Vaudagna, M. V., Aiassa, V., Marcotti, A., Beti, M. F. P., Constantín, M. F., Pérez, M. F., ... & Becerra, M. C. (2023). Titanium Dioxide Nanoparticles in sunscreens and skin photo-damage. Development, synthesis and characterization of a novel biocompatible alternative based on their in vitro and in vivo study. *Journal of Photochemistry and Photobiology*, 15, 100173. <https://doi.org/10.1016/j.jpap.2023.100173>
27. Gupta, M., Mahajan, V. K., Mehta, K. S., & Chauhan, P. S. (2014). Zinc therapy in dermatology: a review. *Dermatology research and practice*, 2014, 709152. <https://doi.org/10.1155/2014/709152>
28. Casale, F., Suh, S., Yale, K., & Mesinkovska, N. A. (2021). Clinical role of oral vitamin C and E therapy in skin and hair disorders. *International Journal of Cosmetics and Dermatology*, 1(1), 12-20. DOI: [10.55124/ijcd.v1i1.44](https://doi.org/10.55124/ijcd.v1i1.44)
29. Dario, M. F., Baby, A. R., & Velasco, M. V. R. (2015). Effects of solar radiation on hair and photoprotection. *Journal of Photochemistry and Photobiology B: Biology*, 153, 240-246. <https://doi.org/10.1016/j.jphotobiol.2015.09.025>
30. Idson, B. (2020). Polymers as conditioning agents for hair and skin. *Conditioning agents for hair and skin*, 251-279.

31. Dario, M. F., Baby, A. R., & Velasco, M. V. R. (2015). Effects of solar radiation on hair and photoprotection. *Journal of Photochemistry and Photobiology B: Biology*, 153, 240-246. <https://doi.org/10.1016/j.jphotobiol.2015.09.025>
32. Idson, B. (2020). Polymers as conditioning agents for hair and skin. *Conditioning agents for hair and skin*, 251-279.
33. Thakare, N. H., Shirole, S. S., Patil, U. R., Deo, S. D., & Yeole, R. R. Review on hair care cosmetic-formulation and evaluation of shampoo bar [solid shampoo]. *International journal of Progressive Research in Engineering Management and Science.*, 4 (1), 519-526
34. Maiman, R. E. (2023). Cosmeceuticals for Hair and Nails. In *Cosmeceutical Science in Clinical Practice* (pp. 105-126). CRC Press. <https://doi.org/10.1201/9781315165905>.
35. Żwawiak, J., Walentkowska, J., Zaprutko, L., & Pawełczyk, A. (2024). The Frequency Ranking of Occurrence of Individual Ingredients in Hair Care Cosmetics Available on the Polish Market. *Cosmetics*, 11(4), 125.
36. Martins, E., Castro, P., Ribeiro, A. B., Pereira, C. F., Casanova, F., Vilarinho, R., ... & Ramos, Ó. L. (2024). Bleached hair as standard template to insight the performance of commercial hair repair products. *Cosmetics*, 11(5), 150. <https://doi.org/10.3390/cosmetics11050150>.
37. McMullen, R. L., & Gillece, T. (2023). Development of a three-point cantilever bending technique to study the mechanical properties of hair styling ingredients. *Skin research and technology: official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)*, 29(1), e13256. <https://doi.org/10.1111/srt.13256>.
38. Karim, M., Klein, E. J., Nohria, A., Taiwo, D., Adotama, P., Cohen, D., ... & Lo Sicco, K. (2023). Potential for allergic contact dermatitis in popular hair care practices and ingredients. *Dermatitis*, 34(6), 484-491. <https://doi.org/10.1089/derm.2023.0045>.
39. Gor, T., Mahida, D. K., Patel, A., & Gondaliya, N. (2025) Biosurfactants and Bioemulsifiers in Cosmetics: A Sustainable Approach to Formulation. In *Microbial Surfactants in Pharmaceuticals and Cosmetics* (pp. 173-188). CRC Press. <https://doi.org/10.1201/9781003424864>.
40. Cortes, N., Alves, I. A., & Aragón, D. M. (2024). Innovative Emulsifiers in Cosmetic Products: A Patent Review (2013–2023). *ACS omega*, 9(50), 48884-48898. <https://doi.org/10.1021/acsomega.4c07305>.
41. Dănilă, E., Kaya, D. A., Anuța, V., Popa, L., Coman, A. E., Chelaru, C., Constantinescu, R. R., Dinu-Pîrvu, C., Albu Kaya, M. G., & Ghica, M. V. (2024). Formulation and Characterization of Niacinamide and Collagen Emulsion and Its Investigation as a

- Potential Cosmeceutical Product. *Cosmetics*, 11(2), 40.  
<https://doi.org/10.3390/cosmetics11020040>.
42. Khadam, V. K. R., Singh, R. P., Prajapati, D., Yunus, M., Prajapat, B., Rai, S. K., ... & Gogoi, D. (2024). An Updated Comprehensive Review on Novel Drug Delivery Systems (NDDS) In the Pharmaceuticals. *Asian Journal of Pharmaceutical Research and Development*, 12(1), 55-64. <https://doi.org/10.22270/ajprd.v12i1.1349>.
  43. Tang, C. H., Chen, H. L., & Dong, J. R. (2023). Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) as food-grade nanovehicles for hydrophobic nutraceuticals or bioactives. *Applied Sciences*, 13(3), 1726. <https://doi.org/10.3390/app13031726>.
  44. Zeng, Q., Wang, Z., Zhu, Z., Hu, Y., Wang, Y., Xue, Y., ... & Liu, Q. (2022). Glycyrrhizin micellar nanocarriers for topical delivery of baicalin to the hair follicles: A targeted approach tailored for alopecia treatment. *International Journal of Pharmaceutics*, 625, 122109. <https://doi.org/10.1016/j.ijpharm.2022.122109>.
  45. James, H. P., John, R., Alex, A., & Anoop, K. R. (2014). Smart polymers for the controlled delivery of drugs – A concise overview. *Acta Pharmaceutica Sinica B*, 4(2), 120–127. <https://doi.org/10.1016/j.apsb.2014.02.005>
  46. Wu, J., Xue, W., Yun, Z., Liu, Q., & Sun, X. (2024). Biomedical applications of stimuli-responsive “smart” interpenetrating polymer network hydrogels. *Materials Today Bio*, 25, 100998. <https://doi.org/10.1016/j.mtbio.2024.100998>
  47. Koike, (2019). Special Issue “Recent Advances in Hair Science and Hair Care Technologies”. *Cosmetics*, 6(4), 61. <https://doi.org/10.3390/cosmetics6040061>
  48. Kost, *et al.* (2022). Exosome therapy in hair regeneration: A literature review of the evidence, challenges, and future opportunities. *Journal of cosmetic dermatology*, 21(8), 3226–3231. <https://doi.org/10.1111/jocd.15008>
  49. Azam, *et al.* (2024). A NEW ERA IN COSMETOLOGY. *European Journal of Biomedical*, 11(5), 91-102.
  50. Shimizu, *et al.* (2022). Regenerative medicine strategies for hair growth and regeneration: A narrative review of literature. *Regenerative therapy*, 21, 527–539. <https://doi.org/10.1016/j.reth.2022.10.005>
  51. Dhanesh, Santosh, and Naikawadi, (2024). Revolutionizing Hair Care with Cosmetic Products. *Asian Journal of Pharmaceutical Research and Development*, 12(3), 157-158. <http://dx.doi.org/10.22270/ajprd.v12i3.1413>

## GUT HEALING WITH HERBS: NATURAL WAYS TO SOOTHE ULCERS

Aarti Zanwar, Ashim Kumar Sen, Dhanya B. Sen and Rajesh A. Maheshwari

Department of Pharmacy,

Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara-391760, Gujarat

### Abstract:

Peptic ulcer disease (PUD) is a common gastrointestinal condition that leads to significant morbidity and mortality worldwide. It occurs due to an imbalance in stomach acid production, often aggravated by factors like *Helicobacter pylori* infection, stress, and the use of NSAIDs. Although traditional treatments, including proton pump inhibitors (PPIs) and antibiotics, are frequently prescribed, concerns about antibiotic resistance and side effects have prompted interest in herbal remedies as alternative treatments for ulcers, thanks to their lower cost, fewer adverse effects, and effectiveness. Several plant-based remedies have shown potential in treating gastric ulcers. For instance, *Curcuma longa* (turmeric) and *Asparagus racemosus* (shatavari) have demonstrated protective effects by reducing stomach acidity, enhancing mucosal defense, and aiding in healing. *Allium sativum* (garlic) has shown gastroprotective properties by lowering oxidative stress and boosting protective factors, while *Sophora flavescens* has proven beneficial in preventing ulcer formation and fighting *H. pylori* infection. Extracts of *Moringa oleifera* (drumstick tree) also promote ulcer healing through their cytoprotective effects. Furthermore, *Picrorhiza kurroa* (kutki), a traditional herb, has demonstrated notable anti-ulcer properties. In animal models, kutki rhizome extract expedited ulcer healing by reducing oxidative damage and boosting antioxidant enzyme activity. It also decreased stomach acidity and helped improve gastric pH, highlighting its potential as a natural remedy for gastric ulcers. These findings underscore the potential of herbal treatments in managing ulcers, offering safer, effective alternatives to conventional therapies. Ongoing research into these plants could lead to valuable insights for developing comprehensive treatments for PUD.

**Keywords:** Peptic Ulcer Disease, Drumstick Tree, Kutki, Garlic, Turmeric

### Introduction:

Peptic ulcer disease (PUD) is a significant global health issue that affects both the gastric and duodenal regions of the digestive tract. For over a century, it has contributed to considerable morbidity and mortality, with peptic ulcers typically developing in the stomach or the upper part of the small intestine. These ulcers result from excessive stomach acid, which damages the protective mucosal lining. This leads to exposed mucosa that extends into deeper tissue layers, such as the submucosa or muscularis propria. Approximately 5-10% of the global population experiences peptic ulcers at some point in their lives, highlighting the widespread nature of the condition. The primary cause of peptic ulcers is an imbalance in the production of stomach acid,

which disrupts the mucosal barrier that normally protects the digestive tract. This disruption is often exacerbated by factors such as poor diet, stress, and certain lifestyle choices. Risk factors for developing peptic ulcers include alcohol and tobacco use, prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs), Zollinger-Ellison syndrome (a condition causing excessive acid production), and infection with *Helicobacter pylori* (*H. pylori*), a bacterium that plays a key role in ulcer formation. *H. pylori* is a spiral-shaped bacterium that is highly mobile and can damage the mucosal lining of the gastrointestinal tract, making it more vulnerable to acid-induced damage. This bacterium is considered the primary causative agent in many cases of peptic ulcers. The damage caused by *H. pylori* leads to inflammation of the mucosal layer, which, over time, can result in ulcer formation. Effective treatment for peptic ulcer disease typically involves two main approaches: reducing stomach acid production and promoting the healing of the mucosal lining. Medications such as proton pump inhibitors (PPIs) and H2 blockers are commonly prescribed to reduce acid production, which helps alleviate symptoms and promote healing. Additionally, antibiotics are often prescribed to eradicate *H. pylori* infection, which is crucial for preventing ulcer recurrence. Lifestyle modifications are also recommended to support healing and prevent further damage. These include avoiding alcohol, smoking, and the overuse of NSAIDs, as well as adopting a healthier diet and managing stress levels. By combining these strategies, the impact of peptic ulcer disease can be significantly reduced, leading to improved outcomes for affected individuals.<sup>[1,5]</sup>

Traditional treatments for peptic ulcers come with a range of challenges, many of which can impact their effectiveness. One of the primary concerns is the high likelihood of ulcer recurrence, especially when the underlying cause, such as *H. pylori* infection, is not fully eradicated, even if initial treatment appears successful. The process of eradicating *H. pylori* can be complicated, particularly due to the growing problem of antibiotic resistance, which can contribute to persistent or recurrent ulcers. Moreover, medications that are commonly used to reduce stomach acid, such as proton pump inhibitors (PPIs) and H2 blockers, can have side effects. Long-term use of these drugs has raised concerns, with studies suggesting they may increase the risk of hip fractures and kidney disease. Additionally, the duration required for traditional treatments to heal ulcers can be lengthy, often resulting in prolonged discomfort or potential complications during the healing process. While protecting the mucosal lining of the stomach is a key component of treatment, conventional therapies may not always provide sufficient protection, leaving the stomach lining vulnerable to continued damage. The success of these treatments can vary significantly among individuals, with some patients experiencing limited or no improvement, or in some cases, adverse reactions to the medications. In severe instances, surgical intervention may become necessary, highlighting the limitations of relying solely on non-surgical treatments for managing peptic ulcers. As a result, healthcare providers

must carefully consider these challenges when developing individualized treatment plans, taking into account factors such as the underlying cause of the ulcer, the patient's medical history, and the potential risks of the prescribed medications. Ongoing research is focused on overcoming these obstacles and enhancing the overall effectiveness of peptic ulcer therapies. In contrast, both clinical and experimental studies suggest that herbal remedies offer a promising alternative, often exhibiting fewer side effects and a higher degree of efficacy in treating peptic ulcers. Notably, the cost of herbal treatments is significantly lower, with estimates suggesting that they are approximately one-sixth of the cost of conventional Western medicine. This chapter explores the safety, effectiveness, and mechanisms behind herbal medications used in the management of peptic ulcers. It emphasizes the potential advantages of incorporating herbal remedies into the treatment strategy for peptic ulcers, offering a more accessible and potentially safer alternative for those seeking effective solutions for this gastrointestinal condition. By considering herbal remedies alongside traditional treatments, patients and healthcare providers may be able to create a more holistic and balanced approach to managing peptic ulcers.<sup>[7-12]</sup>

### **Plant-based remedies for ulcer treatment**

Herbal-based remedies for ulcer treatment have gained attention for their potential to support healing and reduce symptoms. These natural treatments often work by soothing the digestive tract, reducing inflammation, and protecting the stomach lining from further damage. Many of these remedies help balance stomach acid production, promote mucosal healing, and can have fewer side effects compared to conventional medications. As a result, they provide an appealing alternative or complement to traditional ulcer treatments, especially for individuals seeking a more natural approach to managing their condition.

### **Turmeric**

For many decades, traditional medicine has utilized *Curcuma longa* to treat various ailments such as inflammation, gastritis, and stomach ulcers. In experimental studies involving rats, where their stomachs were subjected to pylorus ligation, *C. longa* extract was shown to reduce gastric acid secretion and protect the stomach lining from mucosal damage. The extract's ability to prevent gastric ulcers was attributed to its effect on the H<sub>2</sub> histamine receptor, where it inhibited the production of cAMP in a concentration-dependent manner. Specifically, the ethyl acetate extract of *C. longa* was the most effective at blocking H<sub>2</sub> receptors, while curcumin, its primary component, did not demonstrate this activity. These findings suggest that *C. longa* extract reduces gastric acid secretion by competitively inhibiting the H<sub>2</sub> histamine receptors. Further studies explored the anti-ulcer effects of *C. longa* on gastric ulcers induced by indomethacin in rats. Indomethacin was administered orally to induce ulcers, and the rats were then treated with *C. longa* extract. The results showed that the extract significantly reduced both the number and severity of ulcers, as evidenced by a decrease in ulcer index and an improvement

in healing. This confirmed that *C. longa* has protective effects against gastric ulcers. In human trials, curcumin, the active ingredient in *C. longa*, was incorporated into the treatment for patients with peptic ulcers. The addition of curcumin provided significant relief from dyspepsia symptoms, with the curcumin group experiencing more noticeable improvements compared to the control group. Additionally, a higher percentage of patients in the curcumin group reported complete symptom resolution, compared to those in the placebo group. Despite these positive results in symptom relief, the urea breath test for *H. pylori* eradication showed no significant difference across the treatment groups, indicating that curcumin did not enhance the eradication of the infection. In conclusion, while curcumin offers a safe and effective adjunct for treating dyspepsia in peptic ulcer patients, it does not appear to provide additional benefits in eradicating *H. pylori*. The study highlights the potential of *C. longa* as a complementary therapy for managing peptic ulcers, particularly for its symptom-relieving properties.<sup>[13-15]</sup>

### **Shatavari**

The study investigated the potential of a methanolic extract from the fresh roots of *A. racemosus* (commonly known as Shatavari) for preventing ulcers. The extract was administered orally twice daily for five days, with doses ranging from 25 to 100 mg/kg. The most notable effects were observed at a dose of 50 mg/kg, which significantly prevented acute gastric ulcers caused by cold restraint stress (CRS), pyloric ligation, a combination of aspirin and pyloric ligation, and duodenal ulcers caused by cysteamine. Additionally, this dose facilitated the healing of chronic gastric ulcers induced by acetic acid after ten days of treatment. However, the extract showed limited or no effectiveness against ethanol- or aspirin-induced gastric ulcers. Further studies on gastric juice and mucosal defenses indicated that the *A. racemosus* extract exhibited a significant antioxidant effect, enhancing mucosal protection. The extract increased mucus secretion, cellular mucus, and the lifespan of gastric cells, which are all crucial for protecting the stomach lining. However, it had little impact on aggressive factors such as acid production and pepsin levels, suggesting that its primary mode of action might be through bolstering the stomach's natural protective mechanisms rather than reducing harmful factors. When the crude extract was administered over a 15-day period at a dose of 100 mg/kg/day, it resulted in a significant reduction in the ulcer index compared to the control group. This effect was comparable to the action of ranitidine, a commonly used anti-ulcer medication. The extract also decreased the volume of gastric secretion and reduced both free and total acidity. Additionally, there was a noticeable increase in the total carbohydrate (TC) content and the TC/total protein (TP) ratio in the gastric juice, while total protein levels remained unchanged. These findings suggest that *A. racemosus* has potent anti-ulcer properties that could be on par with pharmaceutical treatments like ranitidine, possibly by inhibiting the production of stomach acid, which in turn helps prevent damage to the gastric mucosa. Beyond its anti-ulcer potential,



*A. racemosus* has been recognized for its therapeutic benefits in treating stomach ulcers and a condition known as Parinama Sula, which is similar to duodenal ulcers. Studies have shown that fresh *A. racemosus* root juice offers significant therapeutic advantages for individuals with duodenal ulcers. Furthermore, a combination of *A. racemosus* and *Terminalia chebula* has been found to provide protection to the stomach mucosa from ulcers induced by pentagastrin and carbachol. This protective effect was evident through a significant reduction in both the extent of ulceration and the ulcer index. Additionally, treated animals exhibited an increase in gastric pH and secretion volume, indicating reduced sensitivity of gastric parietal cells to agents that stimulate acid secretion. The cytoprotective effect is believed to be due to an enhanced production of mucus, which acts as a barrier to gastric acid and other damaging factors. In conclusion, the study suggests that *A. racemosus* possesses strong anti-ulcer properties and may be an effective alternative or complementary treatment for gastric ulcers, offering a natural approach to managing ulcerative conditions.<sup>[16-19]</sup>

### **Garlic**

In this experiment, a positive control group was established, while the other groups received daily doses of either garlic or cabbage juice for seven days. The results revealed that both garlic and cabbage extracts effectively reduced the duration of gastric ulcers, along with total acidity, gastric juice volume, bacterial count, and histological changes induced by aspirin. Notably, the combination of these extracts resulted in a significant increase in the pH of gastric juice, suggesting their therapeutic potential in treating acute stomach ulcers. The study also examined the effects of indomethacin-induced gastric ulcers, which exhibited elevated levels of tumor necrosis factor-alpha and malondialdehyde. At the same time, key protective factors like prostaglandin E2 (PGE2), glutathione (GSH), and nitric oxide (NO) were notably reduced when compared to the normal control group. Pre-treatment with garlic extract resulted in outcomes similar to those observed with the common antiulcer drug, omeprazole. The prevention index for the garlic extract was 83.4%, compared to 94.5% in the omeprazole group. This suggests that garlic extract may help prevent ulcers induced by indomethacin by reducing oxidative stress and promoting the levels of protective factors like NO, PGE2, and GSH. Additionally, garlic extract exhibited significant gastroprotective effects, evidenced by improvements in histopathological damage to the gastric tissue. This further supports the idea that garlic may be an effective treatment for gastric ulcers, both by reducing the factors that contribute to ulcer formation and by promoting healing and protection of the gastric mucosa. The findings of this study suggest that garlic extract, either alone or in combination with other natural extracts like cabbage, holds promise as a potential alternative treatment for gastric ulcers, helping to reduce symptoms and promote healing through its antioxidant and gastroprotective properties.<sup>[20,21]</sup>

### **Sophorae Radix**

The dried root of *Sophora flavescens*, commonly known as *Sophorae Radix*, has been an important component of traditional medicine for centuries, particularly in East Asia. This plant has been recognized for its broad range of medicinal properties, and its use in treating gastrointestinal disorders, including stomach ulcers, is well-documented. Research has identified several active compounds in the root extract, most notably vexibinol, a flavonoid that has demonstrated significant anti-ulcer effects. Vexibinol's efficacy in treating stomach ulcers is attributed to its ability to protect the stomach's mucosal lining and reduce the production of gastric acid, making it a potential therapeutic agent for managing ulcers induced by acidic conditions. In addition to vexibinol, *Sophora flavescens* also contains another active compound called trifolirhizin, which has shown promising results in animal studies. Trifolirhizin has been linked to a reduction in gastric secretion and acid production, and it has demonstrated beneficial effects against *Helicobacter pylori* infection, a common bacterial cause of gastric ulcers. These compounds, through their combined actions, provide a multifaceted approach to ulcer prevention and treatment. Given these findings, *Sophora flavescens* root, with its bioactive components like vexibinol and trifolirhizin, appears to offer significant therapeutic potential for the treatment of stomach ulcers and other related gastrointestinal conditions. Its ability to both protect the stomach lining and combat *H. pylori* infection positions it as a valuable herbal remedy in modern and traditional medicine alike.<sup>[22]</sup>

### **Drumstick tree**

The study investigated the effects of various extracts from the leaves and fruits of *Moringa oleifera*, commonly known as the drumstick tree, on gastric and duodenal ulcers. The leaf extracts, particularly at a dose of 500 mg/kg, displayed gastric antisecretory and cytoprotective properties, promoting the healing of chronic gastric ulcers in several experimental models. In addition, these extracts significantly reduced duodenal ulcers induced by cysteamine and gastric ulcers caused by stress. On the other hand, none of the fruit extracts showed significant anti-ulcer effects. The study suggests that *Moringa* leaves play a vital role in healing gastric ulcers and preventing the development of induced duodenal and gastric ulcers in rats. The research also focused on the protective effects of an alcoholic extract of *Moringa oleifera* leaves (MOLE) against gastric ulceration and inflammation caused by bisphenol A (BPA) in rats. BPA is known to cause gastric ulceration and alter various stomach tissue parameters. However, administration of MOLE alleviated the BPA-induced damage, demonstrating antioxidant, anti-apoptotic, and anti-inflammatory activities, which helped protect the stomach from further injury. Additionally, when acute gastric ulcers were induced by aspirin, both an alkali preparation of *Moringa* root and fresh leaf juice exhibited significant anti-ulcer effects in a dose-dependent manner. Interestingly, the alkali preparation of the root showed stronger anti-ulcer

activity compared to the fresh leaf juice. This anti-ulcer effect of the root is likely due to the presence of alkaloids, as well as anticholinergic and antihistaminic activities, or a combination of these factors. These findings highlight the potential of *Moringa oleifera* as a natural remedy for treating gastric and duodenal ulcers.<sup>[23-25]</sup>

### **Kutki**

In a study involving rats with indomethacin-induced gastric ulcers, the oral administration of an ethanol extract from the rhizome of *Picrorhiza kurroa* (commonly known as kutki) helped accelerate the healing of ulcers over a 10-day period compared to the untreated group. The extract effectively reduced peroxidized lipid levels in the gastric tissue, bringing them back to near normal levels. Additionally, it significantly increased the levels of sulfhydryl groups and improved the activity of antioxidant enzymes like catalase and superoxide dismutase (SOD), which had been reduced in the ulcerated rats. These results suggest that kutki rhizome extract aids in the healing of gastric ulcers through its antioxidant properties and its ability to neutralize free radicals. The protective effects of kutki rhizome extract were assessed at different doses. At a moderate dose, the extract significantly reduced stomach volume, total acidity, and free acidity. At a higher dose, there was a significant reduction in the number of ulcers, along with an increase in the pH of gastric juice. The anti-ulcer effects of the kutki rhizome extract are attributed to its phytochemicals, such as flavonoids, saponins, alkaloids, and tannins. These findings highlight the potential of *Picrorhiza kurroa* as a natural remedy for gastric ulcers, offering an alternative approach for healing and preventing ulcer-related damage.<sup>[26,27]</sup>

### **Conclusion:**

In conclusion, peptic ulcer disease (PUD) is a major global health concern caused by factors like stomach acid imbalance, *H. pylori* infection, NSAID use, stress, and poor diet. Traditional treatments, such as proton pump inhibitors and antibiotics, are effective but come with side effects, recurrence, and resistance issues. This has led to growing interest in herbal remedies, which offer safer, cost-effective alternatives. Herbs like turmeric, shatavari, garlic, and others help promote ulcer healing, reduce acidity, and protect the gastric mucosa, often with fewer side effects than conventional treatments. Ongoing research into these natural remedies provides hope for more personalized and effective approaches to managing PUD.

### **References:**

1. Peterson, W. L. (1991). *Helicobacter pylori* and peptic ulcer disease. *New England Journal of Medicine*, 324(15), 1043–1048.
2. Lanas, A., & Chan, F. K. (2017). Peptic ulcer disease. *The Lancet*, 390(10094), 613–624.
3. Søreide, K., Thorsen, K., Harrison, E. M., Bingener, J., Møller, M. H., Ohene-Yeboah, M., et al. (n.d.). Perforated peptic ulcer. *The Lancet*.

4. Narayanan, M., Reddy, K. M., & Marsicano, E. (2018). Peptic ulcer disease and *Helicobacter pylori* infection. *Missouri Medicine*, 115(3), 219.
5. Malfertheiner, P., Chan, F. K., & McColl, K. E. (2009). Peptic ulcer disease. *The Lancet*, 374(9699), 1449–1461.
6. The cost for treating gastric ulcer. (n.d.). Retrieved from <http://jibing.qiuyi.cn/wky/2013/0509/132036.html>
7. Zittel, T. T., Jehle, E. C., & Becker, H. D. (2000). Surgical management of peptic ulcer disease today—indication, technique, and outcome. *Langenbeck's Archives of Surgery*, 385, 84–96.
8. Behrman, S. W. (2005). Management of complicated peptic ulcer disease. *Archives of Surgery*, 140(2), 201–208.
9. Yang, Y. X., Lewis, J. D., Epstein, S., & Metz, D. C. (2006). Long-term proton pump inhibitor therapy and risk of hip fracture. *JAMA*, 296(24), 2947–2953.
10. Lazarus, B., Chen, Y., Wilson, F. P., Sang, Y., Chang, A. R., Coresh, J., & Grams, M. E. (2016). Proton pump inhibitor use and the risk of chronic kidney disease. *JAMA Internal Medicine*, 176(2), 238–246.
11. Mégraud, F. (2004). Basis for the management of drug-resistant *Helicobacter pylori* infection. *Drugs*, 64, 1893–1904.
12. Malfertheiner, P., Megraud, F., O'Morain, C. A., Gisbert, J. P., Kuipers, E. J., Axon, A. T., et al. (2017). Management of *Helicobacter pylori* infection—the Maastricht V/Florence consensus report. *Gut*, 66(1), 6–30.
13. Khonche, A., Biglarian, O., Panahi, Y., Valizadegan, G., Soflaei, S. S., Ghamarchehreh, M. E., et al. (2016). Adjunctive therapy with curcumin for peptic ulcer: A randomized controlled trial. *Drug Research*, 66(8), 444–448.
14. Nagle, R., Shrman, K., & Sharma, R. K. (2012). Anti-ulcer activity of *Curcuma longa* against indomethacin-induced gastric ulcers in albino rats. *Indian Journal of Veterinary Science and Biotechnology*, 7(4), 29–31.
15. Kim, D. C., Kim, S. H., Choi, B. H., Baek, N. I., Kim, D., Kim, M. J., & Kim, K. T. (2005). *Curcuma longa* extract protects against gastric ulcers by blocking H2 histamine receptors. *Biological & Pharmaceutical Bulletin*, 28(12), 2220–2224.
16. Dahanukar, S. A., Date, S. G., & Karandikar, S. M. (1983). Cytoprotective effect of *Terminalia chebula* and *Asparagus racemosus* on gastric mucosa. *Indian Drugs*, 21, 442–445.
17. Kishore, P., Pandey, P. N., Pandey, S. N., & Dash, S. (1980). Treatment of duodenal ulcer with *Asparagus racemosus* Linn. *Journal of Research in Indian Medicine, Yoga & Homeopathy*, 15, 409–415.

18. Sairam, K., Priyambada, S., Aryya, N. C., & Goel, R. K. (2003). Gastroduodenal ulcer protective activity of *Asparagus racemosus*: An experimental, biochemical, and histological study. *Journal of Ethnopharmacology*, 86(1), 1–10.
19. Bhatnagar, M., & Sisodia, S. S. (2006). Antisecretory and antiulcer activity of *Asparagus racemosus* Willd. against indomethacin plus pyloric ligation-induced gastric ulcer in rats. *Journal of Herbal Pharmacotherapy*, 6(1), 13–20.
20. El-Ashmawy, N. E., Khedr, E. G., El-Bahrawy, H. A., & Selim, H. M. (2016). Gastroprotective effect of garlic in indomethacin-induced gastric ulcer in rats. *Nutrition*, 32(7–8), 849–854.
21. Ben Hadda, T., ElSawy, N. A., Header, E. A., Mabkhot, Y. N., & Mubarak, M. S. (2014). Effect of garlic and cabbage on healing of gastric ulcer in experimental rats. *Medicinal Chemistry Research*, 23, 5110–5119.
22. Yamahara, J., Mochizuki, M., Fujimura, H., Takaishi, Y., Yoshida, M., Tomimatsu, T., & Tamai, Y. (1990). Antiulcer action of *Sophora flavescens* root and an active constituent. *Journal of Ethnopharmacology*, 29(2), 173–177.
23. Ruckmani, K., Kavimani, S., Jayakar, B., & Anandan, R. (1998). Anti-ulcer activity of the alkali preparation of the root and fresh leaf juice of *Moringa oleifera* Lam. *Ancient Science of Life*, 17(3), 220.
24. Abo-Elvoud, R. A., Ahmed Mohamed Abdelaziz, S., Attia Abd Eldaim, M., & Hazzaa, S. M. (2022). *Moringa oleifera* alcoholic extract protected stomach from bisphenol A-induced gastric ulcer in rats via its antioxidant and anti-inflammatory activities. *Environmental Science and Pollution Research*, 29(45), 68830–68841.
25. Devaraj, V. C., Asad, M., & Prasad, S. (2007). Effect of leaves and fruits of *Moringa oleifera* on gastric and duodenal ulcers. *Pharmaceutical Biology*, 45(4), 332–338.
26. Kumari, A., Mohanty, P. K., Kanare, M., & Singhai, A. K. (2023). Evaluation of antiulcer activity on roots of *Picrorhiza kurroa* by using pyloric ligation rat models. *International Journal of Pharmaceutical and Life Sciences*, 14(4), 32–40.
27. Ray, A., Chaudhuri, S. R., Majumdar, B., & Bandyopadhyay, S. K. (2002). Antioxidant activity of ethanol extract of rhizome of *Picrorhiza kurroa* on indomethacin-induced gastric ulcer during healing. *Indian Journal of Clinical Biochemistry*, 17, 44–51.

## **MARCUS GUNN JAW-WINKING SYNDROME: A RARE OCULOMOTOR PHENOMENON AND ITS MANAGEMENT**

**Cyril Sajan**

Department of Pharmacy,

Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara-391760, Gujarat

### **Abstract:**

Marcus Gunn jaw-winking ptosis is a congenital disorder that results in synkinetic movements of the upper eyelid during jaw activities, particularly during chewing. This condition is most often unilateral, though it can occasionally present bilaterally. Dr. Robert Marcus Gunn first described this syndrome in 1883, noting the association between unilateral ptosis and the contraction of the upper eyelid on the same side. Referred to as Marcus-Gunn jaw winking synkinesis, it is classified as a congenital cranial dysinnervation disorder (CCDD) and is marked by varying degrees of eyelid drooping at rest, alongside synkinetic movements of the upper eyelid during jaw actions. Although it is typically unilateral, bilateral cases are possible. The wink reflex results in a brief elevation or retraction of the eyelid, which may rise to or above the level of the opposite eyelid, followed by a quick return. This rapid motion is often seen during activities such as mouth opening, jaw movements, or feeding in infants, which aids in early identification.

**Keywords:** Fasanella-Servat Procedure, Internal Pterygoid-Levator Muscle, And Synkinesis, Congenital Cranial Dysinnervation Condition (CCDD), External Pterygoid-Levator Muscle

### **Introduction:**

Marcus Gunn jaw-winking ptosis is a congenital condition characterized by the involuntary movement of the upper eyelid in response to jaw movements during chewing. This condition typically occurs on one side but can occasionally be bilateral. It affects both males and females equally.[1] Marcus Gunn jaw-winking syndrome (MGJWS) is often observed in cases of congenital blepharoptosis. The syndrome was first documented by Dr. Robert Marcus Gunn, a Scottish ophthalmologist, in 1883, with the initial case involving a 15-year-old girl. This condition is defined by unilateral ptosis that is linked to the contraction of the upper eyelid on the same side. Other terms for this phenomenon include Marcus-Gunn jaw winking phenomena (MGP), Marcus Gunn ptosis, Maxillopalpebral synkinesis, and Pterygoid-levator synkinesis. Individuals with this congenital cranial dysinnervation disorder (CCDD) may display varying degrees of blepharoptosis when at rest. While it predominantly presents unilaterally, bilateral cases are also possible. When the ipsilateral pterygoid muscle is activated, the wink reflex results in a temporary elevation or retraction of the upper eyelid, often reaching a position equal to or higher than the unaffected eyelid, followed by a rapid return to a lower position. The amplitude

of this wink typically decreases when the individual looks down. The most striking aspect of the jaw-winking syndrome is this rapid and unusual eyelid movement, which can be triggered by actions such as opening the mouth, shifting the jaw, chewing, smiling, or sucking. Early identification of these wink phenomena often occurs during feeding, whether bottle or breast.

### **Etiology of Marcus Gunn Jaw-Winking Syndrome**

Marcus Gunn Jaw-Winking Syndrome (MGJWS) is attributed to congenital neurological miswiring that develops during the fetal stage.[2] It is the result of an unusual synkinetic connection between the oculomotor nerve (cranial nerve III) and the mandibular branch of the trigeminal nerve (cranial nerve V).

#### **Key Etiological Factors:**

##### **Aberrant Neural Connections:**

- The levator palpebrae superioris muscle, which is responsible for lifting the eyelid, is typically regulated by the oculomotor nerve (CN III).
- In the case of MGJWS, there is an abnormal connection between fibers of the trigeminal nerve (CN V3), which governs jaw movements, and the levator muscle.
- This abnormality leads to involuntary elevation of the eyelid during jaw activities such as chewing, sucking, or lateral movements.

##### **Congenital Developmental Defect:**

- The miswiring of neural connections occurs during the embryonic development stage and is present from birth.
- While the precise cause remains unclear, it is generally regarded as a sporadic developmental anomaly in the majority of instances.

##### **Genetic Factors:**

- Although MGJWS is predominantly sporadic, there have been rare instances of familial occurrences, indicating a potential genetic link.
- Some research suggests that certain families may exhibit autosomal dominant inheritance with incomplete penetrance.

##### **Association with Other Congenital Anomalies:**

MGJWS is occasionally found in conjunction with various congenital anomalies, such as Duane Retraction Syndrome, congenital ptosis, strabismus, and amblyopia. It may also present as a feature of syndromic conditions, including Goldenhar syndrome or congenital cranial dysinnervation disorders (CCDDs).

While the specific cause is still unclear, the predominant etiology is thought to involve irregular neural pathways established during early fetal development, which leads to the notable jaw-winking phenomenon.[3]


### Pathophysiology:

Marcus Gunn Jaw-Winking Syndrome (MGJWS) is a congenital neurological condition characterized by abnormal neural connections between the oculomotor nerve (cranial nerve III) and the mandibular branch of the trigeminal nerve (cranial nerve V3). Typically, the levator palpebrae superioris muscle, responsible for elevating the upper eyelid, receives innervation exclusively from the oculomotor nerve. In cases of MGJWS, however, misrouted fibers from the trigeminal nerve improperly link to the levator muscle, resulting in involuntary eyelid elevation during jaw movements associated with chewing, sucking, or lateral jaw motion.[4] This leads to the distinctive "jaw-winking" effect, which can vary in intensity. The affected eye may also display congenital ptosis when at rest, and the eyelid lifts abnormally with jaw movement, causing asymmetrical eyelid motion. This dysfunction can disrupt vision and may contribute to conditions such as amblyopia or strabismus. Unlike typical voluntary eyelid control, the jaw-winking reflex is not subject to conscious suppression, as it stems from peripheral miswiring rather than issues within the central nervous system. MGJWS may also occur alongside other congenital disorders, including Duane Retraction Syndrome or Goldenhar Syndrome, suggesting a more extensive developmental anomaly involving multiple cranial nerves.

### Epidemiology:

#### **Marcus Gunn jaw-winking syndrome**

- Accounts for about 5% of all cases of congenital ptosis
- Retraction or 'wink' of ptotic lid in conjunction with stimulation of ipsilateral pterygoid muscles



**Figure 1: Marcus Gunn Jaw-Winking Syndrome**

Marcus Gunn Jaw-Winking Syndrome (MGJWS) is a rare congenital condition, estimated to occur in approximately 1 in 10,000 to 25,000 live births. [5]It constitutes around 2–13% of congenital ptosis cases. The syndrome typically arises sporadically, although there are rare familial instances that suggest a possible autosomal dominant inheritance with incomplete penetrance. MGJWS is usually unilateral, with a higher incidence in the left eye compared to the right. There is no significant gender bias, as it affects both males and females equally. Diagnosis



is often made at birth or during early infancy, primarily due to the characteristic jaw-winking movement observed while feeding or chewing. While MGJWS is often isolated, it can be associated with other congenital conditions such as Duane Retraction Syndrome, strabismus, amblyopia, or Goldenhar Syndrome (Figure 1).

**Risk Factors:**

Marcus Gunn Jaw-Winking Syndrome (MGJWS) is primarily recognized as a congenital developmental disorder, though its precise etiology is not fully understood. [6]

Several risk factors may influence its manifestation:

1. **Genetic Factors** – While the majority of cases are sporadic, there are rare familial instances that imply a potential autosomal dominant inheritance pattern with incomplete penetrance, suggesting a genetic vulnerability in certain individuals.
2. **Abnormal Fetal Neural Development** – The syndrome arises from improper connections between cranial nerves III (oculomotor) and V3 (mandibular branch of the trigeminal nerve) during embryonic development, indicating that any factors affecting fetal nerve formation could pose risks.
3. **Association with Congenital Cranial Dysinnervation Disorders (CCDDs)** – MGJWS is occasionally associated with other congenital neurological disorders, such as Duane Retraction Syndrome or Moebius Syndrome, indicating a broader spectrum of cranial nerve developmental issues.
4. **Congenital Ptosis and Strabismus** – Infants with congenital ptosis or eye movement disorders may have an increased likelihood of also presenting with MGJWS.
5. **Maternal Health and Environmental Factors** – Although not conclusively established, maternal infections, exposure to toxins, or complications during pregnancy that affect fetal nervous system development may potentially contribute to the syndrome. Despite these identified risk factors, MGJWS is largely unpredictable, with most instances occurring sporadically and lacking a definitive hereditary or environmental cause.[7]

**Diagnosis of Marcus Gunn Jaw-Winking Syndrome**

The diagnosis of Marcus Gunn Jaw-Winking Syndrome (MGJWS) is primarily made through clinical observation, focusing on the distinctive involuntary eyelid movement that occurs in response to jaw activity.[8] This condition is typically recognized in infancy when parents observe atypical eyelid movements during activities such as feeding, sucking, or chewing.

**Clinical Examination:**

1. **Observation of Jaw-Winking Phenomenon** - The upper eyelid of the affected eye involuntarily rises when the infant engages in jaw movements (e.g., sucking, chewing, or moving the jaw side to side). - This condition is generally unilateral, though it can occasionally present bilaterally.

2. Assessment of Congenital Ptosis - The affected eye may show mild to moderate ptosis at rest, which tends to improve with jaw movement.
3. Jaw Movements and Eyelid Reflex Testing - The clinician instructs the patient to perform various jaw movements (e.g., opening, lateral movement, or clenching) to evaluate the extent of eyelid elevation.
4. Slit-Lamp Examination & Ophthalmic Evaluation - This examination assesses corneal health, visual acuity, and ocular alignment. - It also helps identify any associated conditions such as strabismus, amblyopia, or Duane Retraction Syndrome.
5. Neurological and Genetic Assessment (if necessary) - In cases with a familial history or when linked to syndromic conditions (e.g., Goldenhar Syndrome, Moebius Syndrome), a neurological assessment or genetic testing may be advised.[9]

**Differential Diagnosis:** MGJWS must be differentiated from other disorders that lead to congenital ptosis or synkinetic eye movements, such as:

- **Isolated Congenital Ptosis** – Lacks the jaw-winking reflex.
- **Blepharophimosis Syndrome** – Exhibits ptosis with a narrowed eyelid opening, but does not include jaw-winking.
- **Duane Retraction Syndrome** – Involves atypical eye movements, which can sometimes coexist with MGJWS.
- **Trigeminal or Facial Synkinesis** – Refers to other forms of abnormal nerve wiring that affect the muscles of the face.
- **Imaging (Rarely Required):** MRI or CT imaging may be considered in cases where neurological abnormalities or cranial nerve anomalies are suspected, though it is not usually necessary for isolated MGJWS.

**Conclusion:**

Marcus Gunn Jaw-Winking Syndrome is diagnosed through clinical evaluation, marked by eyelid elevation linked to jaw movements, congenital ptosis, and other ocular manifestations. Early detection is vital for preventing possible visual issues, including amblyopia or strabismus.

**Clinical Presentation of Marcus Gunn Jaw-Winking Syndrome**

Typically, Marcus Gunn Jaw-Winking Syndrome (MGJWS) is identified at birth or in the early stages of infancy, with caregivers noticing unusual eyelid movements during feeding or jaw activity. The primary clinical signs include: (Table 1)

**1. Jaw-Winking Phenomenon**

- This phenomenon involves the involuntary lifting of the upper eyelid during jaw movements such as sucking, chewing, or lateral motion.[10]
- When the jaw is at rest, the eyelid typically reverts to a drooped position.

- The intensity of the wink can vary significantly, ranging from subtle to pronounced, and is influenced by different jaw activities.

## **2. Congenital Ptosis (Drooping Eyelid at Rest)**

- In cases of congenital ptosis, the affected eyelid is often seen in a drooped state even when the individual is at rest.
- The severity of the drooping can vary from mild to moderate, but it tends to improve with jaw movement.

## **3. Unilateral Involvement (Most Common)**

- The Jaw-Winking Phenomenon is predominantly unilateral, with a higher incidence observed in the left eye compared to the right.
  - Although it is uncommon, there are instances where both eyelids may be affected, leading to abnormal movements in each.
4. Strabismus, characterized by eye misalignment, is observed in up to 50% of cases, frequently presenting as exotropia, which is an outward deviation of the eye. Amblyopia, commonly referred to as lazy eye, may develop in certain patients as a result of disrupted visual input. Additionally, some children may experience refractive errors, such as astigmatism or anisometropia. (Figure 2)
  5. The jaw-winking reflex is an involuntary response that cannot be consciously controlled. While its intensity may vary, it typically persists throughout an individual's life.
  6. There are potential associations with craniofacial or neurological conditions in some cases. These may include links to Goldenhar Syndrome, Duane Retraction Syndrome, or congenital cranial dysinnervation disorders (CCDDs). In rare instances, facial asymmetry or involvement of additional cranial nerves may be noted.



**Figure 2: Strabismus**

**Table 1: Clinical Signs and Symptoms of Marcus Gunn Jaw-Winking Syndrome**

Condition	Description
Jaw-Winking Phenomenon	Involuntary elevation of the upper eyelid with jaw movements (e.g., sucking, chewing, lateral jaw motion).
Congenital Ptosis	Drooping of the upper eyelid present from birth, varying in severity.
Strabismus	Misalignment of the eyes; occurs in approximately 50% of MGJWS cases.
Amblyopia (Lazy Eye)	Reduced vision in one eye due to disuse, often secondary to ptosis or strabismus.
Bilateral Presentation (Rare)	Involvement of both eyes, though most cases are unilateral, with a slight left-eye predominance.
Variable Ptosis Severity	Some patients have mild ptosis, while others experience severe eyelid drooping requiring intervention.
Associated Craniofacial Anomalies	MGJWS may coexist with conditions such as Duane Retraction Syndrome or Goldenhar Syndrome.
Exacerbation with Specific Movements	Symptoms become more apparent during feeding, talking, or chewing.
Compensatory Head Postures	Some individuals adopt abnormal head positions to compensate for eyelid movement irregularities.

**Staging of Marcus Gunn Jaw-Winking Syndrome**

Marcus Gunn Jaw-Winking Syndrome (MGJWS) lacks a standardized formal staging system recognized universally. Nevertheless, it can be classified according to the intensity of the jaw-winking phenomenon and its effects on visual function and daily life. A pragmatic clinical classification may assist in informing management strategies.[11]

**Proposed Staging System for MGJWS**

**1. Mild (Grade I)**

- Jaw-winking is subtle and can only be detected with careful observation.
- There is minimal elevation of the eyelid during jaw movements.
- There is no significant impact on cosmetic appearance or functionality.
- Vision remains unaffected, with no associated conditions such as amblyopia or strabismus.
- Treatment is typically unnecessary.

**2. Moderate (Grade II)**

- Jaw-winking is evident and occurs during routine jaw activities such as chewing or talking.

- There is mild to moderate congenital ptosis present at rest.
- While there may be some cosmetic concerns, visual impairment is minimal.
- There may be mild amblyopia or strabismus that could require intervention.
- Monitoring and non-surgical approaches, such as patching for amblyopia, may be recommended.

### **3. Severe (Grade III)**

Jaw-winking is a significant concern that can lead to various social and functional issues. Patients may suffer from moderate to severe congenital ptosis, which obstructs their vision. Furthermore, there may be notable ocular misalignment (strabismus) and/or amblyopia that require medical intervention. These conditions can have a profound functional and aesthetic effect on an individual's daily activities. Surgical correction, including levator inactivation or ptosis surgery, is commonly needed to enhance both vision and appearance.

#### **Clinical Application**

- Mild cases require only observation and reassurance.
- Moderate cases may benefit from vision therapy (e.g., amblyopia treatment).
- Severe cases often require surgical intervention to correct ptosis and reduce the jaw-winking effect.

This staging helps determine treatment strategies based on the severity of symptoms and their impact on vision and quality of life.

#### **Treatment of Marcus Gunn Jaw-Winking Syndrome**

The management of Marcus Gunn Jaw-Winking Syndrome (MGJWS) is contingent upon the severity of the symptoms, their effect on vision, and any associated cosmetic issues. In instances of mild presentation, intervention may not be required, whereas more severe cases typically call for surgical intervention.[12]

##### **1. Conservative Management (For Mild to Moderate Cases)**

- **Observation & Reassurance:**
  - In cases where jaw-winking is minimal and does not compromise vision, treatment is not warranted.
  - Caregivers are informed about the non-threatening nature of the condition.

- **Amblyopia Management & Strabismus Correction**

In cases of lazy eye (amblyopia), treatment options typically involve occlusion therapy, such as patching, or the use of corrective lenses to enhance visual acuity. For significant eye misalignment (strabismus), surgical intervention on the eye muscles may be necessary to achieve proper alignment.

##### **2. Surgical Treatment (For Severe Cases)**

Surgical intervention is advised for individuals who present with:

- Marked ptosis that interferes with visual clarity.
- Pronounced jaw-winking movements that lead to aesthetic or functional concerns.
- Coexisting ocular conditions such as strabismus or amblyopia.

### **Surgical Procedures:**

1. Jaw-winking movements are eliminated by inactivating or resecting the levator palpebrae superioris muscle, which is preferred in severe cases. In order to enable the forehead muscle to raise the eyelid, a frontalis sling surgery is typically required because this procedure eliminates normal eyelid elevation.
2. When levator function is lost, frontalis sling surgery is used, which relies on contraction of the frontalis muscle to move the eyelids. Fascia lata, silicone rods, or synthetic materials are frequently used.
3. **Levator Resection:** In moderate cases, the levator muscle is tightened to minimize jaw-winking and lessen ptosis. It is appropriate for situations in which jaw-winking is not very severe.
4. **Surgery for Ptosis Alone:** If ptosis is the main issue (with mild jaw-winking), levator advancement or resection of Muller's muscle may be done.

### **3. Additional Considerations**

It may be necessary to undergo a number of surgeries in order to attain the best functional and aesthetic outcomes in complex cases.

- **Post-Surgical Care:** Regular follow-ups, eye patching, and lubrication are crucial for tracking recovery from surgery and visual development.

### **Role of a Pharmacist in Marcus Gunn Jaw-Winking Syndrome (MGJWS) Management**

Marcus Gunn Jaw-Winking Syndrome (MGJWS) is predominantly a neurological and ophthalmic disorder; however, pharmacists are essential in facilitating treatment, overseeing medication management, and providing patient education.[13] Their participation is particularly vital in post-surgical care, addressing related issues such as amblyopia and strabismus, and promoting comprehensive eye health.

#### **1. Patient and Caregiver Education**

Inform parents and caregivers about MGJWS, highlighting its non-threatening nature and the necessity of consistent ophthalmologic check-ups.

- Share details regarding treatment alternatives, encompassing both non-invasive and surgical methods.
- Advise on strategies for eye protection, as patients may experience diminished eyelid function after surgery, which can elevate the risk of dry eyes and corneal exposure.

## **2. Medication Management**

- **Lubricating Eye Drops (Artificial Tears):**

After surgery or in instances of incomplete eyelid closure, pharmacists may suggest or provide lubricating eye drops to mitigate dry eye issues.

- **Antibiotic Eye Drops/Ointments:**

Following ocular surgeries, pharmacists play a crucial role in ensuring the correct application of prescribed antibiotics to avert infections.

- **Pain Management:**

In the event of surgical intervention, pharmacists offer advice on managing post-operative pain, typically recommending paracetamol or NSAIDs, while also monitoring for any adverse reactions.

- **Strabismus or Amblyopia Treatment Support:**

Aid in the distribution of vision-correcting medications (if prescribed) and ensure adherence to eye patching protocols.

## **3. Post-Surgical Care Support**

Educate patients on the importance of adhering to their medication regimen to enhance recovery and reduce the risk of infections. Advise them about possible side effects of their medications and the appropriate circumstances for seeking medical assistance. Emphasize the necessity of attending follow-up appointments with the ophthalmologist to track their progress.

## **4. Interdisciplinary Collaboration**

Collaborate with ophthalmologists, pediatricians, and surgeons to provide holistic patient care. Refer patients to vision therapy programs when necessary.

## **Recent Advances in Treatment of Marcus Gunn Jaw-Winking Syndrome**

Recent studies have significantly advanced our understanding of Marcus Gunn Jaw-Winking Syndrome (MGJWS), particularly regarding its causes, clinical features, and treatment approaches.

### **Etiology and Pathophysiology**

A notable breakthrough in understanding the etiology of MGJWS is the discovery of structural abnormalities in the brainstem of individuals with familial cases. A thorough review spanning 74 years has provided evidence of these abnormal brainstem structures, indicating a potential neurodevelopmental origin for the syndrome.[14] Histopathological investigations have further clarified the pathophysiology of MGJWS. One particular study observed varying levels of fibrosis in the affected levator palpebrae superioris muscle, as well as in the contralateral, non-ptotic muscle, suggesting that these structural alterations in muscle tissue may contribute to the syndrome's symptoms.

### **Clinical Variability**

While MGJWS typically presents unilaterally, bilateral cases have been documented, underscoring the syndrome's clinical variability. A case report detailed a 4-week-old male infant exhibiting repetitive bilateral eyelid blinking during feeding, indicating that bilateral manifestations, though rare, can occur.

Additionally, the phenomenon can present without accompanying ptosis. A study highlighted instances of isolated jaw-winking without ptosis, expanding the clinical spectrum of MGJWS and suggesting that the absence of ptosis does not preclude the diagnosis.

### **Epidemiology**

MGJWS occurs in about 2% to 13% of individuals with congenital ptosis, impacting both males and females equally. Although it is usually unilateral, there are instances of bilateral cases. The severity of ptosis and the extent of jaw-winking differ among patients; some may have mild symptoms that can be addressed with conservative treatments, while others may present with more severe symptoms that require surgical intervention.

### **Management Strategies**

Surgical intervention is a key treatment approach for MGJWS, particularly in instances where there are notable functional or aesthetic issues. A recent case series evaluated the effectiveness of bilateral frontalis suspension (FS) procedures, comparing those performed with levator excision (LE) to those without. The results indicated that bilateral FS without LE is equally effective in minimizing eyelid excursion, presenting a less invasive yet viable surgical alternative.

### **Role of Primary Care Physicians**

Recent literature has underscored the significance of early detection and referral by primary care physicians. A case report illustrated the essential role of family practitioners in recognizing initial symptoms, initiating necessary investigations, and facilitating multidisciplinary care for MGJWS patients. Timely intervention can avert secondary complications and enhance patient outcomes. In conclusion, recent developments in MGJWS research have illuminated its neurodevelopmental roots, varied clinical manifestations, and effective management approaches. Ongoing studies are furthering our comprehension, with the goal of improving diagnostic precision and treatment results for those affected.

### **Conclusion:**

Marcus Gunn Jaw-Winking Syndrome (MGJWS) is a rare congenital neurological disorder characterized by abnormal eyelid elevation that is triggered by jaw movements, resulting from a miswiring between the oculomotor (CN III) and trigeminal (CN V) nerves. While the condition is generally benign, it can lead to functional and cosmetic issues, particularly when associated with congenital ptosis, amblyopia, or strabismus. Diagnosis is primarily clinical,



based on the distinctive jaw-winking reflex observed in infants. Treatment options vary according to severity, ranging from observation and amblyopia management in mild cases to surgical interventions such as levator inactivation and frontalis sling procedures in more severe cases. Pharmacists play a critical role in post-surgical care, medication management, and patient education, ensuring the proper use of eye drops, pain relief, and adherence to vision therapy. A multidisciplinary approach involving ophthalmologists, pediatricians, and pharmacists is essential for achieving optimal patient outcomes.[15] Although MGJWS typically does not progress over time, early diagnosis and intervention are important for preventing visual impairments and improving the quality of life for affected individuals.

### References

1. Senthikumar, V. A., & Tripathy, K. (2023). Marcus Gunn jaw-winking syndrome. In *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK559058/>
2. Demirci, H., Frueh, B. R., & Nelson, C. C. (2010). Marcus Gunn jaw-winking synkinesis: Clinical features and management. *Ophthalmology*, 117(7), 1447-1452. <https://doi.org/10.1016/j.ophtha.2009.11.014>
3. Chaurasiya, S. K., Alam, M., Agarwal, P., & Chauhan, L. (2023). Incidence and clinical profile of Marcus Gunn jaw winking phenomenon in congenital ptosis at a tertiary eye hospital in Western Uttar Pradesh, India. *Latin American Journal of Ophthalmology*, 6, 4. [https://doi.org/10.25259/LAJO\\_3\\_2023](https://doi.org/10.25259/LAJO_3_2023)
4. Doucet, T. W., & Crawford, J. S. (1981). The quantification, natural course, and surgical results in 57 eyes with Marcus-Gunn (jaw-winking) syndrome. *American Journal of Ophthalmology*, 92(5), 702-707. [https://doi.org/10.1016/S0002-9394\(14\)74665-3](https://doi.org/10.1016/S0002-9394(14)74665-3)
5. Johnson, A., Silverman, A., Segal, B., & Beres, S. (2022). Bilateral Marcus Gunn jaw-winking syndrome in a neonate with congenital neurosyphilis. *Journal of Pediatrics*, 252, 223-224. <https://doi.org/10.1016/j.jpeds.2022.09.023>
6. Alam, S., Nishanth, S., Ramasubramania, S., Swaminathan, M., & Mukherjee, B. (2020). The rare phenomenon of Marcus-Gunn jaw winking without ptosis: Report of 14 cases and review of literature. *Indian Journal of Ophthalmology*, 68(6), 1132-1135. [https://doi.org/10.4103/ijo.IJO\\_1099\\_19](https://doi.org/10.4103/ijo.IJO_1099_19)
7. Sobel, R. K., & Allen, R. C. (2014). Incidence of bilateral Marcus Gunn jaw-wink. *Ophthalmic Plastic and Reconstructive Surgery*, 30(3), e54-e55. <https://doi.org/10.1097/IOP.0b013e31829bb405>
8. Kodsi, S. (2000). Marcus Gunn jaw winking with trigemino-abducens synkinesis. *Journal of AAPOS*, 4(5), 316-317. <https://doi.org/10.1067/mpa.2000.107903>

9. Miller, N. R., Newman, N. J., Biousse, V., & Kerrison, J. B. (2005). *Walsh and Hoyt's Clinical Neuro-Ophthalmology* (6th ed.). Philadelphia: Lippincott Williams & Wilkins.
10. Wartenberg, R. (1948). Winking-jaw phenomenon. *Archives of Neurology and Psychiatry*, 59(4), 734-753. <https://doi.org/10.1001/archneurpsyc.1948.02300410045003>
11. David, D., Chiavarolli, V., Lanci, M., Sabatini, L., Greco, S., Carinci, S., et al. (2021). Neonatal diagnosis of Marcus Gunn jaw-winking syndrome. *Clinical Case Reports*, 9(2), 866-869. <https://doi.org/10.1002/ccr3.3664>
12. Dzaman, K., Zborowska-Piskadło, K., Pietniczka-Zaleska, M., & Kantor, I. (2019). Marcus Gunn (jaw-winking) phenomenon in pediatric otorhinolaryngology practice. *International Journal of Pediatric Otorhinolaryngology*, 117, 153-156. <https://doi.org/10.1016/j.ijporl.2018.11.035>
13. Koelsch, E., & John, W. H. (2007). Marcus Gunn jaw winking synkinesis in a neonate. *Movement Disorders*, 22(6), 871-873. <https://doi.org/10.1002/mds.21328>
14. Lelli, G. J. Jr., & Nelson, C. C. (2006). Early habituation of severe blepharoptosis in Marcus Gunn jaw-winking syndrome. *Journal of Pediatric Ophthalmology and Strabismus*, 43(1), 38-40. <https://doi.org/10.3928/01913913-20060101-0>
15. Neuhaus, R. W. (1985). Eyelid suspension with a transposed levator palpebrae superioris muscle. *American Journal of Ophthalmology*, 100(3), 308-311. [https://doi.org/10.1016/0002-9394\(85\)90798-6](https://doi.org/10.1016/0002-9394(85)90798-6)

# Emerging Trends in Pharmaceutical Science Research Volume IV

ISBN: 978-93-48620-60-6

## About Editors



Dr. Chintan Aundhia is Professor, Department of Pharmaceutics, Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University with more than 15 years of teaching and research experience. His research areas include Novel drug delivery and Computer aided drug design. He has an impressive academic record, having published more than 75 research papers and over 30 book chapters in reputed journals and books. His contributions to intellectual property include one patent and three design patents. He has actively participated in over 50 professional engagements, including seminars, workshops, conferences, and Faculty Development Programs. He has recently received the Best Young Researcher Award by Association of Pharmacy Professionals for his consistent and dedicated work in the field. He is the Life member of various scientific and academic bodies like APTI, APP etc. He has also contributed as a reviewer for many scientific journals.



Mrs. Nivedita B. T. M.Sc, B.Ed,(Ph.D) is working as an Assistant Professor in Department of Studies in Botany, Davangere University, Shivagangothri, Davangere, Karnataka, India. Presently she is working as Coordinator in Department of Botany, Jnanagangothri PG Centre Chitradurga. She is pursuing her PhD degree from Kuvempu University Shankaraghatta, Shivamogga. She has 9 Years of Academic Experience in various Educational Institution for the undergraduate and post graduate students. She has attended and presented her work in several National and International symposia and conferences and also attended several online Faculty development program and certificate courses. Her research area of interest lies in Microbiology, Environmental Science and Nanotechnology.



Dr. Shilpi Shrivastava is a Professor and Head of the Department of Chemistry at Kalinga University, Naya Raipur. She holds a Ph.D., M.Phil., M.Sc. in Applied Chemistry, and B.Sc. in ZBC. Her research interests include Photochemistry, Environmental Chemistry, and Nanochemistry. Dr. Shrivastava has an extensive academic and research background, with 80 published research papers, 6 books, 11 book chapters, and 4 patents. She has successfully guided 14 Ph.D. scholars to completion. As an editor, she has contributed to books and reputed national and international journals. Her contributions to the field have earned her six prestigious awards and recognitions. With her expertise in chemistry, she continues to make significant advancements in research and education, mentoring scholars and fostering scientific innovation.



Dr. P. Rizwan Ahmed is Head of the Department of Computer Applications, Data Science and PG & Research Department of Computer Science at Mazharul Uloom College, Ambur, Tamil Nadu, INDIA. His research interests include Machine Learning, Autonomic Computing, and Artificial Intelligence. He is a life member of IAE, Hong Kong, IRED, USA, and ISRD. He received Best Faculty Award, Active Young Researcher Award and Best Author Award. He is keenly interested in developing innovation methods and materials for teaching and learning Computer Science

